0001035443false12/312026Q2http://fasb.org/us-gaap/2026#OtherAssetshttp://fasb.org/us-gaap/2026#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesutr:sqftare:propertyxbrli:pureare:directFinancingLeaseare:landParcelare:investmentutr:Rateare:transferiso4217:CADare:segment00010354432026-01-012026-06-3000010354432026-07-1500010354432026-06-3000010354432025-12-310001035443are:IncomefromrentalsMember2026-04-012026-06-300001035443are:IncomefromrentalsMember2025-04-012025-06-300001035443are:IncomefromrentalsMember2026-01-012026-06-300001035443are:IncomefromrentalsMember2025-01-012025-06-300001035443us-gaap:ProductAndServiceOtherMember2026-04-012026-06-300001035443us-gaap:ProductAndServiceOtherMember2025-04-012025-06-300001035443us-gaap:ProductAndServiceOtherMember2026-01-012026-06-300001035443us-gaap:ProductAndServiceOtherMember2025-01-012025-06-3000010354432026-04-012026-06-3000010354432025-04-012025-06-3000010354432025-01-012025-06-300001035443us-gaap:CommonStockMember2026-03-310001035443us-gaap:AdditionalPaidInCapitalMember2026-03-310001035443us-gaap:RetainedEarningsMember2026-03-310001035443us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001035443us-gaap:NoncontrollingInterestMember2026-03-3100010354432026-03-310001035443are:RedeemableNoncontrollingInterestsMember2026-03-310001035443us-gaap:RetainedEarningsMember2026-04-012026-06-300001035443us-gaap:NoncontrollingInterestMember2026-04-012026-06-300001035443are:RedeemableNoncontrollingInterestsMember2026-04-012026-06-300001035443us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-04-012026-06-300001035443us-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-300001035443us-gaap:CommonStockMember2026-04-012026-06-300001035443us-gaap:CommonStockMember2026-06-300001035443us-gaap:AdditionalPaidInCapitalMember2026-06-300001035443us-gaap:RetainedEarningsMember2026-06-300001035443us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-06-300001035443us-gaap:NoncontrollingInterestMember2026-06-300001035443are:RedeemableNoncontrollingInterestsMember2026-06-300001035443us-gaap:CommonStockMember2025-03-310001035443us-gaap:AdditionalPaidInCapitalMember2025-03-310001035443us-gaap:RetainedEarningsMember2025-03-310001035443us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001035443us-gaap:NoncontrollingInterestMember2025-03-3100010354432025-03-310001035443are:RedeemableNoncontrollingInterestsMember2025-03-310001035443us-gaap:RetainedEarningsMember2025-04-012025-06-300001035443us-gaap:NoncontrollingInterestMember2025-04-012025-06-300001035443are:RedeemableNoncontrollingInterestsMember2025-04-012025-06-300001035443us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300001035443us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001035443us-gaap:CommonStockMember2025-04-012025-06-300001035443us-gaap:CommonStockMember2025-06-300001035443us-gaap:AdditionalPaidInCapitalMember2025-06-300001035443us-gaap:RetainedEarningsMember2025-06-300001035443us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001035443us-gaap:NoncontrollingInterestMember2025-06-3000010354432025-06-300001035443are:RedeemableNoncontrollingInterestsMember2025-06-300001035443us-gaap:CommonStockMember2025-12-310001035443us-gaap:AdditionalPaidInCapitalMember2025-12-310001035443us-gaap:RetainedEarningsMember2025-12-310001035443us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001035443us-gaap:NoncontrollingInterestMember2025-12-310001035443are:RedeemableNoncontrollingInterestsMember2025-12-310001035443us-gaap:RetainedEarningsMember2026-01-012026-06-300001035443us-gaap:NoncontrollingInterestMember2026-01-012026-06-300001035443are:RedeemableNoncontrollingInterestsMember2026-01-012026-06-300001035443us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-06-300001035443us-gaap:AdditionalPaidInCapitalMember2026-01-012026-06-300001035443us-gaap:CommonStockMember2026-01-012026-06-300001035443us-gaap:CommonStockMember2024-12-310001035443us-gaap:AdditionalPaidInCapitalMember2024-12-310001035443us-gaap:RetainedEarningsMember2024-12-310001035443us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001035443us-gaap:NoncontrollingInterestMember2024-12-3100010354432024-12-310001035443are:RedeemableNoncontrollingInterestsMember2024-12-310001035443us-gaap:RetainedEarningsMember2025-01-012025-06-300001035443us-gaap:NoncontrollingInterestMember2025-01-012025-06-300001035443are:RedeemableNoncontrollingInterestsMember2025-01-012025-06-300001035443us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-06-300001035443us-gaap:AdditionalPaidInCapitalMember2025-01-012025-06-300001035443us-gaap:CommonStockMember2025-01-012025-06-300001035443srt:NorthAmericaMemberare:OperatingPropertiesMember2026-06-300001035443srt:NorthAmericaMemberare:ActiveDevelopmentRedevelopmentMember2026-06-300001035443us-gaap:BuildingAndBuildingImprovementsMembersrt:MaximumMember2026-06-300001035443us-gaap:LandImprovementsMembersrt:MaximumMember2026-06-300001035443country:CA2026-06-300001035443srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberare:IncomefromrentalsMember2026-04-012026-06-300001035443srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberare:IncomefromrentalsMember2025-04-012025-06-300001035443srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberare:IncomefromrentalsMember2026-01-012026-06-300001035443srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberare:IncomefromrentalsMember2025-01-012025-06-300001035443srt:NorthAmericaMember2026-06-300001035443srt:NorthAmericaMember2025-12-310001035443us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2026-06-300001035443us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2025-12-310001035443us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberare:OperatingPropertiesMember2026-06-300001035443us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberus-gaap:LandMember2026-06-300001035443us-gaap:SubsequentEventMemberare:A3825And3875FabianWayMember2026-07-310001035443us-gaap:SubsequentEventMemberare:OperatingPropertiesMemberare:A3825And3875FabianWayMember2026-07-310001035443us-gaap:SubsequentEventMemberare:FutureDevelopmentProjectsMemberare:A3825And3875FabianWayMember2026-07-310001035443us-gaap:SubsequentEventMemberare:A3825And3875FabianWayMember2026-07-012026-07-310001035443srt:NorthAmericaMember2026-01-012026-06-300001035443are:OneHampshireStreetMember2026-04-012026-06-300001035443are:OneHampshireStreetMemberare:OperatingPropertiesMember2026-06-300001035443are:OneHampshireStreetMember2025-12-012025-12-310001035443are:SanDiegoMarketMember2026-04-012026-06-300001035443are:SanDiegoMarketMemberus-gaap:LandMember2026-06-300001035443are:A391139314025403140454075SorrentoValleyBlvdMember2026-04-012026-06-300001035443are:A391139314025403140454075SorrentoValleyBlvdMemberare:OperatingPropertiesMember2026-06-300001035443are:A391139314025403140454075SorrentoValleyBlvdMemberus-gaap:LandMember2026-06-300001035443are:A88BluxomeStreetMember2026-04-012026-06-300001035443are:A88BluxomeStreetMemberare:FutureDevelopmentProjectsMember2026-06-300001035443are:A88BluxomeStreetMember2025-12-012025-12-310001035443are:A3825And3875FabianWayMemberare:FutureDevelopmentProjectsMember2026-06-300001035443are:A3825And3875FabianWayMemberare:OperatingPropertiesMember2026-06-300001035443are:A3825And3875FabianWayMember2025-12-012025-12-310001035443are:A3825And3875FabianWayMember2026-06-012026-06-300001035443are:A720BayStreetMember2026-01-012026-06-300001035443are:A720BayStreetMemberare:OperatingPropertiesMember2026-06-300001035443are:MontrealPropertiesMember2026-01-012026-06-300001035443are:CanadaMarketMember2026-06-300001035443are:AlexandriaCenterForLifeScienceNewYorkCityMember2026-06-300001035443are:HHAndEDCLitigationMember2026-04-102026-04-100001035443are:HHAndEDCLitigationMember2026-04-100001035443are:AlexandriaMemberare:A50And60BinneyStreetMember2026-06-300001035443are:AlexandriaMemberare:A75125BinneyStreetMember2026-06-300001035443are:AlexandriaMemberare:A100And225BinneyStreetAnd300ThirdStreetMember2026-06-300001035443are:AlexandriaMemberare:A15NeccoStreetMember2026-06-300001035443are:AlexandriaMemberare:A3215MerryfieldRowMember2026-06-300001035443are:AlexandriaMemberare:CampusPointByAlexandriaMember2026-06-300001035443are:AlexandriaMemberare:A5200IlluminaWayMember2026-06-300001035443are:AlexandriaMemberare:A9625TowneCentreDriveMember2026-06-300001035443are:AlexandriaMemberare:SDTechbyAlexandriaMember2026-06-300001035443are:AlexandriaMemberare:SummersRidgeScienceParkMember2026-06-300001035443are:AlexandriaMemberare:AlexandriaCenterForScienceAndTechnologyMissionBayMember2026-06-300001035443are:AlexandriaMemberare:A211And213EastGrandAvenueMember2026-06-300001035443are:AlexandriaMemberare:A500ForbesBoulevardMember2026-06-300001035443are:AlexandriaMemberare:AlexandriaCenterForLifeScienceMillbraeMember2026-06-300001035443are:AlexandriaMemberare:A1201And1208EastlakeAvenueEastMember2026-06-300001035443are:AlexandriaMemberare:A400DexterAvenueNorthMember2026-06-300001035443are:AlexandriaMemberare:A800MercerStreetMember2026-06-300001035443are:A1655And1725ThirdStreetMember2026-06-300001035443are:A101WestDickmanStreetMember2026-06-300001035443us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2026-06-300001035443us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-12-310001035443are:A99CoolidgeAvenueMember2025-07-310001035443are:A99CoolidgeAvenueMember2025-12-310001035443are:A99CoolidgeAvenueMember2026-01-012026-03-310001035443are:A1655And1725ThirdStreetMember2025-12-310001035443are:A101WestDickmanStreetMember2025-12-310001035443are:OtherunconsolidatedrealestatejointventuresMember2026-06-300001035443are:OtherunconsolidatedrealestatejointventuresMember2025-12-310001035443are:A101WestDickmanStreetMember2026-01-012026-06-300001035443are:A1655And1725ThirdStreetMember2026-01-012026-06-300001035443us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2026-06-300001035443are:PurchaseOptionTermOneMember2026-01-012026-06-300001035443are:PurchaseOptionTermTwoMember2026-01-012026-06-300001035443are:PurchaseOptionTermThreeMember2026-01-012026-06-3000010354432017-10-012017-10-010001035443are:LandparcelssubjecttoleaseagreementthatcontainsapurchaseoptionMember2026-01-012026-06-300001035443are:A1201And1208EastlakeAvenueEastMember2026-06-300001035443are:A1208EastlakeAvenueEastMember2026-06-300001035443are:A1201EastlakeAvenueEastMember2026-06-300001035443are:A1208EastlakeAvenueEastMember2026-01-012026-06-300001035443are:A1201EastlakeAvenueEastMember2026-01-012026-06-300001035443are:OtherOperatingPropertiesMember2026-06-300001035443are:A30003018WesternAvenueMember2026-04-012026-06-300001035443are:GroundandOperatingLeasesMember2026-06-300001035443are:OperatingPropertyWithGroundLeaseMember2026-06-300001035443srt:MinimumMember2026-01-012026-06-300001035443srt:MaximumMember2026-01-012026-06-300001035443are:AlexandriaTechnologySquareMember2025-01-012025-06-300001035443are:DevelopmentEscrowsMember2026-06-300001035443are:DevelopmentEscrowsMember2025-12-310001035443are:SecurityDepositsMember2026-06-300001035443are:SecurityDepositsMember2025-12-310001035443are:OtherrestrictedcashMember2026-06-300001035443are:OtherrestrictedcashMember2025-12-310001035443are:LimitedpartnershipsMember2026-01-012026-06-300001035443are:InvestmentsinpubliclytradedcompaniesMember2026-06-300001035443are:LimitedpartnershipsMember2026-06-300001035443are:EntitieswithobservablepricechangeMemberare:InvestmentsinprivatelyheldentitiesthatdonotreportNAVMember2026-06-300001035443are:EntitieswithoutobservablepricechangesMemberare:InvestmentsinprivatelyheldentitiesthatdonotreportNAVMember2026-06-300001035443are:InvestmentsinpubliclytradedcompaniesMember2025-12-310001035443are:LimitedpartnershipsMember2025-12-310001035443are:EntitieswithobservablepricechangeMemberare:InvestmentsinprivatelyheldentitiesthatdonotreportNAVMember2025-12-310001035443are:EntitieswithoutobservablepricechangesMemberare:InvestmentsinprivatelyheldentitiesthatdonotreportNAVMember2025-12-310001035443us-gaap:EquityMethodInvestmentsMember2026-04-012026-06-300001035443us-gaap:EquityMethodInvestmentsMember2026-01-012026-06-300001035443are:EntitieswithobservablepricechangeMemberare:InvestmentsinprivatelyheldentitiesthatdonotreportNAVMember2026-01-012026-06-300001035443are:EntitieswithobservablepricechangeMemberare:InvestmentsinprivatelyheldentitiesthatdonotreportNAVMember2025-04-012025-06-300001035443are:EntitiesWithObservablePriceChangeMemberare:InvestmentsinprivatelyheldentitiesthatdonotreportNAVMember2026-04-012026-06-300001035443are:EntitiesWithObservablePriceChangeMemberare:InvestmentsinprivatelyheldentitiesthatdonotreportNAVMember2025-04-012025-06-300001035443are:TotalInvestmentsHeldMember2026-01-012026-06-300001035443are:TotalInvestmentsHeldMember2025-04-012025-06-300001035443are:SanDiegoMemberus-gaap:NotesReceivableMember2026-01-012026-06-300001035443are:SanDiegoMemberus-gaap:NotesReceivableMember2026-06-300001035443are:SanDiegoMemberus-gaap:NotesReceivableMember2025-12-310001035443are:GreaterBostonMemberus-gaap:NotesReceivableMember2026-01-012026-06-300001035443are:GreaterBostonMemberus-gaap:NotesReceivableMember2026-06-300001035443are:GreaterBostonMemberus-gaap:NotesReceivableMember2025-12-310001035443are:InvestmentsInPubliclyTradedCompaniesMember2026-06-300001035443are:InvestmentsInPubliclyTradedCompaniesMemberus-gaap:FairValueInputsLevel1Member2026-06-300001035443are:InvestmentsInPubliclyTradedCompaniesMemberus-gaap:FairValueInputsLevel2Member2026-06-300001035443are:InvestmentsInPubliclyTradedCompaniesMemberus-gaap:FairValueInputsLevel3Member2026-06-300001035443are:InvestmentsInPubliclyTradedCompaniesMember2025-12-310001035443are:InvestmentsInPubliclyTradedCompaniesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001035443are:InvestmentsInPubliclyTradedCompaniesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001035443are:InvestmentsInPubliclyTradedCompaniesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001035443us-gaap:CurrencySwapMember2026-06-300001035443us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel1Member2026-06-300001035443us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel2Member2026-06-300001035443us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel3Member2026-06-300001035443us-gaap:CurrencySwapMember2025-12-310001035443us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel1Member2025-12-310001035443us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel2Member2025-12-310001035443us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel3Member2025-12-310001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsNonrecurringMember2026-06-300001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel1Member2026-06-300001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel2Member2026-06-300001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel3Member2026-06-300001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsNonrecurringMember2025-12-310001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel3Member2025-12-310001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberare:EntitieswithoutobservablepricechangesMemberare:InvestmentsinprivatelyheldentitiesthatdonotreportNAVMemberus-gaap:FairValueMeasurementsNonrecurringMember2026-06-300001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberare:EntitieswithoutobservablepricechangesMemberare:InvestmentsinprivatelyheldentitiesthatdonotreportNAVMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel1Member2026-06-300001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberare:EntitieswithoutobservablepricechangesMemberare:InvestmentsinprivatelyheldentitiesthatdonotreportNAVMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel2Member2026-06-300001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberare:EntitieswithoutobservablepricechangesMemberare:InvestmentsinprivatelyheldentitiesthatdonotreportNAVMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel3Member2026-06-300001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberare:EntitieswithoutobservablepricechangesMemberare:InvestmentsinprivatelyheldentitiesthatdonotreportNAVMemberus-gaap:FairValueMeasurementsNonrecurringMember2025-12-310001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberare:EntitieswithoutobservablepricechangesMemberare:InvestmentsinprivatelyheldentitiesthatdonotreportNAVMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberare:EntitieswithoutobservablepricechangesMemberare:InvestmentsinprivatelyheldentitiesthatdonotreportNAVMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberare:EntitieswithoutobservablepricechangesMemberare:InvestmentsinprivatelyheldentitiesthatdonotreportNAVMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel3Member2025-12-310001035443us-gaap:CarryingReportedAmountFairValueDisclosureMember2026-06-300001035443us-gaap:CarryingReportedAmountFairValueDisclosureMemberare:A22BillionUnsecuredSeniorLineOfCreditMember2026-06-300001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberare:A22BillionUnsecuredSeniorLineOfCreditMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel1Member2026-06-300001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberare:A22BillionUnsecuredSeniorLineOfCreditMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel2Member2026-06-300001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberare:A22BillionUnsecuredSeniorLineOfCreditMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel3Member2026-06-300001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberare:A22BillionUnsecuredSeniorLineOfCreditMemberus-gaap:FairValueMeasurementsNonrecurringMember2026-06-300001035443us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CommercialPaperMember2026-06-300001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel1Member2026-06-300001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel2Member2026-06-300001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel3Member2026-06-300001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsNonrecurringMember2026-06-300001035443us-gaap:CarryingReportedAmountFairValueDisclosureMember2025-12-310001035443us-gaap:CarryingReportedAmountFairValueDisclosureMemberare:A22BillionUnsecuredSeniorLineOfCreditMember2025-12-310001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberare:A22BillionUnsecuredSeniorLineOfCreditMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberare:A22BillionUnsecuredSeniorLineOfCreditMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberare:A22BillionUnsecuredSeniorLineOfCreditMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel3Member2025-12-310001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberare:A22BillionUnsecuredSeniorLineOfCreditMemberus-gaap:FairValueMeasurementsNonrecurringMember2025-12-310001035443us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CommercialPaperMember2025-12-310001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:FairValueInputsLevel3Member2025-12-310001035443us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsNonrecurringMember2025-12-310001035443us-gaap:LineOfCreditMemberus-gaap:CommercialPaperMember2026-06-300001035443us-gaap:LineOfCreditMemberus-gaap:CommercialPaperMember2026-01-012026-06-300001035443are:A3.95UnsecuredSeniorNotesPayableMember2026-06-300001035443are:A3.95UnsecuredSeniorNotesPayableMember2026-01-012026-06-300001035443are:A3.95UnsecuredSeniorNotesPayableDuein2028Member2026-06-300001035443are:A3.95UnsecuredSeniorNotesPayableDuein2028Member2026-01-012026-06-300001035443are:UnsecuredSeniorNotesDueinJuly2029Member2026-06-300001035443are:UnsecuredSeniorNotesDueinJuly2029Member2026-01-012026-06-300001035443are:A2.75UnsecuredSeniorNotesPayableDue2029Member2026-06-300001035443are:A2.75UnsecuredSeniorNotesPayableDue2029Member2026-01-012026-06-300001035443are:A4.70UnsecuredSeniorNotesPayableMember2026-06-300001035443are:A4.70UnsecuredSeniorNotesPayableMember2026-01-012026-06-300001035443are:A4.90UnsecuredSeniorNotesPayableMember2026-06-300001035443are:A4.90UnsecuredSeniorNotesPayableMember2026-01-012026-06-300001035443are:A3.375UnsecuredSeniorNotesPayableMember2026-06-300001035443are:A3.375UnsecuredSeniorNotesPayableMember2026-01-012026-06-300001035443are:A200UnsecuredSeniorNotesPayableMember2026-06-300001035443are:A200UnsecuredSeniorNotesPayableMember2026-01-012026-06-300001035443are:A1875UnsecuredSeniorNotesPayableMember2026-06-300001035443are:A1875UnsecuredSeniorNotesPayableMember2026-01-012026-06-300001035443are:A295UnsecuredSeniorNotesPayableMember2026-06-300001035443are:A295UnsecuredSeniorNotesPayableMember2026-01-012026-06-300001035443are:A475UnsecuredSeniorNotesPayableMember2026-06-300001035443are:A475UnsecuredSeniorNotesPayableMember2026-01-012026-06-300001035443are:A5.50UnsecuredSeniorNotesPayableMember2026-06-300001035443are:A5.50UnsecuredSeniorNotesPayableMember2026-01-012026-06-300001035443are:A5.25UnsecuredSeniorNotesPayableDue2036Member2026-06-300001035443are:A5.25UnsecuredSeniorNotesPayableDue2036Member2026-01-012026-06-300001035443are:A5.25UnsecuredSeniorNotesPayableMember2026-06-300001035443are:A5.25UnsecuredSeniorNotesPayableMember2026-01-012026-06-300001035443are:A4.85UnsecuredSeniorNotePayableMember2026-06-300001035443are:A4.85UnsecuredSeniorNotePayableMember2026-01-012026-06-300001035443are:A4.00UnsecuredSeniorNotesPayableMember2026-06-300001035443are:A4.00UnsecuredSeniorNotesPayableMember2026-01-012026-06-300001035443are:A300UnsecuredSeniorNotesPayableMember2026-06-300001035443are:A300UnsecuredSeniorNotesPayableMember2026-01-012026-06-300001035443are:A355UnsecuredSeniorNotesPayableMember2026-06-300001035443are:A355UnsecuredSeniorNotesPayableMember2026-01-012026-06-300001035443are:A515UnsecuredSeniorNotesPayableMember2026-06-300001035443are:A515UnsecuredSeniorNotesPayableMember2026-01-012026-06-300001035443are:A5.625UnsecuredSeniorNotesPayableMember2026-06-300001035443are:A5.625UnsecuredSeniorNotesPayableMember2026-01-012026-06-300001035443us-gaap:UnsecuredDebtMember2026-06-300001035443us-gaap:LineOfCreditMember2026-06-300001035443us-gaap:LineOfCreditMemberus-gaap:SubsequentEventMember2026-07-012026-07-310001035443us-gaap:LineOfCreditMember2026-01-012026-06-300001035443us-gaap:SeniorNotesMember2026-06-300001035443us-gaap:SeniorNotesMember2026-01-012026-06-300001035443us-gaap:CommercialPaperMember2026-06-300001035443us-gaap:CommercialPaperMember2026-01-012026-06-300001035443are:A4.00UnsecuredSeniorNotes3.00UnsecuredSeniorNotesAnd3.55UnsecuredSeniorNotesMember2026-02-100001035443are:A4.00UnsecuredSeniorNotes3.00UnsecuredSeniorNotesAnd3.55UnsecuredSeniorNotesMember2026-02-012026-02-280001035443are:A5.25UnsecuredSeniorNotesPayableMember2025-02-280001035443are:A4.00UnsecuredSeniorNotes3.00UnsecuredSeniorNotesAnd3.55UnsecuredSeniorNotesMemberus-gaap:CommercialPaperMember2026-02-012026-02-280001035443are:A4.00UnsecuredSeniorNotes3.00UnsecuredSeniorNotesAnd3.55UnsecuredSeniorNotesMember2026-01-012026-03-310001035443are:A4.30UnsecuredSeniorNotesPayableMember2026-01-012026-03-310001035443are:A4.30UnsecuredSeniorNotesPayableMember2025-12-310001035443are:A3.80UnsecuredSeniorNotesPayableMember2026-04-012026-06-300001035443are:A3.80UnsecuredSeniorNotesPayableMember2025-12-310001035443us-gaap:LineOfCreditMember2026-01-012026-03-310001035443us-gaap:LineOfCreditMember2025-01-012025-09-300001035443us-gaap:CommercialPaperMembersrt:MinimumMember2026-01-012026-06-300001035443us-gaap:CommercialPaperMembersrt:MaximumMember2026-01-012026-06-300001035443us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMember2026-04-300001035443us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMember2026-06-300001035443us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMember2025-12-310001035443us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2026-04-012026-06-300001035443us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2026-01-012026-06-300001035443us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2026-01-012026-03-310001035443are:December2025SharesRepurchaseProgramMember2026-06-300001035443are:December2025SharesRepurchaseProgramMember2026-01-012026-06-300001035443are:ATMCommonStockOfferingProgramEstablishedFebruary2024Member2024-02-150001035443are:ATMCommonStockOfferingProgramEstablishedFebruary2024Member2026-06-3000010354432026-01-012026-03-310001035443us-gaap:CorporateMember2026-01-012026-06-300001035443us-gaap:CorporateAndOtherMember2026-01-012026-06-300001035443are:IncomeFromRentalsMemberus-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2026-04-012026-06-300001035443are:IncomeFromRentalsMemberus-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2025-04-012025-06-300001035443are:IncomeFromRentalsMemberus-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2026-01-012026-06-300001035443are:IncomeFromRentalsMemberus-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2025-01-012025-06-300001035443us-gaap:ProductAndServiceOtherMemberus-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2026-04-012026-06-300001035443us-gaap:ProductAndServiceOtherMemberus-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2025-04-012025-06-300001035443us-gaap:ProductAndServiceOtherMemberus-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2026-01-012026-06-300001035443us-gaap:ProductAndServiceOtherMemberus-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2025-01-012025-06-300001035443us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2026-04-012026-06-300001035443us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2025-04-012025-06-300001035443us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2026-01-012026-06-300001035443us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2025-01-012025-06-300001035443us-gaap:AllOtherSegmentsMember2026-04-012026-06-300001035443us-gaap:AllOtherSegmentsMember2025-04-012025-06-300001035443us-gaap:AllOtherSegmentsMember2026-01-012026-06-300001035443us-gaap:AllOtherSegmentsMember2025-01-012025-06-300001035443us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2026-06-300001035443us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2025-12-310001035443us-gaap:AllOtherSegmentsMember2026-06-300001035443us-gaap:AllOtherSegmentsMember2025-12-310001035443are:MarcE.BindaMember2026-04-012026-06-300001035443are:MarcE.BindaMember2026-06-300001035443are:HallieE.KuhnMember2026-04-012026-06-300001035443are:HallieE.KuhnMember2026-06-300001035443are:HartColeMember2026-04-012026-06-300001035443are:HartColeMember2026-06-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q 
(Mark One)
    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
          EXCHANGE ACT OF 1934 
For the quarterly period ended June 30, 2026
OR
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ____________ to ____________
Commission file number 1-12993
ALEXANDRIA REAL ESTATE EQUITIES, INC.
(Exact name of registrant as specified in its charter)
Maryland
 
95-4502084
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer Identification Number)
 26 North Euclid Avenue, Pasadena, California 91101
(Address of principal executive offices) (Zip code)
(626) 578-0777
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par value per share
ARE
New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes   No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and
posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period
that the registrant was required to submit and post such files). Yes   No 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting
company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Smaller reporting company 
Accelerated filer 
Emerging growth company 
Non-accelerated filer
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   No
As of July 15, 2026, 174,247,570 shares of common stock, par value $0.01 per share, were outstanding.
i
TABLE OF CONTENTS
 
 
Page
 
 
 
 
Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025 .............................................................
 
Consolidated Financial Statements for the Three and Six Months Ended June 30, 2026 and 2025:
 
Consolidated Statements of Operations ...................................................................................................................
 
 
Consolidated Statements of Comprehensive Income ............................................................................................
 
 
 
Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2026 and 2025 ................................
 
 
Notes to Consolidated Financial Statements ....................................................................................................................
 
OPERATIONS ........................................................................................................................................................................
 
 
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK .........................................................
 
 
CONTROLS AND PROCEDURES .....................................................................................................................................
LEGAL PROCEEDINGS ......................................................................................................................................................
RISK FACTORS ....................................................................................................................................................................
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS ...................................................
OTHER INFORMATION .......................................................................................................................................................
EXHIBITS ...............................................................................................................................................................................
 
 
SIGNATURES .................................................................................................................................................................................................
ii
GLOSSARY
The following abbreviations or acronyms that may be used in this document
have the meanings set forth below:
ASU
Accounting Standards Update
ATM
At the Market
CAD
Canadian Dollar
CIP
Construction in Progress
EPS
Earnings per Share
FASB
Financial Accounting Standards Board
FFO
Funds From Operations
GAAP
U.S. Generally Accepted Accounting Principles
IRS
Internal Revenue Service
JV
Joint Venture
Nareit
National Association of Real Estate Investment Trusts
NAV
Net Asset Value
NYSE
New York Stock Exchange
REIT
Real Estate Investment Trust
RSF
Rentable Square Feet/Foot
SEC
Securities and Exchange Commission
SF
Square Feet/Foot
SoDo
South of Downtown submarket of Seattle
SOFR
Secured Overnight Financing Rate
U.S.
United States
USD
U.S. Dollar
VIE
Variable Interest Entity
1
PART I – FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
Alexandria Real Estate Equities, Inc.
Consolidated Balance Sheets
(In thousands)
June 30, 2026
December 31, 2025
(Unaudited)
Assets
Investments in real estate
$29,125,895
$28,689,996
Investments in unconsolidated real estate joint ventures
28,910
30,677
Cash and cash equivalents
470,449
549,062
Restricted cash
4,690
4,693
Tenant receivables
7,661
6,672
Deferred rent
1,209,722
1,179,403
Deferred leasing costs
453,761
458,311
Investments
1,685,695
1,501,249
Other assets
1,645,443
1,661,772
Total assets
$34,632,226
$34,081,835
Liabilities, Noncontrolling Interests, and Equity
Unsecured senior notes payable
$10,818,366
$12,047,394
Unsecured senior line of credit and commercial paper
1,994,508
353,161
Accounts payable, accrued expenses, and other liabilities
2,513,526
2,397,073
Dividends payable
130,468
127,771
Total liabilities
15,456,868
14,925,399
Commitments and contingencies
Redeemable noncontrolling interests
9,119
58,788
Alexandria Real Estate Equities, Inc.’s stockholders’ equity:
Common stock
1,707
1,705
Additional paid-in capital
15,585,296
15,497,760
Accumulated other comprehensive loss
(33,027)
(29,395)
Alexandria Real Estate Equities, Inc.’s stockholders’ equity
15,553,976
15,470,070
Noncontrolling interests
3,612,263
3,627,578
Total equity
19,166,239
19,097,648
Total liabilities, noncontrolling interests, and equity
$34,632,226
$34,081,835
The accompanying notes are an integral part of these consolidated financial statements.
2
Alexandria Real Estate Equities, Inc.
Consolidated Statements of Operations
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Revenues:
Income from rentals
$643,210
$737,279
$1,296,223
$1,480,454
Other income
19,574
24,761
37,583
39,744
Total revenues
662,784
762,040
1,333,806
1,520,198
Expenses:
Rental operations
207,336
224,433
431,478
450,828
General and administrative
36,861
29,128
71,546
59,803
Interest
64,342
55,296
128,926
106,172
Depreciation and amortization
304,384
346,123
609,825
688,185
Impairment of real estate
222,470
129,606
227,969
161,760
Total expenses
835,393
784,586
1,469,744
1,466,748
Equity in earnings (losses) of unconsolidated real estate joint
ventures
413
(9,021)
266
(9,528)
Investment income (losses)
133,227
(30,622)
128,645
(80,614)
Gain on early extinguishment of debt
366,435
Gain on sales of real estate
13,165
Net (loss) income
(38,969)
(62,189)
359,408
(23,527)
Net income attributable to noncontrolling interests
(33,814)
(44,813)
(70,538)
(92,414)
Net (loss) income attributable to Alexandria Real Estate Equities,
Inc.’s stockholders
(72,783)
(107,002)
288,870
(115,941)
Net income attributable to unvested restricted stock awards
(908)
(2,609)
(2,149)
(5,269)
Net (loss) income attributable to Alexandria Real Estate Equities,
Inc.’s common stockholders
$(73,691)
$(109,611)
$286,721
$(121,210)
Net (loss) income per share attributable to Alexandria Real Estate
Equities, Inc.’s common stockholders:
Basic
$(0.43)
$(0.64)
$1.68
$(0.71)
Diluted
$(0.43)
$(0.64)
$1.68
$(0.71)
The accompanying notes are an integral part of these consolidated financial statements.
3
Alexandria Real Estate Equities, Inc.
Consolidated Statements of Comprehensive Income
(In thousands)
(Unaudited)
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Net (loss) income
$(38,969)
$(62,189)
$359,408
$(23,527)
Other comprehensive (loss) income
Change in foreign currency translation adjustments:
Unrealized foreign currency translation (losses)
gains arising during the period
(2,091)
18,787
(3,609)
18,837
Reclassification of gains
(23)
Unrealized (losses) gains on foreign currency
translation, net
(2,091)
18,787
(3,632)
18,837
Total other comprehensive (loss) income
(2,091)
18,787
(3,632)
18,837
Comprehensive (loss) income
(41,060)
(43,402)
355,776
(4,690)
Less: comprehensive income attributable to
noncontrolling interests
(33,814)
(44,813)
(70,538)
(92,414)
Comprehensive (loss) income attributable to Alexandria
Real Estate Equities, Inc.’s stockholders
$(74,874)
$(88,215)
$285,238
$(97,104)
The accompanying notes are an integral part of these consolidated financial statements.
4
Alexandria Real Estate Equities, Inc.
Consolidated Statement of Changes in Stockholders’ Equity and Noncontrolling Interests
(Dollars in thousands)
(Unaudited)
Alexandria Real Estate Equities, Inc.’s Stockholders’ Equity
Number of
Common
Shares
Common
Stock
Additional
Paid-In
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
Noncontrolling
Interests
Total
Equity
Redeemable
Noncontrolling
Interests
Balance as of March 31, 2026
170,712,290
$1,707
$15,763,321
$
$(30,936)
$3,620,414
$19,354,506
$9,234
Net (loss) income
(72,783)
33,622
(39,161)
192
Total other comprehensive loss
(2,091)
(2,091)
Contributions from and sales of noncontrolling interests
(716)
10,288
9,572
Distributions to and redemption of noncontrolling interests
(52,061)
(52,061)
(307)
Issuance pursuant to stock plan
26,501
21,399
21,399
Taxes related to the net settlement of equity awards
(9,875)
(477)
(477)
Dividends declared on common stock ($0.72 per share)
(125,448)
(125,448)
Reclassification of net loss and distributions
(198,231)
198,231
Balance as of June 30, 2026
170,728,916
$1,707
$15,585,296
$
$(33,027)
$3,612,263
$19,166,239
$9,119
The accompanying notes are an integral part of these consolidated financial statements.
5
Alexandria Real Estate Equities, Inc.
Consolidated Statement of Changes in Stockholders’ Equity and Noncontrolling Interests
(Dollars in thousands)
(Unaudited)
Alexandria Real Estate Equities, Inc.’s Stockholders’ Equity
Number of
Common
Shares
Common
Stock
Additional
Paid-In
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
Noncontrolling
Interests
Total
Equity
Redeemable
Noncontrolling
Interests
Balance as of March 31, 2025
170,129,883
$1,701
$17,509,148
$
$(46,202)
$4,525,299
$21,989,946
$9,612
Net (loss) income
(107,002)
44,612
(62,390)
201
Total other comprehensive income
18,787
18,787
Contributions from and sales of noncontrolling interests
19
41,628
41,647
Distributions to and redemption of noncontrolling interests
(57,383)
(57,383)
(201)
Issuance pursuant to stock plan
25,786
27,776
27,776
Taxes related to the net settlement of equity awards
(9,600)
(693)
(693)
Dividends declared on common stock ($1.32 per share)
(228,299)
(228,299)
Reclassification of net loss and distributions
(335,301)
335,301
Balance as of June 30, 2025
170,146,069
$1,701
$17,200,949
$
$(27,415)
$4,554,156
$21,729,391
$9,612
The accompanying notes are an integral part of these consolidated financial statements.
6
Alexandria Real Estate Equities, Inc.
Consolidated Statement of Changes in Stockholders’ Equity and Noncontrolling Interests
(Dollars in thousands)
(Unaudited)
Alexandria Real Estate Equities, Inc.’s Stockholders’ Equity
Number of
Common
Shares
Common
Stock
Additional
Paid-In
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
Noncontrolling
Interests
Total
Equity
Redeemable
Noncontrolling
Interests
Balance as of December 31, 2025
170,537,867
$1,705
$15,497,760
$
$(29,395)
$3,627,578
$19,097,648
$58,788
Net income
288,870
69,999
358,869
539
Total other comprehensive loss
(3,632)
(3,632)
Contributions from and sales of noncontrolling interests
6,363
26,665
33,028
Distributions to and redemption of noncontrolling interests
(111,979)
(111,979)
(50,208)
Issuance pursuant to stock plan
315,986
3
49,661
49,664
Taxes related to the net settlement of equity awards
(124,937)
(1)
(6,437)
(6,438)
Dividends declared on common stock ($1.44 per share)
(250,921)
(250,921)
Reclassification of earnings in excess of distributions
37,949
(37,949)
Balance as of June 30, 2026
170,728,916
$1,707
$15,585,296
$
$(33,027)
$3,612,263
$19,166,239
$9,119
The accompanying notes are an integral part of these consolidated financial statements.
7
Alexandria Real Estate Equities, Inc.
Consolidated Statement of Changes in Stockholders’ Equity and Noncontrolling Interests
(Dollars in thousands)
(Unaudited)
Alexandria Real Estate Equities, Inc.’s Stockholders’ Equity
Number of
Common
Shares
Common
Stock
Additional
Paid-In
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
Noncontrolling
Interests
Total
Equity
Redeemable
Noncontrolling
Interests
Balance as of December 31, 2024
172,203,443
$1,722
$17,933,572
$
$(46,252)
$4,489,447
$22,378,489
$19,972
Net (loss) income
(115,941)
91,943
(23,998)
471
Total other comprehensive income
18,837
18,837
Contributions from and sales of noncontrolling interests
73
95,982
96,055
Distributions to and redemption of noncontrolling interests
(7,048)
(123,216)
(130,264)
(10,831)
Issuance pursuant to stock plan
151,066
1
60,531
60,532
Taxes related to the net settlement of equity awards
(56,147)
(5,428)
(5,428)
Repurchase of common stock
(2,152,293)
(22)
(208,165)
(208,187)
Dividends declared on common stock ($2.64 per share)
(456,645)
(456,645)
Reclassification of net loss and distributions
(572,586)
572,586
Balance as of June 30, 2025
170,146,069
$1,701
$17,200,949
$
$(27,415)
$4,554,156
$21,729,391
$9,612
The accompanying notes are an integral part of these consolidated financial statements.
8
Alexandria Real Estate Equities, Inc.
Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
Six Months Ended June 30,
2026
2025
Operating Activities:
Net income (loss)
$359,408
$(23,527)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization
609,825
688,185
Impairment of real estate
227,969
161,760
Gain on sales of real estate
(13,165)
Gain on early extinguishment of debt
(366,435)
Equity in (earnings) losses of unconsolidated real estate joint ventures
(266)
9,528
Distributions of earnings from unconsolidated real estate joint ventures
599
1,289
Amortization of loan fees
8,845
9,306
Amortization of debt discounts
672
684
Amortization of acquired above- and below-market leases
(13,996)
(25,418)
Deferred rent
(18,763)
(40,559)
Stock compensation expense
21,178
22,594
Investment (income) losses
(128,645)
80,614
Changes in operating assets and liabilities:
Tenant receivables
(1,018)
168
Deferred leasing costs
(38,593)
(43,727)
Other assets
423
(10,750)
Accounts payable, accrued expenses, and other liabilities
(127,611)
(148,792)
Net cash provided by operating activities
533,592
668,190
Investing Activities:
Proceeds from sales of real estate
4,766
149,027
Additions to investments in real estate
(949,318)
(1,081,006)
Sale of interests in unconsolidated real estate joint ventures
1,917
Investments in unconsolidated real estate joint ventures
(557)
(11,055)
Change in escrow deposits
(8,108)
Return of capital from unconsolidated real estate joint ventures
113
Additions to non-real estate investments
(127,740)
(120,645)
Sales of and distributions from non-real estate investments
76,273
42,134
Net cash used in investing activities
$(994,546)
$(1,029,653)
9
Alexandria Real Estate Equities, Inc.
Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
Six Months Ended June 30,
2026
2025
Financing Activities:
Borrowings under secured note payable
$
$4,029
Repayments of borrowings under secured notes payable
(8,892)
Proceeds from issuance of unsecured senior notes payable
747,592
548,532
Repayments of unsecured senior notes payable
(1,602,203)
(600,000)
Proceeds from issuances under commercial paper program
24,727,914
8,468,015
Repayments of borrowings under commercial paper program
(23,084,555)
(7,368,015)
Payments of loan fees
(8,813)
(5,406)
Taxes paid related to net settlement of equity awards
(6,438)
(6,271)
Repurchase of common stock
(208,187)
Dividends on common stock
(247,594)
(457,217)
Contributions from and sales of noncontrolling interests
27,636
96,055
Distributions to noncontrolling interests
(111,860)
(123,618)
Purchases and redemptions of noncontrolling interests
(49,822)
(17,818)
Net cash provided by financing activities
382,965
330,099
Effect of foreign exchange rate changes on cash and cash equivalents
(627)
(535)
Net decrease in cash, cash equivalents, and restricted cash
(78,616)
(31,899)
Cash, cash equivalents, and restricted cash as of the beginning of period
553,755
559,847
Cash, cash equivalents, and restricted cash as of the end of period
$475,139
$527,948
Supplemental Disclosure and Non-Cash Investing and Financing Activities:
Cash paid during the period for interest, net of interest capitalized
$126,481
$87,986
Accrued construction for current-period additions to real estate
$216,572
$206,036
Transfer of real estate assets and/or equipment from tenants
$371,746
$171,153
Acquisition of real estate and other assets in connection with the assumption of related
secured notes payable of an unconsolidated real estate joint venture
$8,892
$
Notes receivable issued in connection with sales of real estate
$
$91,000
Derecognition of net investment in real estate from sales-type lease
$
$4,677
The accompanying notes are an integral part of these consolidated financial statements.
10
Alexandria Real Estate Equities, Inc.
Notes to Consolidated Financial Statements
(Unaudited)
1.ORGANIZATION AND BASIS OF PRESENTATION
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® life science REIT, is the pioneer of the life science real estate
niche since its founding in 1994. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative
Megacampus™ ecosystems in AAA life science and advanced technology innovation cluster locations, including Greater Boston, San
Diego, the San Francisco Bay Area, Seattle, Maryland, Research Triangle, and New York City. As of June 30, 2026, Alexandria has a
total market capitalization of $21.84 billion and an asset base that includes 36.0 million RSF of operating properties and 2.8 million RSF
of Class A/A+ properties undergoing construction. As used in this quarterly report on Form 10-Q, references to the “Company,”
“Alexandria,” “ARE,” “we,” “us,” and “our” refer to Alexandria Real Estate Equities, Inc. and its consolidated subsidiaries. The
accompanying unaudited consolidated financial statements include the accounts of Alexandria Real Estate Equities, Inc. and its
consolidated subsidiaries. All significant intercompany balances and transactions have been eliminated.
We have prepared the accompanying interim consolidated financial statements in accordance with GAAP and in conformity
with the rules and regulations of the SEC. In our opinion, these interim consolidated financial statements presented herein reflect all
adjustments of a normal recurring nature necessary to fairly present the interim consolidated financial statements. The results of
operations for the interim period are not necessarily indicative of the results that may be expected for the year ending December 31,
2026. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial
statements and the notes thereto included in our annual report on Form 10-K for the year ended December 31, 2025. Any references to
our total market capitalization, number or quality of buildings or tenants, quality of location, square footage, number of leases, or
occupancy percentage, and any amounts derived from these values in these notes to consolidated financial statements are outside the
scope of our independent registered public accounting firm’s procedures.
2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Consolidation
On an ongoing basis, as circumstances indicate the need for reconsideration, we evaluate each legal entity that is not wholly
owned by us in accordance with the consolidation accounting guidance. Our evaluation considers all of our variable interests, including
equity ownership, as well as fees paid to us for our involvement in the management of each partially owned entity. To fall within the
scope of the consolidation guidance, an entity must meet both of the following criteria:
The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity
can be in the form of a partnership, limited liability company, or corporation, among others; and
We have a variable interest in the legal entity — i.e., variable interests that are contractual, such as equity ownership, or
other financial interests that change with changes in the fair value of the entity’s net assets.
If an entity does not meet both criteria above, we apply other accounting literature, such as the equity method of accounting. If
an entity does meet both criteria above, we evaluate such entity for consolidation under either the variable interest model if the legal
entity meets any of the characteristics below to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.
A legal entity is determined to be a VIE if it has any of the following three characteristics:
1)The entity does not have sufficient equity to finance its activities without additional subordinated financial support;
2)The entity is established with non-substantive voting rights (i.e., the entity deprives the majority economic interest
holder(s) of voting rights); or
3)The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion
if they lack any of the following:
The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence
the entity’s economic performance, as evidenced by:
Substantive participating rights in day-to-day management of the entity’s activities; or
Substantive kick-out rights over the party responsible for significant decisions;
The obligation to absorb the entity’s expected losses; or
The right to receive the entity’s expected residual returns.
11
2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
For an entity, including our real estate joint ventures, structured as a limited partnership or a limited liability company, our
evaluation of whether the equity holders (equity partners other than the general partner or the managing member of a joint venture) lack
the characteristics of a controlling financial interest includes the evaluation of whether the limited partners or non-managing members
(the noncontrolling equity holders) lack both substantive participating rights and substantive kick-out rights, defined as follows:
Participating rights provide the noncontrolling equity holders the ability to direct significant financial and operating
decisions made in the ordinary course of business that most significantly influence the entity’s economic performance.
Kick-out rights allow the noncontrolling equity holders to remove the general partner or managing member without cause.
If we conclude that any of the three characteristics of a VIE is met, including that the equity holders lack the characteristics of a
controlling financial interest because they lack both substantive participating rights and substantive kick-out rights, we conclude that the
entity is a VIE and evaluate it for consolidation under the variable interest model.
Variable interest model
If an entity is determined to be a VIE, we evaluate whether we are the primary beneficiary. The primary beneficiary analysis is
a qualitative analysis based on power and benefits. We consolidate a VIE if we have both power and benefits — that is, (i) we have the
power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power) and (ii) we have the
obligation to absorb losses of or the right to receive benefits from the VIE that could potentially be significant to the VIE (benefits). We
consolidate VIEs whenever we determine that we are the primary beneficiary. Refer to Note 4 – “Consolidated and unconsolidated real
estate joint ventures” and Note 7 – “Investments” to our unaudited consolidated financial statements for information on specific entities
that qualify as VIEs. If we have a variable interest in a VIE but are not the primary beneficiary, we account for our investment using the
equity method.
Voting model
If a legal entity fails to meet any of the three characteristics of a VIE (i.e., insufficiency of equity, existence of non-substantive
voting rights, or lack of a controlling financial interest), we then evaluate such entity under the voting model. Under the voting model, we
consolidate the entity if we determine that we, directly or indirectly, have greater than 50% of the voting shares (or own a majority of the
limited partnership’s kick-out rights through voting interests), and that other equity holders do not have substantive participating rights.
Refer to Note 4 – “Consolidated and unconsolidated real estate joint ventures” to our unaudited consolidated financial statements for
information on specific real estate joint ventures that qualify for evaluation under the voting model.
Noncontrolling interests in consolidated real estate joint ventures
Noncontrolling interests represent the third-party interests in consolidated real estate joint ventures in which we have a
controlling interest. Certain of our partners’ noncontrolling interests have the right to require us to redeem their ownership interests in
the respective entities. We classify the ownership interests in these entities as redeemable noncontrolling interests outside of total
equity in our consolidated balance sheets. Redeemable noncontrolling interests are adjusted for additional contributions and
distributions, the proportionate share of net earnings or losses, and other comprehensive income or loss. If the amount of a redeemable
noncontrolling interest is less than the maximum redemption value at the balance sheet date, such amount is adjusted to the maximum
redemption value. Subsequent declines in the redemption value are recognized only to the extent that previous increases have been
recognized.
Use of estimates
The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions
that affect the reported amounts of assets, liabilities, and equity; the disclosure of contingent assets and liabilities as of the date of the
consolidated financial statements; and the amounts of revenues and expenses during the reporting period. Actual results could
materially differ from those estimates.
12
2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Investments in real estate
Evaluation of business combination or asset acquisition
We evaluate each acquisition of real estate or in-substance real estate (including equity interests in entities that predominantly
hold real estate assets) to determine whether the integrated set of assets and activities acquired meets the definition of a business and
must be accounted for as a business combination. An acquisition of an integrated set of assets and activities that does not meet the
definition of a business is accounted for as an asset acquisition. If either of the following criteria is met, the integrated set of assets and
activities acquired would not qualify as a business:
Substantially all of the fair value of the gross assets acquired is concentrated in either a single identifiable asset or a group
of similar identifiable assets; or
The integrated set of assets and activities is lacking, at a minimum, an input and a substantive process that together
significantly contribute to the ability to create outputs (i.e., revenue generated before and after the transaction).
An acquired process is considered substantive if:
The process includes an organized workforce (or includes an acquired contract that provides access to an organized
workforce) that is skilled, knowledgeable, and experienced in performing the process;
The process cannot be replaced without significant cost, effort, or delay; or
The process is considered unique or scarce.
Generally, our acquisitions of real estate or in-substance real estate do not meet the definition of a business because
substantially all of the fair value is concentrated in a single identifiable asset or group of similar identifiable assets (i.e., land, buildings,
and related intangible assets) or because the acquisition does not include a substantive process in the form of an acquired workforce or
an acquired contract that cannot be replaced without significant cost, effort, or delay. When evaluating acquired service or management
contracts, we consider the nature of the services performed, the terms of the contract relative to similar arm’s-length contracts, and the
availability of comparable vendors in evaluating whether the acquired contract constitutes a substantive process.
Recognition of real estate acquired
We evaluate each acquisition of real estate or in-substance real estate (including equity interests in entities that predominantly
hold real estate assets) to determine whether the integrated set of assets and activities acquired meets the definition of a business and
must be accounted for as a business combination. An acquisition of an integrated set of assets and activities that does not meet the
definition of a business is accounted for as an asset acquisition.
For acquisitions of real estate or in-substance real estate that are accounted for as business combinations, we allocate the
acquisition consideration (excluding acquisition costs) to the assets acquired, liabilities assumed, noncontrolling interests, and
previously existing ownership interests at fair value as of the acquisition date. Assets include intangible assets such as tenant
relationships, acquired in-place leases, and favorable intangibles associated with in-place leases in which we are the lessor. Liabilities
include unfavorable intangibles associated with in-place leases in which we are the lessor. In addition, for acquired in-place finance or
operating leases in which we are the lessee, acquisition consideration is allocated to lease liabilities and related right-of-use assets,
adjusted to reflect favorable or unfavorable terms of the lease when compared with market terms. Any excess (deficit) of the
consideration transferred relative to the fair value of the net assets acquired is accounted for as goodwill (bargain purchase gain).
Acquisition costs related to business combinations are expensed as incurred.
Generally, we expect that acquisitions of real estate or in-substance real estate will not meet the definition of a business
because substantially all of the fair value is concentrated in a single identifiable asset or group of similar identifiable assets (i.e., land,
buildings, and related intangible assets). The accounting model for asset acquisitions is similar to the accounting model for business
combinations, except that the acquisition consideration (including acquisition costs) is allocated to the individual assets acquired and
liabilities assumed on a relative fair value basis. Any excess (deficit) of the consideration transferred relative to the sum of the fair value
of the assets acquired and liabilities assumed is allocated to the individual assets and liabilities based on their relative fair values. As a
result, asset acquisitions do not result in the recognition of goodwill or a bargain purchase gain. Incremental and external direct
acquisition costs related to acquisitions of real estate or in-substance real estate (such as legal and other third-party services) are
capitalized.
13
2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
We exercise judgment to determine the key assumptions used to allocate the purchase price of real estate acquired among its
components. The allocation of the consideration to the various components of properties acquired during the year can have an effect on
our net income due to the useful depreciable and amortizable lives applicable to each component and the recognition of the related
depreciation and amortization expense in our consolidated statements of operations. We apply judgment in utilizing available
comparable market information to assess relative fair value. We assess the relative fair values of tangible and intangible assets and
liabilities based on available comparable market information, including estimated replacement costs, rental rates, and recent market
transactions. In addition, we may use estimated cash flow projections that utilize appropriate discount and capitalization rates.
Estimates of future cash flows are based on a number of factors, including the historical operating results, known and anticipated
trends, and market/economic conditions that may affect the property.
The value of tangible assets acquired is based upon our estimation of fair value on an “as if vacant” basis. The value of
acquired in-place leases includes the estimated costs during the hypothetical lease-up period and other costs that would have been
incurred in the execution of similar leases under the market conditions at the acquisition date of the acquired in-place lease. If there is a
bargain fixed-rate renewal option for the period beyond the noncancelable lease term of an in-place lease, we evaluate intangible
factors, such as the business conditions in the industry in which the lessee operates, the economic conditions in the area in which the
property is located, and the ability of the lessee to sublease the property during the renewal term, in order to determine the likelihood
that the lessee will renew. When we determine that the lessee is reasonably certain to exercise such bargain renewal option, we
consider the option in determining the intangible value of such lease and its related amortization period. We also recognize the relative
fair values of assets acquired, the liabilities assumed, and any noncontrolling interest in acquisitions of less than a 100% interest when
the acquisition constitutes a change in control of the acquired entity.
Depreciation and amortization
The values allocated to buildings and building improvements, land improvements, tenant improvements, and equipment are
depreciated on a straight-line basis. For buildings and building improvements, we depreciate using the shorter of the respective ground
lease terms or their estimated useful lives, not to exceed 40 years. Land improvements are depreciated over their estimated useful
lives, not to exceed 20 years. Tenant improvements are depreciated over their respective lease terms or estimated useful lives, and
equipment is depreciated over the shorter of the lease term or its estimated useful life. Right-of-use assets are amortized on a straight-
line basis over the remaining terms of each related lease. The values of acquired in-place leases and associated favorable intangibles
(i.e., acquired above-market leases) are classified in other assets in our consolidated balance sheets and are amortized over the
remaining terms of the related leases as a reduction of income from rentals in our consolidated statements of operations. The values of
unfavorable intangibles (i.e., acquired below-market leases) associated with acquired in-place leases are classified in accounts
payable, accrued expenses, and other liabilities in our consolidated balance sheets and are amortized over the remaining terms of the
related leases as an increase in income from rentals in our consolidated statements of operations.
Capitalized project costs
We capitalize project costs, including pre-construction costs, interest, property taxes, insurance, and other costs directly
related and essential to the development, redevelopment, pre-construction, or construction of a project. Capitalization of development,
redevelopment, pre-construction, and construction costs is required while activities are ongoing to prepare an asset for its intended use.
Fluctuations in our development, redevelopment, pre-construction, and construction activities could result in significant changes to total
expenses and net income. Costs incurred after a project is substantially complete and ready for its intended use are expensed as
incurred. Should development, redevelopment, pre-construction, or construction activity cease, interest, property taxes, insurance, and
certain other costs would no longer be eligible for capitalization and would be expensed as incurred. Expenditures for repairs and
maintenance are expensed as incurred.
Real estate sales
A property is classified as held for sale when all of the following criteria for a plan of sale have been met: (i) management,
having the authority to approve the action, commits to a plan to sell the property; (ii) the property is available for immediate sale in its
present condition, subject only to terms that are usual and customary; (iii) an active program to locate a buyer and other actions
required to complete the plan to sell have been initiated; (iv) the sale of the property is probable and is expected to be completed within
one year; (v) the property is being actively marketed for sale at a price that is reasonable in relation to its current fair value; and
(vi) actions necessary to complete the plan of sale indicate that it is unlikely that significant changes to the plan will be made or that the
plan will be withdrawn. Depreciation of assets ceases upon designation of a property as held for sale.
If the disposal of a property represents a strategic shift that has (or will have) a major effect on our operations or financial
results, such as (i) a major line of business, (ii) a major geographic area, (iii) a major equity method investment, or (iv) other major parts
of an entity, then the operations of the property, including any interest expense directly attributable to it, are classified as discontinued
operations in our consolidated statements of operations, and amounts for all prior periods presented are reclassified from continuing
operations to discontinued operations. The disposal of an individual property generally will not represent a strategic shift and therefore
will typically not meet the criteria for classification as a discontinued operation.
14
2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
We recognize gains or losses on real estate sales in accordance with the accounting standard on the derecognition of
nonfinancial assets arising from contracts with noncustomers. Our ordinary output activities consist of the leasing of space to our
tenants in our operating properties, not the sales of real estate. Therefore, sales of real estate (in which we are the seller) qualify as
contracts with noncustomers. In our transactions with noncustomers, we apply certain recognition and measurement principles
consistent with our method of recognizing revenue arising from contracts with customers. Derecognition of the asset is based on the
transfer of control. If a real estate sales contract includes our ongoing involvement with the property, then we evaluate each promised
good or service under the contract to determine whether it represents a separate performance obligation, constitutes a guarantee, or
prevents the transfer of control. If a good or service is considered a separate performance obligation, an allocated portion of the
transaction price is recognized as revenue as we transfer the related good or service to the buyer.
The recognition of gain or loss on the sale of a partial interest also depends on whether we retain a controlling or
noncontrolling interest in the property. If we retain a controlling interest in the property upon completion of the sale, we continue to
reflect the asset at its book value, record a noncontrolling interest for the book value of the partial interest sold, and recognize additional
paid-in capital for the difference between the consideration received and the partial interest at book value. Conversely, if we retain a
noncontrolling interest upon completion of the sale of a partial interest of real estate, we recognize a gain or loss as if 100% of the asset
were sold.
Impairment of long-lived assets
Prior to and subsequent to the end of each quarter, we review current activities and changes in the business conditions of all of
our long-lived assets to determine the existence of any triggering events or impairment indicators requiring an impairment analysis. If
triggering events or impairment indicators are identified, we review an estimate of the future undiscounted cash flows, including, if
necessary, a probability-weighted approach if multiple outcomes are under consideration.
Long-lived assets to be held and used, including our rental properties, CIP, land held for development, right-of-use assets
related to operating leases in which we are the lessee, and intangibles, are individually evaluated for impairment when conditions exist
that may indicate that the carrying amount of a long-lived asset may not be recoverable. The carrying amount of a long-lived asset to be
held and used is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual
disposition of the asset. Triggering events or impairment indicators for long-lived assets to be held and used are assessed by project
and include significant fluctuations in estimated net operating income, occupancy changes, significant near-term lease expirations,
current and historical operating and/or cash flow losses, construction costs, estimated completion dates, rental rates, and other market
factors. We assess the expected undiscounted cash flows based upon numerous factors, including, but not limited to, projected rental
rates, estimated exit capitalization rates, and anticipated construction costs for projects under construction, which are based on
available market information, current and historical operating results, known trends, current market/economic conditions that may affect
the asset, and our assumptions about the use of the asset, including, if necessary, a probability-weighted approach if multiple outcomes
are under consideration. 
Upon determination that an impairment has occurred, a write-down is recognized to reduce the carrying amount of the asset to
its estimated fair value. If an impairment charge is not required to be recognized, the recognition of depreciation or amortization is
adjusted prospectively, as necessary, to reduce the carrying amount of the asset to its estimated disposition value over the remaining
period that the asset is expected to be held and used. We may adjust depreciation of properties that are expected to be disposed of or
redeveloped prior to the end of their useful lives.
We use the held for sale impairment model for our properties classified as held for sale, which is different from the held and
used impairment model. Under the held for sale impairment model, an impairment charge is recognized if the carrying amount of the
long-lived asset classified as held for sale exceeds its fair value less cost to sell. Because of these two different models, it is possible for
a long-lived asset previously classified as held and used to require the recognition of an impairment charge upon classification as held
for sale.
International operations
As of June 30, 2026, in addition to operating properties in the U.S., we had 11 properties in Canada. The functional currency
for our subsidiaries operating in the U.S. is the U.S. dollar. The local currency of a foreign subsidiary serves as its functional currency.
The assets and liabilities of our foreign subsidiaries are translated into U.S. dollars at the exchange rate in effect as of the financial
statement date. Revenue and expense accounts of our foreign subsidiaries are translated using the weighted-average exchange rate
for the periods presented. Gains or losses resulting from the translation are classified in accumulated other comprehensive income
(loss) as a separate component of total equity and are excluded from net income (loss).
15
2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Whenever a foreign investment meets the criteria for classification as held for sale, we evaluate the recoverability of the
investment under the held for sale impairment model. We may recognize an impairment charge if the carrying amount of the investment
exceeds its fair value less cost to sell. In determining an investment’s carrying amount, we consider its net book value and any
cumulative unrealized foreign currency translation adjustment related to the investment. The appropriate amounts of foreign exchange
rate gains or losses classified in accumulated other comprehensive income (loss) are reclassified to net income (loss) when realized
upon the sale of our investment or upon the complete or substantially complete liquidation of our investment.
Investments
We hold investments in publicly traded companies and privately held entities primarily involved in the life science industry. As a
REIT, we generally limit our ownership of each individual entity’s voting stock to less than 10%. We evaluate each investment to
determine whether we have the ability to exercise significant influence, but not control, over an investee. We evaluate investments in
which our ownership is equal to or greater than 20%, but less than or equal to 50%, of an investee’s voting stock with a presumption
that we have this ability. For our investments in limited partnerships that maintain specific ownership accounts, we presume that such
ability exists when our ownership interest exceeds 3% to 5%. In addition to our ownership interest, we consider whether we have a
board seat or whether we participate in the investee’s policy-making process, among other criteria, to determine if we have the ability to
exert significant influence, but not control, over an investee. If we determine that we have such ability, we account for the investment
under the equity method, as described below. From time to time, we may hold equity investments in publicly traded companies that are
subject to temporary contractual sale restrictions. We do not recognize a discount related to a contractual sale restriction.
Investments accounted for under the equity method
Under the equity method of accounting, we initially recognize our investment at cost and subsequently adjust the carrying
amount of the investment for our share of earnings or losses reported by the investee, distributions received, and other-than-temporary
impairments. For additional information about our investments accounted for under the equity method, refer to Note 7 – “Investments” to
our unaudited consolidated financial statements.
Investments that do not qualify for the equity method of accounting
For investees over which we determine that we do not have the ability to exercise significant influence or control, we account
for each investment depending on whether it is an investment in a (i) publicly traded company, (ii) privately held entity that reports NAV
per share, or (iii) privately held entity that does not report NAV per share, as described below.
Investments in publicly traded companies
Our investments in publicly traded companies are classified as investments with readily determinable fair values and are
presented at fair value in our consolidated balance sheets, with changes in fair value classified in investment income (loss) in our
consolidated statements of operations. The fair values for our investments in publicly traded companies are determined based on sales
prices or quotes available on securities exchanges.
Investments in privately held companies
Our investments in privately held entities without readily determinable fair values consist of (i) investments in privately held
entities that report NAV per share and (ii) investments in privately held entities that do not report NAV per share. These investments are
accounted for as follows:
Investments in privately held entities that report NAV per share
Investments in privately held entities that report NAV per share, such as our privately held investments in limited partnerships,
are presented at fair value using NAV as a practical expedient, with changes in fair value classified in investment income (loss) in our
consolidated statements of operations. We use NAV per share reported by limited partnerships generally without adjustment, unless we
are aware of information indicating that the NAV reported by a limited partnership does not accurately reflect the fair value of the
investment at our reporting date.
Investments in privately held entities that do not report NAV per share
Investments in privately held entities that do not report NAV per share are accounted for using a measurement alternative
under which these investments are measured at cost, adjusted for observable price changes and impairments, with changes classified
in investment income (loss) in our consolidated statements of operations.
16
2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
An observable price arises from an orderly transaction for an identical or similar investment of the same issuer, which is
observed by an investor without expending undue cost and effort. Observable price changes result from, among other things, equity
transactions of the same issuer executed during the reporting period, including subsequent equity offerings or other reported equity
transactions related to the same issuer. To determine whether these transactions are indicative of an observable price change, we
evaluate, among other factors, whether these transactions have similar rights and obligations, including voting rights, distribution
preferences, and conversion rights to the investments we hold.
Impairment evaluation of equity method investments and investments in privately held entities that do not report NAV per share
We monitor equity method investments and investments in privately held entities that do not report NAV per share for new
developments, including operating results, prospects and results of clinical trials, new product initiatives, new collaborative agreements,
capital-raising events, and merger and acquisition activities. These investments are evaluated on the basis of a qualitative assessment
for indicators of impairment by monitoring the presence of the following triggering events or impairment indicators:
(i)a significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee;
(ii)a significant adverse change in the regulatory, economic, or technological environment of the investee;
(iii)a significant adverse change in the general market condition, including the research and development of technology and
products that the investee is bringing or attempting to bring to the market;
(iv)significant concerns about the investee’s ability to continue as a going concern; and/or
(v)a decision by investors to cease providing support or reduce their financial commitment to the investee.
If such indicators are present, we are required to estimate the investment’s fair value and immediately recognize an
impairment charge in an amount equal to the investment’s carrying value in excess of its estimated fair value.
Investment income/loss recognition and classification
We recognize both realized and unrealized gains and losses in our consolidated statements of operations, classified in
investment income (loss) in our consolidated statements of operations. Unrealized gains and losses represent:
(i)changes in fair value for investments in publicly traded companies;
(ii)changes in NAV for investments in privately held entities that report NAV per share;
(iii)observable price changes for investments in privately held entities that do not report NAV per share; and
(iv)our share of unrealized gains or losses reported by our equity method investees.
Realized gains and losses on our investments represent the difference between proceeds received upon disposition of
investments and their historical or adjusted cost basis. For our equity method investments, realized gains and losses represent our
share of realized gains or losses reported by the investee. Impairments are realized losses, which result in an adjusted cost basis, and
represent charges to reduce the carrying values of investments in privately held entities that do not report NAV per share and equity
method investments, if impairments are deemed other than temporary, to their estimated fair value.
Revenues
The table below provides details of our consolidated total revenues for the three and six months ended June 30, 2026 and
2025 (in thousands):
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Income from rentals:
Revenues subject to the lease accounting standard:
Operating leases
$629,408
$722,935
$1,270,067
$1,454,356
Direct financing and sales-type leases
892
1,089
1,856
1,899
Revenues subject to the lease accounting standard
630,300
724,024
1,271,923
1,456,255
Revenues subject to the revenue recognition
accounting standard
12,910
13,255
24,300
24,199
Income from rentals
643,210
737,279
1,296,223
1,480,454
Other income
19,574
24,761
37,583
39,744
Total revenues
$662,784
$762,040
$1,333,806
$1,520,198
17
2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
During the three and six months ended June 30, 2026, revenues that were subject to the lease accounting standard
aggregated $630.3 million and $1.27 billion, respectively, and represented 95.1% and 95.4% of our total revenues. During the three and
six months ended June 30, 2025, revenues that were subject to the lease accounting standard aggregated $724.0 million and
$1.46 billion, respectively, and represented 95.0% and 95.8% of our total revenues. Our other income consisted primarily of
management fees and interest income earned during each period presented. For a detailed discussion related to our revenue streams,
refer to “Lease accounting” and “Recognition of revenue arising from contracts with customers” in Note 2 – “Summary of significant
accounting policies” to our unaudited consolidated financial statements.
Lease accounting
Definition and classification of a lease
When we enter into a contract or amend an existing contract, we evaluate whether the contract meets the definition of a lease.
To meet the definition of a lease, the contract must meet all three criteria:
(i)One party (lessor) must hold an identified asset;
(ii)The counterparty (lessee) must have the right to obtain substantially all of the economic benefits from the use of the asset
throughout the period of the contract; and
(iii)The counterparty (lessee) must have the right to direct the use of the identified asset throughout the period of the contract.
We classify our leases as either finance leases or operating leases if we are the lessee, or sales-type, direct financing, or
operating leases if we are the lessor. We use the following criteria to determine if a lease is a finance lease (as a lessee) or sales-type
or direct financing lease (as a lessor):
(i)Ownership is transferred from lessor to lessee by the end of the lease term;
(ii)An option to purchase is reasonably certain to be exercised;
(iii)The lease term is for the major part of the underlying asset’s remaining economic life;
(iv)The present value of lease payments equals or exceeds substantially all of the fair value of the underlying asset; or
(v)The underlying asset is specialized and is expected to have no alternative use at the end of the lease term.
If a lease meets any of the above criteria, we account for it as a finance, a sales-type, or a direct financing lease. If a lease
does not meet any of the criteria, we account for it as an operating lease.
A lease is accounted for as a sales-type lease if it is considered to transfer control of the underlying asset to the lessee. A
lease is accounted for as a direct financing lease if risks and rewards are conveyed without the transfer of control, which is normally
indicated by the existence of a residual value guarantee from an unrelated third party other than the lessee.
This classification will determine the method of recognition of the lease:
For an operating lease, we recognize income from rentals if we are the lessor, or rental operations expense if we are the
lessee, over the term of the lease on a straight-line basis.
For a sales-type lease or a direct financing lease, we recognize the income from rentals, or for a finance lease, we
recognize rental operations expense, over the term of the lease using the effective interest method.
At inception of a sales-type lease or a direct financing lease, if we determine the fair value of the leased property is lower
than its carrying amount, we recognize a selling loss immediately at lease commencement. If fair value exceeds the
carrying amount of a lease, a gain is recognized at lease commencement on a sales-type lease. For a direct financing
lease, a gain is deferred at lease commencement and amortized over the lease term.
18
2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Lessor accounting
Costs to execute leases
We capitalize initial direct costs, which represent only incremental costs to execute a lease that would not have been incurred
if the lease had not been obtained. Costs that we incur to negotiate or arrange a lease, regardless of its outcome, such as for fixed
employee compensation, tax or legal advice to negotiate lease terms, and other costs, are expensed as incurred.
Operating leases
We account for the revenue from our lease contracts by utilizing the single component accounting policy. This policy requires
us to account for, by class of underlying asset, the lease component and nonlease component(s) associated with each lease as a single
component if two criteria are met:
(i)The timing and pattern of transfer of the lease component and the nonlease component(s) are the same; and
(ii)The lease component would be classified as an operating lease if it were accounted for separately.
Lease components consist primarily of fixed rental payments, which represent scheduled rental amounts due under our
leases, and contingent rental payments. Nonlease components consist primarily of tenant recoveries representing reimbursements of
rental operating expenses under our triple net lease structure, including recoveries for property taxes, insurance, utilities, repairs and
maintenance, and common area expenses.
If the lease component is the predominant component, we account for all revenues under such lease as a single component in
accordance with the lease accounting standard. Conversely, if the nonlease component is the predominant component, all revenues
under such lease are accounted for in accordance with the revenue recognition accounting standard. Our operating leases qualify for
the single component accounting, and the lease component in each of our leases is predominant. Therefore, we account for all
revenues from our operating leases under the lease accounting standard and classify these revenues as income from rentals in our
consolidated statements of operations.
We commence recognition of income from rentals related to the operating leases at the date the property is ready for its
intended use by the tenant and the tenant takes possession or controls the physical use of the leased asset. When a lease includes
construction of improvements, we determine whether the improvements are landlord or tenant assets. In determining if the
improvements are landlord or tenant improvements, we consider various factors, including, but not limited to, the following:
Which party retains legal title to the improvements upon lease expiration;
Whether the improvements are expected to have significant residual value at the end of the lease term;
Whether the improvements are unique to the tenant;
What happens to the improvements upon lease expiration (i.e., whether they are removed or preserved for the landlord);
Which party bears all costs of the improvements (including the risk of cost overruns); and
Which party supervises the construction of the improvements.
If the improvements are landlord assets, we capitalize such improvements. If the improvements are tenant assets, we do not
capitalize these assets. Improvements that qualify as tenant assets, if funded by us, are accounted for as lease incentives and
amortized as a reduction of revenue over the term of the lease. If the tenant funds improvements without reimbursement from us, and
we determine these improvements to be landlord assets, we consider the amount associated with the improvements to be non-cash
lease payments, which are recognized as incremental revenue over the term of the related lease.
Income from rentals related to fixed rental payments under operating leases is recognized on a straight-line basis over the
respective operating lease terms. We classify amounts expected to be received in later periods as deferred rent in our consolidated
balance sheets. Amounts received currently but recognized as revenue in future periods are classified in accounts payable, accrued
expenses, and other liabilities in our consolidated balance sheets.
Income from rentals related to variable payments includes tenant recoveries and contingent rental payments. Tenant
recoveries, including reimbursements of utilities, repairs and maintenance, common area expenses, real estate taxes and insurance,
and other operating expenses, are recognized as revenue in the period during which the applicable expenses are incurred and the
tenant’s obligation to reimburse us arises. Income from rentals related to other variable payments is recognized when associated
contingencies are removed.
We assess collectibility of future lease payments from our tenants for each of our operating leases. If we determine that
collectibility is probable, we recognize income from rentals based on the methodology described above. If we determine that
collectibility is not probable, we recognize an adjustment to lower our income from rentals. Furthermore, we may recognize a general
allowance at a portfolio level (not the individual level) if we do not expect to collect future lease payments in full.
19
2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
For each lease for which we determine that collectibility of future lease payments is not probable, we cease the recognition of
income from rentals on a straight-line basis and limit the recognition of income to the lesser of payments collected from the lessee or
lease income that would have been recognized on a straight-line basis. We do not resume straight-line recognition of income from
rentals for these leases until we determine that the collectibility of future payments related to these leases is probable. We also record a
general allowance related to the deferred rent balances that at the portfolio level (not the individual level) are not expected to be
collected in full through the lease term. As of June 30, 2026 and December 31, 2025, our general allowance balance aggregated
$18.8 million and $14.3 million, respectively.
Direct financing and sales-type leases
Income from rentals related to direct financing and sales-type leases is recognized over the lease term using the effective
interest rate method. At lease commencement, we derecognize the underlying asset classified within investments in real estate and
record net investment in a lease within other assets in our consolidated balance sheets. This initial net investment is determined by
aggregating the present values of the total future lease payments and the estimated residual value of the property, less any unearned
income related to a direct financing lease. Over the lease term, the investment in the lease accretes in value, producing a constant
periodic rate of return on the net investment in the lease. Income from these leases is classified in income from rentals in our
consolidated statements of operations. Lease payments received reduce the net investment in the lease.
We evaluate our net investment in direct financing and sales-type leases for impairment under the current expected credit
losses accounting standard. For additional information, refer to “Provision for expected credit losses” in Note 2 – “Summary of
significant accounting policies” to our unaudited consolidated financial statements.
As a lessor, we classify a lease with variable lease payments that do not depend on an index or a rate as an operating lease
on the commencement date of the lease if both of the following criteria are met:
(i)The lease would have been classified as a sales-type lease or direct financing lease under the current lease accounting
standard; and
(ii)The sales-type lease or direct financing lease classification would have resulted in a selling loss at lease commencement.
We do not derecognize the underlying asset and do not recognize a loss upon lease commencement but continue to
depreciate the underlying asset over its useful life.
Lessee accounting
We have operating lease agreements in which we are the lessee consisting of ground and office leases. At the lease
commencement date (or at the acquisition date if the lease is acquired as part of a real estate acquisition), we are required to recognize
a liability to account for our future obligations under these operating leases, and a corresponding right-of-use asset.
The lease liability is measured based on the present value of the future lease payments, including payments during the term
under our extension options that we are reasonably certain to exercise. The present value of the future lease payments is calculated for
each operating lease using each respective remaining lease term and a corresponding estimated incremental borrowing rate, which is
the interest rate that we estimate we would have to pay to borrow on a collateralized basis over a similar term for an amount equal to
the lease payments. Subsequently, the lease liability is accreted by applying a discount rate established at the lease commencement
date to the lease liability balance as of the beginning of the period and is reduced by the payments made during the period. We classify
the operating lease liability in accounts payable, accrued expenses, and other liabilities in our consolidated balance sheets.
The right-of-use asset is measured based on the corresponding lease liability, adjusted for initial direct leasing costs and any
other consideration exchanged with the landlord prior to the commencement of the lease, as well as adjustments to reflect favorable or
unfavorable terms of an acquired lease when compared with market terms at the time of acquisition. Subsequently, the right-of-use
asset is amortized on a straight-line basis during the lease term. We classify the right-of-use asset in other assets in our consolidated
balance sheets.
Recognition of revenue arising from contracts with customers
We recognize revenues associated with transactions arising from contracts with customers, excluding revenues subject to the
lease accounting standard discussed in “Lease accounting” above, in accordance with the revenue recognition accounting standard. A
customer is distinguished from a noncustomer by the nature of the goods or services that are transferred. Customers are provided with
goods or services that are generated by a company’s ordinary output activities, whereas noncustomers are provided with nonfinancial
assets that are outside of a company’s ordinary output activities.
20
2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
We generally recognize revenue representing the transfer of goods and services to customers in an amount that reflects the
consideration to which we expect to be entitled in the exchange. In order to determine the recognition of revenue from customer
contracts, we use a five-step model to (i) identify the contract with the customer, (ii) identify the performance obligations in the contract,
(iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will
not occur, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) we
satisfy the performance obligation.
We identify contractual performance obligations and determine whether revenue should be recognized at a point in time or
over time, based on when control of goods and services transfers to a customer. We consider whether we control the goods or services
prior to the transfer to the customer in order to determine whether we should account for the arrangement as a principal or agent. If we
determine that we control the goods or services provided to the customer, then we are the principal to the transaction, and we recognize
the gross amount of consideration expected in the exchange. If we simply arrange but do not control the goods or services being
transferred to the customer, then we are considered to be an agent to the transaction, and we recognize the net amount of
consideration we are entitled to retain in the exchange.
Total revenues subject to the revenue recognition accounting standard and classified within income from rentals in our
consolidated statements of operations for the three and six months ended June 30, 2026 included $12.9 million and $24.3 million,
respectively, primarily related to short-term parking revenues associated with long-term lease agreements. Short-term parking revenues
do not qualify for the single component accounting policy, as discussed in “Lessor accounting” in Note 2 – “Summary of significant
accounting policies,” due to the difference in the timing and pattern of transfer of our parking service obligations and associated lease
components within the same lease agreement. We recognize short-term parking revenues in accordance with the revenue recognition
accounting standard when the service is provided and the performance obligation is satisfied, which normally occurs at a point in time.
Monitoring of tenant credit quality
During the term of each lease, we monitor the credit quality and any related material changes of our tenants by (i) monitoring
the credit rating of tenants that are rated by a nationally recognized credit rating agency, (ii) reviewing financial statements of the
tenants that are publicly available or that are required to be delivered to us pursuant to the applicable lease, (iii) monitoring news
reports regarding our tenants and their respective businesses, and (iv) monitoring the timeliness of lease payments.
Notes receivable
We carry notes receivable at amortized cost, adjusted for an estimated provision for expected credit losses. Interest income on
notes receivable is recognized using the effective interest rate method and is classified within other income in our consolidated
statements of operations. Direct costs incurred in originating notes, along with any premium or discount, are deferred and amortized as
an adjustment to interest income over the note’s term using the effective interest rate method. Notes receivable are classified within
other assets in our consolidated balance sheets. Refer to Note 8 – “Other assets” to our unaudited consolidated financial statements for
additional details.
Provision for expected credit losses
We are required to estimate and recognize lifetime expected losses, rather than incurred losses, for most financial assets
measured at amortized cost and certain other instruments, including trade, notes, and other receivables (excluding receivables arising
from operating leases), loans, held-to-maturity debt securities, net investments in leases arising from sales-type and direct financing
leases, and off-balance-sheet credit exposures (e.g., loan commitments). The recognition of such expected losses, even if the expected
risk of credit loss is remote, typically results in earlier recognition of credit losses. At each reporting date, we reassess our provision for
expected credit losses, and, if necessary, we recognize an adjustment for our current estimate of expected credit losses. Refer to
Note 5 – “Leases” and Note 8 – “Other assets” to our unaudited consolidated financial statements for additional details.
An assessment of the collectibility of operating lease payments and the recognition of an adjustment to lease income based on
this assessment is governed by the lease accounting standard discussed in “Lease accounting” earlier in Note 2 — “Summary of
significant accounting policies” to our unaudited consolidated financial statements.
Income taxes
We are organized and operate as a REIT pursuant to the Internal Revenue Code (the “Code”). Under the Code, a REIT that
distributes at least 90% of its REIT taxable income to its stockholders annually (excluding net capital gains) and meets certain other
conditions is not subject to federal income tax on its distributed taxable income, but could be subject to certain federal, foreign, state,
and local taxes. We distribute 100% of our taxable income annually; therefore, a provision for federal income taxes is not required. In
addition to our REIT returns, we file federal, foreign, state, and local tax returns for our subsidiaries. We file with jurisdictions located in
the U.S., Canada, and other international locations. Our tax returns are subject to routine examination in various jurisdictions for the
2020 through 2025 calendar years.
21
2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Employee and non-employee share-based awards
We have implemented an entity-wide accounting policy to account for forfeitures related to unmet service conditions of share-
based awards granted to employees and non-employees when they occur. Under this policy, when forfeitures occur, any previously
recognized expense related to those forfeited awards is reversed in the period of forfeiture.
Our employee and non-employee share-based awards are measured at fair value on the grant date and recognized over the
recipient’s required service period. For share-based awards with performance conditions, we continue to assess the probability of
achieving the performance conditions and recognize expense only when it becomes probable that the performance targets will be met.
Conversely, for share-based awards with market conditions, expense is recognized regardless of whether the market condition is met.
Dividends paid on share-based awards with nonforfeitable dividends are initially classified in retained earnings and reclassified
to compensation cost only if the underlying awards are forfeited. Conversely, for share-based awards with forfeitable dividends,
declared dividends are initially classified in retained earnings and in dividends payable within our consolidated balance sheets. If the
underlying awards are forfeited, the corresponding accrued dividend is reversed in the period of forfeiture. Upon vesting of the
underlying share-based awards with forfeitable dividends, the accumulated dividend payment is made and the dividend payable liability
is settled.
Forward equity sales agreements
From time to time, we enter into forward equity sales agreements and account for them in accordance with the accounting
guidance governing financial instruments and derivatives. Under the accounting guidance, our forward equity sales agreements are not
deemed to be liabilities as they do not embody obligations to repurchase our shares, nor do they embody obligations to issue a variable
number of shares for which the monetary value is predominantly fixed, varied with something other than the fair value of our shares, or
varied inversely in relation to our shares. We also evaluate whether the agreements meet the derivatives and hedging guidance scope
exception to be accounted for as equity instruments. Our forward equity sales agreements are classified as equity contracts based on
the following assessment: (i) none of the agreements’ exercise contingencies are based on observable markets or indices besides
those related to the market for our own stock price and operations; and (ii) none of the settlement provisions preclude the agreements
from being indexed to our own stock.
Hedge accounting
From time to time, we utilize derivative instruments to manage our exposure to certain risks, including interest rate and foreign
currency exchange rate risks. We are exposed to foreign currency exchange rate risk related to our net investment in Canada. To
mitigate the impact of fluctuations in the USD-CAD exchange rate associated with our net investment in Canada, we use cross-currency
swap agreements designated and qualifying as net investment hedges under applicable derivatives and hedging standards.
We designate the USD-CAD cross-currency swap agreements as net investment hedges using the spot method to assess
hedge effectiveness. The spot component represents changes in fair value attributable to movements in the USD-CAD spot exchange
rate, which reflects the market exchange rate between the two currencies as of each reporting date. Changes in the fair value of the
designated spot component are recorded in other comprehensive income (loss) as part of the foreign currency translation adjustment,
to the extent the relationship is highly effective, until the net investment is sold or substantially liquidated. The related amounts due from
or due to counterparties are included in other assets or in accounts payable, accrued expenses, and other liabilities, respectively, within
our consolidated balance sheet.
We elected to account for the forward points (the portion of the derivative’s fair value attributable to the difference between the
forward exchange rate and spot exchange rate) as an excluded component in accordance with applicable derivatives and hedging
accounting standards. The excluded component is recognized over the life of the cross-currency swap agreements using a systematic
and rational basis (as interest settlements occur) and is classified within other income in our consolidated statement of operations.
Issuer and guarantor subsidiaries of guaranteed securities
Generally, a parent entity of an issuer that holds guaranteed securities must provide separate subsidiary issuer or guarantor
financial statements, unless it qualifies for disclosure exceptions. A parent entity may be eligible for disclosure exceptions if it meets the
following criteria:
(i)The subsidiary issuer or guarantor is a consolidated subsidiary of the parent company, and
(ii)The subsidiary issues a registered security that is:
issued jointly and severally with the parent company, or
fully and unconditionally guaranteed by the parent company.
A parent entity that meets the above criteria may instead present summarized financial information (“alternative disclosures”)
either within the consolidated financial statements or in “Item 2. Management’s discussion and analysis of financial condition and results
of operations” (“Item 2”). We evaluated the criteria and determined that we are eligible for the disclosure exceptions, which allow us to
provide alternative disclosures; as such, we present alternative disclosures in Item 2.
22
2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Loan fees
Fees incurred in obtaining long-term financing are capitalized and classified with the corresponding debt instrument appearing
on our consolidated balance sheets. Loan fees related to our unsecured senior line of credit are capitalized and classified within other
assets. Capitalized amounts are amortized over the term of the related loan, and the amortization is classified in interest expense in our
consolidated statements of operations.
Distributions from equity method investments
We use the “nature of the distribution” approach to determine the classification within our consolidated statements of cash
flows of cash distributions received from equity method investments, including our unconsolidated real estate joint ventures and equity
method non-real estate investments. Under this approach, distributions are classified based on the nature of the underlying activity that
generated the cash distributions. If we lack the information necessary to apply this approach in the future, we will be required to apply
the “cumulative earnings” approach as an accounting change on a retrospective basis. Under the cumulative earnings approach,
distributions up to the amount of cumulative equity in earnings recognized are classified as cash inflows from operating activities, and
those in excess of that amount are classified as cash inflows from investing activities.
Restricted cash
We present cash and cash equivalents separately from restricted cash within our consolidated balance sheets. However, we
include restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown
in the consolidated statements of cash flows. We provide a reconciliation between the consolidated balance sheets and the
consolidated statements of cash flows, which is required when the balance includes more than one line item for cash, cash equivalents,
and restricted cash. We also provide a disclosure of the nature of the restrictions related to material restricted cash balances.
Recent accounting pronouncements
On November 4, 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which will require
entities to provide enhanced disclosures related to certain expense categories included in line items on the statement of operations.
The ASU aims to increase transparency and provide investors with additional detailed information about the nature of expenses
reported on the face of the income statement. The new standard does not change the requirements for the presentation of expenses on
the face of the statement of operations.
Under this ASU, entities are required to disaggregate, in a tabular format, expense line items presented on the face of the
statement of operations — excluding earnings or losses from equity method investments — if they include any of the following expense
categories: employee compensation, depreciation, intangible asset amortization, depletion, and purchases of inventory. For any
remaining items within each relevant expense line item, entities must provide a qualitative description of the nature of those expenses.
The new ASU is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after
December 15, 2027. Early adoption is permitted. We expect to adopt this ASU on January 1, 2027. Although the adoption is not
expected to have an impact on our financial statements, it is expected to result in incremental disclosures within the notes to our
consolidated financial statements.
23
3.INVESTMENTS IN REAL ESTATE
Our consolidated investments in real estate consisted of the following as of June 30, 2026 and December 31, 2025 (in
thousands):
June 30, 2026
December 31, 2025
Rental properties:
Land (related to rental properties)
$3,630,519
$3,204,479
Buildings and building improvements
20,447,338
19,738,825
Other improvements
4,605,876
4,371,720
Rental properties
28,683,733
27,315,024
Current and future development and redevelopment projects
6,446,196
6,788,464
Gross investments in real estate
35,129,929
34,103,488
Less: accumulated depreciation
(6,460,716)
(5,970,171)
Investments in real estate assets held for sale, less accumulated depreciation(1)
456,682
556,679
Investments in real estate
$29,125,895
$28,689,996
(1)Refer to “Assets held for sale” below.
Assets held for sale
As of June 30, 2026, we had 23 operating properties aggregating 1.7 million RSF and land parcels aggregating 2.0 million SF
that were classified as held for sale.
The disposal of the properties classified as held for sale does not represent a strategic shift that has, or will have, a major
effect on our operations or financial results, as the dispositions relate to an individual asset or a group of assets across multiple markets
and do not represent the exit from any significant market. Accordingly, these assets do not meet the criteria for classification as
discontinued operations. We cease depreciation of our properties upon their classification as held for sale.
The following table presents the components of net assets related to real estate investments that met the criteria for
classification as held for sale as of June 30, 2026 and December 31, 2025 (in thousands):
June 30, 2026
December 31, 2025
Investments in real estate, less accumulated depreciation
$456,682
$556,679
Other assets
73,267
37,859
Total assets
529,949
594,538
Total liabilities
(7,190)
(12,235)
Total accumulated other comprehensive loss (income)
33,027
(566)
Net assets classified as held for sale
$555,786
$581,737
For additional information, refer to “Real estate sales” in Note 2 – “Summary of significant accounting policies” to our unaudited
consolidated financial statements.
24
3.INVESTMENTS IN REAL ESTATE (continued)
Sales of real estate assets and impairment of real estate
Our completed dispositions of real estate assets during the six months ended June 30, 2026 and in July 2026 consisted of
the following (dollars in thousands):
Square Footage
Sales Price
(Our Share)
Property
Submarket/Market
Date of
Sale
Interest
Sold
Operating
Land and
Future
Completed during six months ended June 30, 2026
$7,350
Completed in July 2026:
3825 and 3875 Fabian Way
Palo Alto/San Francisco Bay Area
7/14/26
100%
228,000
250,000
163,000
$170,350
(1)
(1)Represents the aggregate contractual sales price of our dispositions, which differs from sales proceeds disclosed in our consolidated statement of cash flows under
“Investing activities” (proceeds from sales of real estate), “Financing activities” (contributions from and sales of noncontrolling interests), and “Supplemental disclosure
and non-cash investing and financing activities" (non-cash consideration) primarily due to the timing of payment, closing costs, and other sales adjustments such as
prorations of rents and expenses.
Impairment of real estate
During the six months ended June 30, 2026, we recognized impairment charges aggregating $228.0 million, classified within
impairment of real estate in our consolidated statement of operations, primarily related to the following assets:
Greater Boston market
During the three months ended June 30, 2026, we recognized an additional impairment charge of $24.8 million related to one
vacant office property, aggregating 104,956 RSF, in the Cambridge submarket of our Greater Boston market, to reduce its
carrying amount to its updated estimated fair value less costs to sell of approximately $43.7 million based on recent
negotiations with a potential buyer. This asset was classified as held for sale in December 2025 following our assessment of
the project’s financial outlook, including the significant capital required to redevelop and lease the property. As a result, we
decided to sell this asset and reinvest the sales proceeds in other projects with greater value-creation opportunities, and
recognized an impairment charge of $105.7 million in December 2025. We expect to complete the sale within 12 months.
San Diego market
Impairment charge of $64.2 million was recognized to reduce the carrying amount of a land parcel located outside of a
Megacampus aggregating 425,000 SF in Sorrento Mesa, to its estimated fair value less costs to sell of approximately $43.1
million. The land parcel met the criteria for classification as held for sale as of June 30, 2026, following our reevaluation of the
capital required to develop the site and its alignment with our Megacampus strategy, resulting in our decision to monetize the
asset and reallocate capital to other projects with greater value-creation opportunities. The asset is expected to be sold to a
residential developer and we expect to complete the sale within the next 12 months.
Impairment charge of $28.2 million was recognized to reduce the carrying amounts of five operating properties, primarily
comprising non-laboratory space, aggregating 95,814 RSF and one land parcel aggregating 144,000 SF in the Sorrento Valley
submarket of our San Diego market, to their estimated fair values less costs to sell of approximately $26.7 million. These
assets met the criteria for classification as held for sale as of June 30, 2026, following our evaluation of the significant capital
that would have been required to convert these properties through redevelopment for laboratory use and their alignment with
our Megacampus strategy, resulting in our decision to monetize these assets and reallocate capital to other projects with
greater value-creation opportunities. We expect to complete the sale within the next 12 months.
San Francisco Bay Area market
During the three months ended June 30, 2026, we recognized an additional impairment charge of $29.3 million related to one
future development project, aggregating 1.1 million SF, in the SoMa submarket of our San Francisco Bay Area market. The
additional impairment charge was recognized to reduce the carrying amount of this asset to its updated estimated fair value
less costs to sell of approximately $41.3 million based on recent negotiations with a potential buyer. The asset was classified
as held for sale in December 2025 following our commitment to dispose of it and reinvest the sales proceeds in other projects
with greater value-creation opportunities, resulting in an impairment charge of $333.4 million recognized in December 2025.
We expect to complete the sale within 12 months.
25
3.INVESTMENTS IN REAL ESTATE (continued)
In June 2026, we entered into a purchase and sale agreement to sell a previously impaired future development project
aggregating 250,000 SF and one operating property aggregating 228,000 RSF in the Palo Alto submarket of our San
Francisco Bay Area market. These assets were classified as held for sale in December 2025, at which time we recognized an
impairment charge of $144.7 million. We recognized a $23.3 million partial reversal of the impairment charge to increase the
carrying values of the assets to their aggregate sales price of $163.0 million, less costs to sell. This adjustment was recorded
as a partial offset to impairment of real estate in our consolidated statements of operations and did not exceed the cumulative
impairment previously recognized on these assets. The sale was completed in July 2026, with no gain or loss recognized.
Canada (Non-cluster) market
Impairment charge of $61.6 million was recognized to reduce the carrying amount of one non-laboratory property aggregating
247,743 RSF in Canada, a non-cluster market, to its estimated fair value less costs to sell of approximately $42.4 million. The
property met the criteria for classification as held for sale as of June 30, 2026, following our decision to sell the asset and
reallocate the substantial near-term capital that redeveloping the asset would have required toward other projects with greater
value-creation opportunities. We expect to complete the sale within the next 12 months.
In addition, we recognized an impairment charge of $27.8 million in connection with an amendment to the sales agreement for
our Montreal portfolio, reducing its carrying amount to its estimated fair value less costs to sell of approximately $134.5 million.
This portfolio has been classified as held for sale since the fourth quarter of 2025. The disposition of our Canadian portfolio
does not represent a strategic shift that has had, or will have, a major effect on our operations or financial results and,
therefore, does not meet the criteria for classification as discontinued operations.
In determining the carrying amounts of the assets for the impairment analyses, we considered their net book values, estimated
costs to sell, and the effect of approximately $33.0 million of cumulative net foreign currency translation losses recorded in
accumulated other comprehensive income. These losses are expected to be reclassified to earnings upon substantial
completion of the disposition of our Canada assets.
26
3.INVESTMENTS IN REAL ESTATE (continued)
Other
ARE‑East River Science Park, LLC (“ARE”), a subsidiary of Alexandria Real Estate Equities, Inc., holds an option granted in
2006 to incorporate a land parcel adjacent to and north of the Alexandria Center® for Life Science – New York City campus (the “Option
Parcel”) into the existing ground lease, which would allow for the future development of an additional life science building within the
campus. ARE’s investment in pre‑construction costs related to the Option Parcel aggregated $183.0 million as of June 30, 2026.
On August 6, 2024, ARE filed a lawsuit in the U.S. District Court for the Southern District of New York against New York City
Health + Hospitals Corporation (“H+H”) and the New York City Economic Development Corporation (“EDC”) relating to disputes under
the ground lease and option arrangements governing the Option Parcel. ARE filed an amended complaint on January 24, 2025,
asserting claims for fraudulent inducement, breach of contract, breach of the implied covenant of good faith and fair dealing, and
declaratory relief concerning the continued validity of the option.
On March 27, 2026, the court granted defendants’ partial motion to dismiss the fraud in the inducement and implied covenant
of good faith and fair dealing claims. ARE intends to appeal this order at the appropriate time and to vigorously pursue its claims. The
court did not dismiss ARE’s claim for declaratory relief, which remains pending.
On April 10, 2026, H+H and EDC answered the amended complaint and asserted counterclaims seeking, among other things,
declaratory relief relating to the alleged expiration of the option and entitlement to a $5.0 million security deposit, and damages of at
least $3.8 million. As a result of the foregoing matters, the timing of any development of the Option Parcel is currently indeterminate.
Excluding the potential impact of the counterclaims filed by H+H and EDC, this matter exposes us to potential losses ranging from zero
to the full amount of the investment in the project aggregating $183.0 million as of June 30, 2026, depending on the resolution of the
remaining declaratory relief proceedings, the outcome of any appeal, and/or the ability to develop the project. We performed a
probability-weighted recoverability analysis based on initial estimates of various possible outcomes and determined no impairment was
present as of June 30, 2026.
Separately from, and not as part of, the pending litigation related to the Option Parcel, EDC, on behalf of H+H as the landlord
and itself as lease administrator, delivered on April 20, 2026, a notice alleging that ARE is in default of certain information delivery
obligations under the ground lease relating to the existing operating towers at the Alexandria Center for Life Science – New York City
campus, including sublease, tax, and financial information. The notice asserts that the failure to cure the alleged defaults within the
applicable 30-day cure period would result in daily charges of $1,000 increasing thereafter up to $2,000. ARE disputes the allegations
set forth in the notice of default and intends to vigorously defend against them.
On May 12, 2026, ARE filed a lawsuit in the Commercial Division of the New York State Supreme Court against H+H and EDC,
seeking a Yellowstone injunction, a preliminary injunction, and a temporary restraining order to toll all cure periods under the notice of
default and to enjoin EDC and H+H from issuing a notice of termination (the “NYS Action”). The court denied ARE’s request for a
temporary restraining order on May 13, 2026, and denied ARE’s request for a Yellowstone injunction and a preliminary injunction on
June 15, 2026. On June 17, 2026, ARE filed a notice of appeal from the court’s order, dated June 15, 2026. On July 1, 2026, ARE filed
an application for interim relief pending appeal. Following oral argument before a single justice, the application was denied without
prejudice to determination by a full panel. ARE’s appeal remains pending.
On July 2, 2026, ARE filed an amended complaint in the NYS Action, adding claims for breach of contract, breach of the
implied covenant of good faith and fair dealing, tortious interference, and unfair competition, and is seeking declaratory and injunctive
relief, based on the defendants’ alleged misuse of ARE’s confidential subtenant information and diversion of an ARE subtenant to a
competing City-sponsored project. The NYS Action remains pending.
27
4.CONSOLIDATED AND UNCONSOLIDATED REAL ESTATE JOINT VENTURES
From time to time, we enter into joint venture agreements through which we own a partial interest in real estate entities that
own, develop, and operate real estate properties. As of June 30, 2026, our real estate joint ventures held the following properties:
Property(1)
Market
Submarket
Our Ownership
Interest
Consolidated real estate joint ventures:
50 and 60 Binney Street
Greater Boston
Cambridge/Inner Suburbs
34.0%
75/125 Binney Street
Greater Boston
Cambridge/Inner Suburbs
40.0%
100 and 225 Binney Street and 300 Third Street
Greater Boston
Cambridge/Inner Suburbs
30.0%
15 Necco Street
Greater Boston
Seaport Innovation District
56.7%
3215 Merryfield Row
San Diego
Torrey Pines
30.0%
Campus Point by Alexandria(2)
San Diego
University Town Center
58.2%
(3)
5200 Illumina Way
San Diego
University Town Center
51.0%
9625 Towne Centre Drive
San Diego
University Town Center
30.0%
SD Tech by Alexandria(4)
San Diego
Sorrento Mesa
50.0%
Summers Ridge Science Park(5)
San Diego
Sorrento Mesa
30.0%
Alexandria Center® for Science and Technology –
Mission Bay(6)
San Francisco Bay Area
Mission Bay
25.0%
211 and 213 East Grand Avenue
San Francisco Bay Area
South San Francisco
30.0%
500 Forbes Boulevard
San Francisco Bay Area
South San Francisco
10.0%
Alexandria Center® for Life Science – Millbrae
San Francisco Bay Area
South San Francisco
48.6%
1201 and 1208 Eastlake Avenue East
Seattle
Lake Union
30.0%
400 Dexter Avenue North
Seattle
Lake Union
30.0%
800 Mercer Street
Seattle
Lake Union
60.0%
Unconsolidated real estate joint ventures:
1655 and 1725 Third Street
San Francisco Bay Area
Mission Bay
10.0%
101 West Dickman Street
Maryland
Beltsville
58.4%
(7)
(1)Refer to the table on the next page that shows the categorization of our real estate joint ventures under the consolidation framework.
(2)Includes 10200, 10290, and 10300 Campus Point Drive and 4135, 4155, 4165, 4224, and 4242 Campus Point Court.
(3)The noncontrolling interest share of our joint venture partner is anticipated to decrease to 25%, as we expect to fund the majority of future construction costs at the
campus until our ownership interest increases to 75%, after which future capital would be contributed pro rata with our partner.
(4)Includes 9605, 9645, 9675, 9725, 9735, 9805, 9808, 9855, and 9868 Scranton Road and 10055, 10065, and 10075 Barnes Canyon Road.
(5)Includes 9965, 9975, 9985, and 9995 Summers Ridge Road.
(6)Includes 1450, 1500, and 1700 Owens Street, and 455 Mission Bay Boulevard South.
(7)Represents a joint venture with a local real estate operator in which our joint venture partner manages the day-to-day activities that significantly affect the economic
performance of the joint venture.
Our consolidation policy is described under “Consolidation” in Note 2 – “Summary of significant accounting policies” to our
unaudited consolidated financial statements. Consolidation accounting is highly technical, but its framework is primarily based on the
controlling financial interests and benefits of the joint ventures. We generally consolidate a joint venture that is a legal entity we control
(i.e., we have the power to direct the activities of the joint venture that most significantly affect its economic performance) through
contractual rights, regardless of our ownership interest, and where we determine that we have benefits through the allocation of
earnings or losses and fees paid to us that could be significant to the joint venture (the “VIE model”).
We also generally consolidate joint ventures when we have a controlling financial interest through voting rights and where our
voting interest is greater than 50% (the “voting model”). Voting interest differs from ownership interest for some joint ventures. We
account for joint ventures that do not meet the consolidation criteria under the equity method of accounting by recognizing our share of
income and losses.
28
4.CONSOLIDATED AND UNCONSOLIDATED REAL ESTATE JOINT VENTURES (continued)
The table below shows the categorization of our real estate joint ventures under the consolidation framework:
Property
Consolidation
Model
Voting Interest
Consolidation Analysis
Conclusion
50 and 60 Binney Street
VIE model
Not applicable
under VIE
model
Consolidated
75/125 Binney Street
We have:
100 and 225 Binney Street and 300
Third Street
15 Necco Street
(i)
The power to direct the
activities of the joint venture
that most significantly affect its
economic performance; and
3215 Merryfield Row
Campus Point by Alexandria
5200 Illumina Way
9625 Towne Centre Drive
(ii)
Benefits that can be significant
to the joint venture.
SD Tech by Alexandria
Summers Ridge Science Park
Alexandria Center® for Science and
Technology – Mission Bay
211 and 213 East Grand Avenue
Therefore, we are the primary
beneficiary of each VIE
500 Forbes Boulevard
Alexandria Center® for Life Science –
Millbrae
1201 and 1208 Eastlake Avenue East
400 Dexter Avenue North
800 Mercer Street
101 West Dickman Street
We do not control the joint venture
and are therefore not the primary
beneficiary.
Equity method
of accounting
1655 and 1725 Third Street
Voting model
Does not
exceed 50%
Our voting interest is 50% or less.
Consolidated real estate joint ventures
Consolidated VIEs’ balance sheet information
We, together with joint venture partners, hold interests in real estate joint ventures that we consolidate in our financial
statements. These existing joint ventures provide significant equity capital to fund a portion of our future construction spending, and our
joint venture partners may also contribute equity into these entities for financing-related activities.
The table below aggregates the balance sheet information of our consolidated VIEs (in thousands):
June 30, 2026
December 31, 2025
Investments in real estate
$6,102,291
$6,129,668
Cash and cash equivalents
200,422
258,755
Other assets
714,801
712,154
Total assets
$7,017,514
$7,100,577
Secured note payable
$
$
Other liabilities
578,147
324,513
Total liabilities
578,147
324,513
Redeemable noncontrolling interests
49,554
Alexandria Real Estate Equities, Inc.’s share of equity
2,827,104
3,098,932
Noncontrolling interests’ share of equity
3,612,263
3,627,578
Total liabilities and equity
$7,017,514
$7,100,577
29
4.CONSOLIDATED AND UNCONSOLIDATED REAL ESTATE JOINT VENTURES (continued)
In determining whether to aggregate the balance sheet information of consolidated VIEs, we considered the similarity of each
VIE, including the primary purpose of these entities to own, manage, operate, and lease real estate properties owned by the VIEs, and
the similar nature of our involvement in each VIE as a managing member. Due to the similarity of the characteristics, we present the
balance sheet information of these entities on an aggregated basis. None of our consolidated VIEs’ assets have restrictions that limit
their use to settle specific obligations of the VIE. There are no creditors or other partners of our consolidated VIEs that have recourse to
our general credit, and our maximum exposure to our consolidated VIEs is limited to our variable interests in each VIE.
99 Coolidge Avenue
In July 2025, we amended the agreement for our consolidated real estate joint venture at 99 Coolidge Avenue in our
Cambridge/Inner Suburbs submarket. Pursuant to the amendment, the carrying amount of our partner’s noncontrolling interest was
adjusted from $42.0 million to $48.7 million, and converted into a redeemable noncontrolling interest that accrued a fixed 4.05% annual
preferred return (“distributions”). In January 2026, the partner exercised its option to require us to purchase its entire preferred interest,
and the redemption was completed in January 2026 for $49.7 million, inclusive of unpaid distributions. 
Noncontrolling interests in consolidated real estate joint ventures
Noncontrolling interests represent the third-party interests in consolidated real estate joint ventures in which we have a
controlling interest. Noncontrolling interests are adjusted for additional contributions and distributions, the proportionate share of the net
earnings or losses, and other comprehensive income or loss. Distributions, profits, and losses related to these entities are allocated in
accordance with the respective operating agreements. During the six months ended June 30, 2026 and 2025, we distributed
$112.4 million and $123.6 million, respectively, to our consolidated real estate joint venture partners.
Unconsolidated real estate joint ventures
Our investments in unconsolidated real estate joint ventures, accounted for under the equity method and classified in
investments in unconsolidated real estate joint ventures in our consolidated balance sheets, consisted of the following as of June 30,
2026 and December 31, 2025 (in thousands):
Property
June 30, 2026
December 31, 2025
1655 and 1725 Third Street
$19,062
$19,484
101 West Dickman Street
9,848
9,669
Other
1,524
$28,910
$30,677
Our maximum exposure related to our only unconsolidated VIE, 101 West Dickman Street, is limited to our investment in this
joint venture and a guarantee of up to $5.4 million of the outstanding balance related to the VIE’s secured construction loan.
Below are key terms of unconsolidated real estate joint ventures’ secured loans as of June 30, 2026 (dollars in thousands):
Interest
Rate(1)
At 100%
Our
Share
Unconsolidated Joint Venture
Maturity Date
Stated Rate
Aggregate
Commitment
Debt
Balance(2)
101 West Dickman Street
10/29/26
(3)
SOFR+1.95%
(4)
5.68%
$26,750
$19,445
58.4%
1655 and 1725 Third Street
2/10/35
6.37%
6.44%
500,000
497,052
10.0%
$526,750
$516,497
(1)Includes interest expense and amortization of loan fees.
(2)Represents outstanding principal, net of unamortized deferred financing costs, as of June 30, 2026.
(3)The unconsolidated real estate joint venture is in the process of working with prospective lenders to refinance this debt. As of June 30, 2026, our investment in this
unconsolidated real estate joint venture was $9.8 million.
(4)This loan is subject to a SOFR floor of 0.75%.
30
5.LEASES
Refer to “Lease accounting” in Note 2 – “Summary of significant accounting policies” to our unaudited consolidated financial
statements for information about lease accounting standards that set principles for the recognition, measurement, presentation, and
disclosure of leases for both parties to a lease agreement (i.e., lessees and lessors).
Leases in which we are the lessor
As of June 30, 2026, we had 336 properties aggregating 36.0 million operating RSF in key cluster locations, including Greater
Boston, San Diego, the San Francisco Bay Area, Seattle, Maryland, Research Triangle, and New York City. We primarily focus on
developing Class A/A+ properties in AAA life science and advanced technology innovation clusters that offer the scale and strategic
design integral to our Megacampus strategy. Strategically located near top academic and medical research institutions, our
Megacampus ecosystems feature curated amenities and services and convenient access to transit, creating environments that help our
tenants attract and retain top talent.
As of June 30, 2026, all leases in which we are the lessor were classified as operating leases, with the exception of one direct
financing and one sales-type lease. Our leases are described below.
Operating leases
As of June 30, 2026, our 336 properties were subject to operating lease agreements. Five of these properties are subject to
operating lease agreements that each contain a purchase option as described below:
(i)Two of these properties, representing two land parcels in the San Francisco Bay Area market, are subject to lease
agreements that each contain an option for the lessee to purchase the underlying asset from us at fair market value during
each of the 30-day periods commencing on the dates that are 15 years, 30 years, and 74.5 years after the rent
commencement date of October 1, 2017. The remaining lease term related to each of the two land parcels is 66.4 years.
(ii)Two operating properties in the Seattle market, held by a consolidated real estate joint venture, are subject to purchase
options held by our partner in this joint venture, which is also a tenant at these properties. One purchase option allows our
partner to purchase our 30% interest in one property for $40.0 million in 2031. Contingent upon the exercise of this option,
the second purchase option allows our partner to purchase our 30% interest in one property for $69.1 million in 2034. Our
partner’s remaining lease terms for these operating leases are 6.7 years and 18.3 years, respectively.
(iii)One property subject to an operating lease agreement contains a purchase option exercisable at fair market value in
March 2034.
Certain operating leases contain options for tenants to extend their leases at prevailing market rates at the time of expiration.
In addition, certain operating leases contain an early termination option that requires advance notification and payment of an early
termination fee by the tenant.
At the commencement of each lease, we establish the lease term comprising the noncancelable period for each lease together
with periods covered by options to extend or terminate the lease that we determine the lessee is reasonably certain to exercise. Our
assessment of whether a lessee is reasonably certain to exercise or not exercise an option considers all economic factors relevant to
the assessment, including property-based, market-based, and tenant-based factors. We do not reassess the lease term or a lessee
option to purchase the underlying asset unless there is a lease modification that is not accounted for as a separate contract.
Future lease payments to be received under the terms of our operating lease agreements, excluding expense
reimbursements, in effect as of June 30, 2026 are outlined in the table below (in thousands):
Year
Amount
2026
$766,659
2027
1,469,218
2028
1,355,606
2029
1,266,050
2030
1,203,290
Thereafter
7,504,611
Total
$13,565,434
Refer to Note 3 – “Investments in real estate” to our unaudited consolidated financial statements for additional information
about our owned real estate assets, which are the underlying assets under our operating leases.
31
5.LEASES (continued)
Direct financing and sales-type leases
As of June 30, 2026, we have one direct financing lease agreement, with a net investment balance of $43.0 million, for a
parking structure with a remaining lease term of 66.4 years. The lessee has an option to purchase the underlying asset at fair market
value during each of the 30-day periods commencing on the dates that are 15 years, 30 years, and 74.5 years after the rent
commencement date of October 1, 2017.
As of June 30, 2026, we also have one sales-type lease for a property in the Seattle market. As of June 30, 2026, the net
investment in this lease is $16.9 million. At the end of the lease term in 2026, title to the property under this lease will transfer to the
tenant for a sales price of approximately $18.5 million.
As of June 30, 2026, our estimated provision for expected credit losses related to our direct financing and sales-type leases
aggregated $1.8 million, which was predominantly related to our direct financing lease. We estimate the provision for expected credit
losses related to our direct financing lease using a probability of default methodology, which incorporates the borrower’s investment-
grade credit rating from S&P Global Ratings, to evaluate the probability of default. Additionally, we incorporate the projected value of the
real estate securing the investments to estimate potential recoveries in the event of default, among other inputs. The estimate of the
expected credit loss related to our sales-type lease was determined using historical industry losses and transaction-specific information,
including the estimated fair value of the underlying real estate asset securing this transaction, the short-term nature of this lease, and
other available information. For further details, refer to “Provision for expected credit losses” in Note 2 – “Summary of significant
accounting policies” to our unaudited consolidated financial statements.
The components of our aggregate net investment in our direct financing and sales-type leases as of June 30, 2026 and
December 31, 2025 are summarized in the table below (in thousands):
June 30, 2026
December 31, 2025
Gross investment in direct financing and sales-type leases
$265,315
$265,839
Less: unearned income on direct financing lease
(203,671)
(205,037)
Less: provision for expected credit losses
(1,817)
(1,817)
Net investment in leases
$59,827
$58,985
Future lease payments to be received under the terms of our direct financing and sales-type leases as of June 30, 2026 are
outlined in the table below (in thousands):
Year
Total
2026
$17,922
2027
2,097
2028
2,160
2029
2,224
2030
2,291
Thereafter
238,621
Total
$265,315
Income from rentals
Our income from rentals includes revenue related to agreements for the rental of our real estate, which primarily includes
revenues subject to the lease accounting standard and the revenue recognition accounting standard as shown below (in thousands):
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Income from rentals:
Revenues subject to the lease accounting standard:
Operating leases
$629,408
$722,935
$1,270,067
$1,454,356
Direct financing and sales-type leases
892
1,089
1,856
1,899
Revenues subject to the lease accounting standard
630,300
724,024
1,271,923
1,456,255
Revenues subject to the revenue recognition accounting
standard
12,910
13,255
24,300
24,199
Income from rentals
$643,210
$737,279
$1,296,223
$1,480,454
32
5.LEASES (continued)
Revenues subject to the revenue recognition accounting standard and classified in income from rentals consist primarily of
short-term parking revenues that are not considered lease revenues under the lease accounting standard. Refer to “Revenues” and
Recognition of revenue arising from contracts with customers” in Note 2 – “Summary of significant accounting policies” to our
unaudited consolidated financial statements for additional information.
Residual value risk management strategy
Our leases do not have guarantees of residual value on the underlying assets. We manage risk associated with the residual
value of our leased assets by (i) evaluating each potential acquisition of real estate to determine whether it meets our business
objective to invest primarily in high-demand markets, (ii) directly managing our leased properties, conducting frequent property
inspections, proactively addressing potential maintenance issues, and/or timely resolving any occurring issues, and (iii) carefully
selecting our tenants and monitoring their credit quality throughout their respective lease terms.
Leases in which we are the lessee
Operating lease agreements
We have ground and office operating lease agreements in which we are the lessee. Certain of these leases have options to
extend or terminate the contract terms upon meeting certain criteria. There are no notable restrictions or covenants imposed by the
leases, nor guarantees of residual value.
We recognize a right-of-use asset, which is classified within other assets in our consolidated balance sheets, and a related
liability, which is classified within accounts payable, accrued expenses, and other liabilities in our consolidated balance sheets, to
account for our future obligations under ground and office lease arrangements in which we are the lessee. Refer to “Lessee accounting
in Note 2 – “Summary of significant accounting policies” to our unaudited consolidated financial statements.
As of June 30, 2026, the present value of the remaining contractual payments aggregating $759.4 million under our operating
lease agreements, including our extension options that we are reasonably certain to exercise, was $354.9 million. Our corresponding
operating lease right-of-use assets, adjusted for initial direct leasing costs and other consideration exchanged with the landlord prior to
the commencement of the lease, aggregated $689.2 million. As of June 30, 2026, the weighted-average remaining lease term of
operating leases in which we are the lessee was approximately 61 years, including extension options that we are reasonably certain to
exercise, and the weighted-average discount rate was 4.7%. The weighted-average discount rate is based on the incremental
borrowing rate estimated for each lease, which is the interest rate that we estimate we would have to pay to borrow on a collateralized
basis over a similar term for an amount equal to the lease payments.
Ground lease obligations as of June 30, 2026 included leases for 31 of our properties, which accounted for approximately 9%
of our total number of properties. Excluding one ground lease that expires in 2036 related to one operating property with a net book
value of $3.3 million as of June 30, 2026, our ground lease obligations have remaining lease terms ranging from approximately 28 to 97
years, including extension options that we are reasonably certain to exercise.
The reconciliation of future lease payments under noncancelable operating leases in which we are the lessee to the operating
lease liability reflected in our unaudited consolidated balance sheet as of June 30, 2026 is in the table below (in thousands):
Year
Total
2026
$9,981
2027
21,003
2028
21,318
2029
20,825
2030
20,743
Thereafter
665,496
Total future payments under our operating leases in which we are the lessee
759,366
Effect of discounting
(404,461)
Operating lease liability
$354,905
33
5.LEASES (continued)
Lessee operating costs
Operating lease costs relate to our ground and office leases in which we are the lessee. Ground leases generally require fixed
annual rent payments and may also include escalation clauses and renewal options. For the six months ended June 30, 2026 and
2025, amounts paid and classified as operating activities in our unaudited consolidated statements of cash flows for leases in which we
are the lessee aggregated $12.2 million and $156.1 million, respectively. The decrease is primarily due to the ground lease prepayment
of $135.0 million made in January 2025 for a 24-year lease term extension to our existing ground lease agreement at the Alexandria
Technology Square® Megacampus in our Cambridge submarket.
Our operating lease obligations related to our office leases have remaining terms of up to 10 years, exclusive of extension
options. For the three and six months ended June 30, 2026 and 2025, our costs for operating leases in which we are the lessee were
as follows (in thousands):
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Gross operating lease costs
$8,003
$12,859
$16,420
$25,218
Capitalized lease costs
(1,086)
(720)
(1,845)
(1,413)
Expenses for operating leases in which we are the
lessee
$6,917
$12,139
$14,575
$23,805
6. CASH, CASH EQUIVALENTS, AND RESTRICTED CASH
Cash, cash equivalents, and restricted cash consisted of the following as of June 30, 2026 and December 31, 2025 (in
thousands):
 
June 30, 2026
December 31, 2025
Cash and cash equivalents
$470,449
$549,062
Restricted cash:
Development escrows
2,130
2,142
Security deposits
1,809
1,729
Other
751
822
4,690
4,693
Total
$475,139
$553,755
34
7.INVESTMENTS
We hold investments in publicly traded companies and privately held entities primarily involved in the life science industry. As a
REIT, we generally limit our ownership of each individual entity’s voting stock to less than 10%. We evaluate each investment to
determine whether we have the ability to exercise significant influence, but not control, over an investee. We evaluate investments in
which our ownership is equal to or greater than 20%, but less than or equal to 50%, of an investee’s voting stock with a presumption
that we have this ability. For our investments in limited partnerships that maintain specific ownership accounts, we presume that such
ability exists when our ownership interest exceeds 3% to 5%. In addition to our ownership interest, we consider whether we have a
board seat or whether we participate in the investee’s policy-making process, among other criteria, to determine if we have the ability to
exert significant influence, but not control, over an investee. If we determine that we have such ability, we account for the investment
under the equity method, as described below.
From time to time, we may hold equity investments in publicly traded companies that are subject to temporary contractual sale
restrictions. We do not recognize a discount related to such contractual sale restrictions.
Investments accounted for under the equity method
Under the equity method of accounting, we initially recognize our investment at cost and subsequently adjust the carrying
amount of the investment for our share of earnings or losses reported by the investee, distributions received, and other-than-temporary
impairments.
As of June 30, 2026, we had nine investments in limited partnerships maintaining specific ownership accounts for each
investor, which were accounted for under the equity method. These investments aggregated $397.4 million. Our ownership interest in
each of these nine investments was greater than 5%.
Investments that do not qualify for the equity method of accounting
For investees over which we determine that we do not have the ability to exercise significant influence or control, we account
for each investment depending on whether it is an investment in a (i) publicly traded company, (ii) privately held entity that reports NAV
per share, or (iii) privately held entity that does not report NAV per share, as described below.
Investments in publicly traded companies
Our investments in publicly traded companies are classified as investments with readily determinable fair values and are
presented at fair value in our consolidated balance sheets, with changes in fair value classified in investment income (loss) in our
consolidated statements of operations. The fair values for our investments in publicly traded companies are determined based on sales
prices or quotes available on securities exchanges.
Investments in privately held companies
Our investments in privately held entities without readily determinable fair values consist of (i) investments in privately held
entities that report NAV per share and (ii) investments in privately held entities that do not report NAV per share. These investments are
accounted for as follows:
Investments in privately held entities that report NAV per share
Investments in privately held entities that report NAV per share, such as our privately held investments in limited partnerships,
are presented at fair value using NAV as a practical expedient, with changes in fair value classified in investment income (loss) in our
consolidated statements of operations. We use NAV per share reported by limited partnerships generally without adjustment, unless we
are aware of information indicating that the NAV reported by a limited partnership does not accurately reflect the fair value of the
investment at our reporting date.
Investments in privately held entities that do not report NAV per share
Investments in privately held entities that do not report NAV per share are accounted for using a measurement alternative
under which these investments are measured at cost, adjusted for observable price changes and impairments, with changes classified
in investment income (loss) in our consolidated statements of operations.
An observable price arises from an orderly transaction for an identical or similar investment of the same issuer, which is
observed by an investor without expending undue cost and effort. Observable price changes result from, among other things, equity
transactions of the same issuer executed during the reporting period, including subsequent equity offerings or other reported equity
transactions related to the same issuer. To determine whether these transactions are indicative of an observable price change, we
evaluate, among other factors, whether these transactions have similar rights and obligations, including voting rights, distribution
preferences, and conversion rights to the investments we hold.
35
7.INVESTMENTS (continued)
Impairment evaluation of equity method investments and investments in privately held entities that do not report NAV per share
We monitor equity method investments and investments in privately held entities that do not report NAV per share for new
developments, including operating results, prospects and results of clinical trials, new product initiatives, new collaborative agreements,
capital-raising events, and merger and acquisition activities. These investments are evaluated on the basis of a qualitative assessment
for indicators of impairment by monitoring the presence of the following triggering events or impairment indicators:
(i)a significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee;
(ii)a significant adverse change in the regulatory, economic, or technological environment of the investee;
(iii)a significant adverse change in the general market condition, including the research and development of technology and
products that the investee is bringing or attempting to bring to the market;
(iv)significant concerns about the investee’s ability to continue as a going concern; and/or
(v)a decision by investors to cease providing support or reduce their financial commitment to the investee.
If such indicators are present, we are required to estimate the investment’s fair value and immediately recognize an
impairment charge in an amount equal to the investment’s carrying value in excess of its estimated fair value.
Investment income/loss recognition and classification
We recognize both realized and unrealized gains and losses in our consolidated statements of operations, classified in
investment income (loss) in our consolidated statements of operations. Unrealized gains and losses represent:
(i)changes in fair value for investments in publicly traded companies;
(ii)changes in NAV for investments in privately held entities that report NAV per share;
(iii)observable price changes for investments in privately held entities that do not report NAV per share; and
(iv)our share of unrealized gains or losses reported by our equity method investees.
Realized gains and losses on our investments represent the difference between proceeds received upon disposition of
investments and their historical or adjusted cost basis. For our equity method investments, realized gains and losses represent our
share of realized gains or losses reported by the investee. Impairments are realized losses, which result in an adjusted cost basis, and
represent charges to reduce the carrying values of investments in privately held entities that do not report NAV per share and equity
method investments, if impairments are deemed other than temporary, to their estimated fair value.
Funding commitments to investments in privately held entities that report NAV
We are committed to funding approximately $317.6 million for our investments in privately held entities that report NAV. Our
funding commitments expire at various dates over the next 12 years, with a weighted-average expiration of 7.9 years as of June 30,
2026. These investments are not redeemable by us, but we may receive distributions from these investments throughout their terms.
Our investments in privately held entities that report NAV generally have expected initial terms in excess of 10 years. The weighted-
average remaining term during which these investments are expected to be liquidated was 5.5 years as of June 30, 2026.
The following tables summarize our investments as of June 30, 2026 and December 31, 2025 (in thousands):
June 30, 2026
Cost
Unrealized
Gains
Unrealized
Losses
Carrying
Amount
Publicly traded companies
$86,268
$50,949
$(14,405)
$122,812
Entities that report NAV
496,043
180,952
(40,937)
636,058
Entities that do not report NAV:
Entities with observable price changes
91,621
58,568
(11,210)
138,979
Entities without observable price changes
390,401
390,401
Investments accounted for under the equity method
N/A
N/A
N/A
397,445
Total investments
$1,064,333
$290,469
$(66,552)
$1,685,695
36
7.INVESTMENTS (continued)
December 31, 2025
Cost
Unrealized
Gains
Unrealized
Losses
Carrying
Amount
Publicly traded companies
$54,752
$44,319
$(4,143)
$94,928
Entities that report NAV
460,160
89,514
(37,298)
512,376
Entities that do not report NAV:
Entities with observable price changes
82,252
50,601
(9,615)
123,238
Entities without observable price changes
413,324
413,324
Investments accounted for under the equity method
N/A
N/A
N/A
357,383
Total investments
$1,010,488
$184,434
$(51,056)
$1,501,249
Cumulative gains and losses (realized and unrealized) on investments in privately held entities that do not report NAV still held
as of June 30, 2026 aggregated to a loss of $122.8 million, which consisted of upward adjustments aggregating $58.6 million,
downward adjustments aggregating $11.2 million, and impairments aggregating $170.2 million.
Our investment income (loss) for the three and six months ended June 30, 2026 and 2025 consisted of the following (in
thousands):
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Realized gains (losses)
$1,294
(1)
$(8,684)
$7,044
(1)
$9,469
Unrealized gains (losses)
131,933
(21,938)
121,601
(90,083)
Investment income (losses)
$133,227
(2)
$(30,622)
$128,645
(2)
$(80,614)
(1)Consists of realized gains of $10.3 million and $28.5 million, partially offset by impairment charges of $9.0 million and $21.4 million during the three and six months
ended June 30, 2026, respectively.
(2)Investment income of $133.2 million and $128.6 million included $30.2 million and $28.5 million of equity in earnings of our equity method investments during the three
and six months ended June 30, 2026, respectively.
Additional details on our non-real estate investments still held as of the end of each period are presented below (in thousands):
Six Months Ended June 30,
2026
2025
Investments in privately held entities that do not report NAV still held as of the end of
each period:
Upward adjustments
$12,308
$8,800
Downward adjustments and impairments
(26,518)
(66,397)
$(14,210)
$(57,597)
Unrealized gains (losses) on non-real estate investments still held as of the end of
each period (excluding equity method investments)
$107,222
$(30,745)
Refer to “Investments” in Note 2 – “Summary of significant accounting policies” to our unaudited consolidated financial
statements for additional information.
37
8. OTHER ASSETS
The following table summarizes the components of other assets as of June 30, 2026 and December 31, 2025 (in thousands):
June 30, 2026
December 31, 2025
Acquired in-place leases
$178,540
$204,008
Deferred compensation plan
61,096
53,529
Deferred financing costs – unsecured senior line of credit
34,581
39,406
Deposits
28,034
28,618
Furniture, fixtures, equipment, and software
76,474
70,311
Net investment in leases
59,827
58,985
Notes receivable
269,737
258,033
Operating lease right-of-use assets
689,153
697,865
Other assets
92,017
87,036
Prepaid expenses
27,323
33,718
Property, plant, and equipment
128,661
130,263
Total
$1,645,443
$1,661,772
Notes receivable
Our notes receivable as of June 30, 2026 and December 31, 2025 consisted of the following (dollars in thousands): 
June 30, 2026
Weighted-Average
Notes Receivable
Effective
Interest Rate
Maturity
Date
Balance
December 31, 2025
Secured by real estate assets in San Diego
9.9%
1/10/29
$254,890
$240,476
Secured by real estate assets in Greater Boston
6.1%
12/16/29
15,379
18,089
Less: provision for expected credit losses
(532)
(532)
Notes receivable
$269,737
$258,033
Our notes receivable represent held-to-maturity debt securities carried at amortized cost and are generally secured by real
estate. Under the current expected credit losses accounting standard, we are required to estimate and, if necessary, recognize a
provision for expected credit losses related to these notes. We do not have a history of losses on such securities; therefore, we utilize
available information on historical losses for the commercial real estate industry. We determine expected credit losses for our notes
receivable using historical industry losses and considering loan-specific information, including credit ratings of the borrowers, estimated
fair values of underlying real estate assets, loan-to-value ratios, the presence of guarantors, and/or other available information. During
the three and six months ended June 30, 2026, no adjustment to the provision for expected credit losses related to our notes receivable
was required. The provision is evaluated on an ongoing basis, with any necessary adjustments recognized in the corresponding period.
38
9.FAIR VALUE MEASUREMENTS
We provide fair value information about all financial instruments for which it is practicable to estimate fair value. We measure
and disclose the estimated fair value of financial assets and liabilities by utilizing a fair value hierarchy that distinguishes between data
obtained from sources independent of the reporting entity and the reporting entity’s own assumptions about market participant
assumptions. This hierarchy consists of three broad levels, as follows: (i) quoted prices in active markets for identical assets or liabilities
(Level 1), (ii) significant other observable inputs (Level 2), and (iii) significant unobservable inputs (Level 3). Significant other observable
inputs can include quoted prices for similar assets or liabilities in active markets, as well as inputs that are observable for the asset or
liability, such as interest rates, foreign exchange rates, and yield curves. Significant unobservable inputs are typically based on an
entity’s own assumptions, since there is little, if any, related market activity. In instances in which the determination of the fair value
measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the
entire fair value measurement falls is based on the lowest level of input that is significant to the fair value measurement in its entirety.
Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers
factors specific to the asset or liability.
Assets and liabilities measured at fair value on a recurring basis
The following table sets forth the assets and liabilities that we measure at fair value on a recurring basis by level in the fair
value hierarchy as of June 30, 2026 and December 31, 2025 (in thousands). There were no transfers of assets measured at fair value
on a recurring basis to or from Level 3 in the fair value hierarchy during the six months ended June 30, 2026.
Fair Value Measurement Using
Description
Total
Quoted Prices in
Active Markets
for Identical Assets
(Level 1)
Significant
Other
Observable Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Assets:
Investments in publicly traded companies:
As of June 30, 2026
$122,812
$122,812
$
$
As of December 31, 2025
$94,928
$94,928
$
$
Cross-currency swap agreements:
As of June 30, 2026
$6,455
$
$6,455
$
Liabilities:
Cross-currency swap agreements:
As of December 31, 2025
$928
$
$928
$
Our investments in publicly traded companies represent investments with readily determinable fair values, and are carried at
fair value, with changes in fair value classified in investment income (loss) in our consolidated financial statements. We also hold
investments in privately held entities, which consist of (i) investments that report NAV and (ii) investments that do not report NAV, as
further described below.
Our investments in privately held entities that report NAV, such as our privately held investments in limited partnerships, are
carried at fair value using NAV as a practical expedient, with changes in fair value classified in net income. As of June 30, 2026 and
December 31, 2025, the carrying values of investments in privately held entities that report NAV aggregated $636.1 million and
$512.4 million, respectively. These investments are excluded from the fair value hierarchy above as required by the fair value
accounting standard. We estimate the fair value of each of our investments in limited partnerships based on the most recent NAV
prepared by the general partner and reported by each limited partnership. As a result, the determination of fair values of our
investments in privately held entities that report NAV generally does not involve significant estimates, assumptions, or judgments on our
part.
Our cross-currency swap agreements are recognized at fair value. Refer to Note 2 – “Summary of significant accounting
policies” and Note 11 – “Hedge agreements” to our unaudited consolidated financial statements for additional information.
39
9.FAIR VALUE MEASUREMENTS (continued)
Assets and liabilities measured at fair value on a nonrecurring basis
The following table sets forth our assets measured at fair value on a nonrecurring basis, categorized by level within the fair
value hierarchy, as of June 30, 2026 and December 31, 2025 (in thousands).
Fair Value Measurement Using
Description
Carrying
Amount
Quoted Prices in
Active Markets
for Identical Assets
(Level 1)
Significant
Other
Observable Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Real estate assets with carrying values adjusted
based on fair values during the:
Six months ended June 30, 2026
$616,998
(1)
$
$
$616,998
Year ended December 31, 2025
$581,737
(1)
$
$
$581,737
Investments in privately held entities that do not
report NAV with carrying values adjusted based on
fair values during the:
Six months ended June 30, 2026
$46,008
$
$45,239
(2)
$769
(3)
Year ended December 31, 2025
$68,738
$
$62,261
(2)
$6,477
(3)
(1)These amounts represent the aggregate carrying amounts of real estate assets for which adjustments based on nonrecurring fair value measurements were recognized
during the respective periods, including assets for which impairment losses or reversals of previously recognized impairment losses were recorded. These assets
primarily include a subset of our total real estate assets classified as held for sale as of June 30, 2026 and December 31, 2025. The fair values for these real estate
assets were estimated based on executed purchase and sale agreements, letters of intent, valuations provided by third-party real estate brokers, or market comparables
from recent transactions. Refer to “Investments in real estate” in Note 2 – “Summary of significant accounting policies” and “Assets held for sale” in Note 3 –
Investments in real estate” to our unaudited consolidated financial statements for additional information.
(2)These amounts represent the carrying amounts of our equity investments in privately held entities with observable price changes for which adjustments based on
nonrecurring fair value measurements were recognized during the respective periods. These amounts are included in the investment balances of $1.69 billion and $1.50
billion in our unaudited consolidated balance sheets as of June 30, 2026 and December 31, 2025, respectively, disclosed in Note 7 – “Investments” to our unaudited
consolidated financial statements.
(3)These amounts are included in the investments in privately held entities without observable price changes balances aggregating $390.4 million and $413.3 million as of
June 30, 2026 and December 31, 2025, respectively, disclosed in Note 7 – “Investments” to our unaudited consolidated financial statements, and represent the carrying
amounts of investments in privately held entities that do not report NAV for which impairments have been recognized during the respective periods in accordance with
the measurement alternative guidance described in “Investments” in Note 2 – “Summary of significant accounting policies” to our unaudited consolidated financial
statements.
Investments in privately held entities that do not report NAV
Our investments in privately held entities that do not report NAV are measured at cost, adjusted for observable price changes
and impairments, with changes recognized in net income (loss). These investments are adjusted based on the observable price
changes in orderly transactions for the identical or similar investment of the same issuer. Further adjustments are not made until
another observable transaction occurs. Therefore, the determination of fair values of our investments in privately held entities that do
not report NAV does not involve significant estimates and assumptions or subjective and complex judgments.
We also subject our investments in privately held entities that do not report NAV to a qualitative assessment for indicators of
impairment. If indicators of impairment are present, we are required to estimate the investment’s fair value and immediately recognize
an impairment charge in an amount equal to the investment’s carrying value in excess of its estimated fair value.
The estimates of fair value typically incorporate valuation techniques that include an income approach reflecting a discounted
cash flow analysis, and a market approach that includes a comparative analysis of acquisition multiples and pricing multiples generated
by market participants. In certain instances, we may use multiple valuation techniques for a particular investment and estimate its fair
value based on an average of multiple valuation results.
Refer to Note 7 – “Investments” to our unaudited consolidated financial statements for additional information.
Assets and liabilities not measured at fair value in the statement of financial position but for which the fair value is disclosed
The fair values of our unsecured senior notes payable and the amounts outstanding on our unsecured senior line of credit and
commercial paper program were estimated using widely accepted valuation techniques, including discounted cash flow analyses using
significant other observable inputs such as available market information on discount and borrowing rates with similar terms, maturities,
and credit ratings. Because the valuations of our financial instruments are based on these types of estimates, the actual fair value of our
financial instruments may differ materially if our estimates do not prove to be accurate. Additionally, the use of different market
assumptions or estimation methods may have a material effect on the estimated fair value amounts.
40
9.FAIR VALUE MEASUREMENTS (continued)
As of June 30, 2026 and December 31, 2025, the book and estimated fair values of our unsecured senior notes payable and
the amounts outstanding under our unsecured senior line of credit and commercial paper program, including the level within the fair
value hierarchy for which the estimates were derived, were as follows (in thousands):
June 30, 2026
Book Value
Fair Value Hierarchy
Estimated
Fair Value
Quoted Prices in
Active Markets
for Identical Assets
(Level 1)
Significant
Other
Observable Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Liabilities:
Unsecured senior notes payable
$10,818,366
$
$9,805,510
$
$9,805,510
Unsecured senior line of credit
$
$
$
$
$
Commercial paper program
$1,994,508
$
$1,995,070
$
$1,995,070
December 31, 2025
Book Value
Fair Value Hierarchy
Estimated
Fair Value
Quoted Prices in
Active Markets
for Identical Assets
(Level 1)
Significant
Other
Observable Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Liabilities:
Unsecured senior notes payable
$12,047,394
$
$10,675,433
$
$10,675,433
Unsecured senior line of credit
$
$
$
$
$
Commercial paper program
$353,161
$
$353,189
$
$353,189
The carrying values of cash and cash equivalents, restricted cash, tenant receivables, deposits, notes receivable, accounts
payable, accrued expenses, and other short-term liabilities approximate their fair value.
41
10.SECURED AND UNSECURED SENIOR DEBT
The following table summarizes our outstanding indebtedness and respective principal payments remaining as of June 30, 2026 (dollars in thousands):
Stated 
Rate
Interest
Rate(1)
Maturity
Date(2)
Principal Payments Remaining for the Periods Ending December 31,
Unamortized
(Deferred
Financing
Cost),
(Discount)/
Premium
Debt
2026
2027
2028
2029
2030
Thereafter
Principal
Total
Unsecured senior line of credit and
commercial paper program(3)
(3)
4.27%
(3)
1/22/30
(3)
$
$
$
$
$1,996,859
$
$1,996,859
$(2,351)
$1,994,508
Unsecured senior notes payable
3.95%
4.13
1/15/27
350,000
350,000
(296)
349,704
Unsecured senior notes payable
3.95%
4.07
1/15/28
425,000
425,000
(675)
424,325
Unsecured senior notes payable
4.50%
4.60
7/30/29
300,000
300,000
(693)
299,307
Unsecured senior notes payable
2.75%
2.87
12/15/29
400,000
400,000
(1,449)
398,551
Unsecured senior notes payable
4.70%
4.81
7/1/30
450,000
450,000
(1,501)
448,499
Unsecured senior notes payable
4.90%
5.05
12/15/30
700,000
700,000
(3,555)
696,445
Unsecured senior notes payable
3.375%
3.48
8/15/31
750,000
750,000
(3,381)
746,619
Unsecured senior notes payable
2.00%
2.12
5/18/32
900,000
900,000
(5,579)
894,421
Unsecured senior notes payable
1.875%
1.97
2/1/33
1,000,000
1,000,000
(5,805)
994,195
Unsecured senior notes payable
2.95%
3.07
3/15/34
800,000
800,000
(6,096)
793,904
Unsecured senior notes payable
4.75%
4.88
4/15/35
500,000
500,000
(4,270)
495,730
Unsecured senior notes payable
5.50%
5.66
10/1/35
550,000
550,000
(6,007)
543,993
Unsecured senior notes payable
5.25%
5.41
3/15/36
750,000
750,000
(10,866)
739,134
Unsecured senior notes payable
5.25%
5.38
5/15/36
400,000
400,000
(3,595)
396,405
Unsecured senior notes payable
4.85%
4.93
4/15/49
300,000
300,000
(2,698)
297,302
Unsecured senior notes payable
4.00%
3.95
2/1/50
390,801
390,801
5,441
396,242
Unsecured senior notes payable
3.00%
3.16
5/18/51
352,398
352,398
(4,413)
347,985
Unsecured senior notes payable
3.55%
3.70
3/15/52
475,406
475,406
(6,180)
469,226
Unsecured senior notes payable
5.15%
5.26
4/15/53
500,000
500,000
(7,260)
492,740
Unsecured senior notes payable
5.625%
5.71
5/15/54
600,000
600,000
(6,361)
593,639
Unsecured debt weighted-average interest
rate/Total
4.08%
$
$350,000
$425,000
$700,000
$3,146,859
$8,268,605
$12,890,464
$(77,590)
$12,812,874
(1)Represents the weighted-average interest rate as of the end of the applicable period, including amortization of loan fees, amortization of debt premiums (discounts), and other bank fees.
(2)Reflects any extension options that we control.
(3)Refer to footnote 3 on the following page. In July 2026, we executed an agreement to amend our $5.0 billion unsecured senior line of credit. The amendment is expected to become effective in September 2026, upon the satisfaction of
certain conditions. The amendment extends the maturity date from January 22, 2030 to January 22, 2032, including extension options that we control. In addition, the amendment reduces the applicable borrowing rate and eliminates the
existing sustainability-linked pricing adjustments, resulting in an applicable borrowing rate and facility fee of SOFR plus 0.725% and 0.15%, respectively, from the currently applicable borrowing rate and facility fee of SOFR plus 0.835% and
0.14%, respectively.
42
10.SECURED AND UNSECURED SENIOR DEBT (continued)
The following table summarizes our unsecured senior debt and amounts outstanding under our unsecured senior line of credit
and commercial paper program as of June 30, 2026 (dollars in thousands):
Fixed-Rate
Debt
Variable-Rate
Debt
Weighted-Average
Interest
Remaining
Term
(in years)
Total
Percentage
Rate(1)
Unsecured senior notes payable
$10,818,366
$
$10,818,366
84.4%
4.04%
10.9
Unsecured senior line of credit
and commercial paper program
1,994,508
1,994,508
(2)
15.6
4.27
(2)
3.6
(3)
Total/weighted average
$10,818,366
$1,994,508
$12,812,874
100.0%
4.08%
9.7
(3)
Percentage of total debt
84.4%
15.6%
100%
(1)Represents the weighted-average interest rate as of the end of the applicable period, including expense/income related to the amortization of loan fees, amortization of
debt premiums (discounts), and other bank fees.
(2)As of June 30, 2026, we had no outstanding balance on our unsecured senior line of credit and $1.99 billion of commercial paper notes outstanding.
(3)We calculate the weighted-average remaining term of our commercial paper notes by using the maturity date of our unsecured senior line of credit. Using the maturity
date of our outstanding commercial paper notes, the consolidated weighted-average maturity of our debt is 9.2 years. The commercial paper notes sold during the six
months ended June 30, 2026 were issued at a weighted-average yield to maturity of 4.17% and had a weighted-average maturity term of 15 days.
Issuance and repayments of unsecured senior notes payable
In February 2026, we completed tender offers to repurchase an aggregate debt principal amount of approximately $1.33 billion
of a portion of our outstanding 4.00% Senior Notes due 2050, 3.00% Senior Notes due 2051, and 3.55% Senior Notes due 2052. Cash
consideration paid was $952.2 million. The repurchase was primarily funded through the issuance of $750.0 million of 5.25% unsecured
senior notes due 2036, and approximately $200 million of short-term borrowings under our commercial paper program. In connection
with the debt repurchase, we recognized a gain on early extinguishment of debt aggregating $366.4 million, including the write-off of
unamortized debt issuance costs and other transaction-related costs.
In January 2026, we repaid $300.0 million of 4.30% unsecured senior notes payable upon maturity. No gain or loss was
incurred in connection with this repayment.
In April 2026, we repaid $350.0 million of 3.80% unsecured senior notes payable upon maturity. No gain or loss was incurred
in connection with this repayment.
$5.0 billion unsecured senior line of credit
As of June 30, 2026, our unsecured senior line of credit, which matures in 2030, including extension options under our control,
had aggregate commitments of $5.0 billion, and bore an interest rate of SOFR plus 0.835%. In addition to the cost of borrowing, the
unsecured senior line of credit is subject to an annual facility fee of 0.14% based on the aggregate commitments outstanding. Based on
achievement of certain annual sustainability metrics, the interest rate and facility fee rate are also subject to upward or downward
adjustments of up to four basis points with respect to the interest rate and up to one basis point with respect to the facility fee rate.
During the three months ended March 31, 2026, we achieved certain annual sustainability targets, as described in our
unsecured senior line of credit agreement, which reduced the borrowing rate by four basis points for a one-year period to SOFR plus
0.835%, from SOFR plus 0.875%, and reduced the facility fee by one basis point to 0.14% from 0.15%. As of June 30, 2026, we had no
outstanding balance on our unsecured senior line of credit.
In July 2026, we executed an agreement to amend our $5.0 billion unsecured senior line of credit. The amendment is expected
to become effective in September 2026, upon the satisfaction of certain conditions. The amendment extends the maturity date from
January 22, 2030 to January 22, 2032, including extension options that we control. In addition, the amendment reduces the applicable
borrowing rate and eliminates the existing sustainability-linked pricing adjustments, resulting in an applicable borrowing rate and facility
fee of SOFR plus 0.725% and 0.15%, respectively, from the currently applicable borrowing rate and facility fee of SOFR plus 0.835%
and 0.14%, respectively. In connection with the amendment, we expect to recognize a loss on early extinguishment of debt of
approximately $3.3 million for the partial write-off of unamortized loan fees.
$2.50 billion commercial paper program
Our commercial paper program allows us to issue up to $2.50 billion of commercial paper notes that bear interest at short-term
fixed rates with a maturity of generally 30 days or less and a maximum maturity of 397 days from the date of issuance. This program is
back-stopped by our unsecured senior line of credit, and at all times we expect to retain a minimum undrawn amount of borrowing
capacity under our unsecured senior line of credit equal to the amount of commercial paper notes outstanding. We use the net
proceeds from the issuances of the notes for general working capital and other general corporate purposes, which may include, but are
not limited to, the repayment of other debt and selective development, redevelopment, or acquisition of properties. During the six
43
10.SECURED AND UNSECURED SENIOR DEBT (continued)
months ended June 30, 2026, the notes were issued at a weighted-average yield to maturity of 4.17% and had a weighted-average
maturity term of 15 days. As of June 30, 2026, we had $1.99 billion outstanding under our commercial paper program.
Interest expense
The following table summarizes interest expense for the three and six months ended June 30, 2026 and 2025 (in thousands):
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Interest incurred
$138,059
$137,719
$272,616
$268,660
Capitalized interest
(73,717)
(82,423)
(143,690)
(162,488)
Interest expense
$64,342
$55,296
$128,926
$106,172
11. HEDGE AGREEMENTS
We have fixed-to-fixed cross-currency swap agreements designated as net investment hedges to mitigate the impact of
fluctuations in the USDCAD exchange rate on our real estate investments in Canada. Under the terms of the swap agreements, USD
fixed interest amounts are payable to us and CAD fixed interest amounts are payable to the counterparty.
On April 30, 2026, our cross-currency swap agreements with an aggregate notional amount of CAD $340.0 million matured.
The maturity of the swap agreements did not result in the reclassification of amounts previously recognized in accumulated other
comprehensive income to earnings because the related net investment had not been sold or substantially liquidated as of June 30,
2026.
During the three months ended June 30, 2026, we entered into new fixed-to-fixed cross-currency swap agreements
designated as net investment hedges, which were deemed effective on the commencement date and remained highly effective as of
June 30, 2026. As of June 30, 2026, the aggregate notional amount of our outstanding cross-currency swap agreements was CAD
$270.0 million, and the corresponding total USD notional amount was approximately $197.3 million. The new swap agreements mature
on January 29, 2027.
As of June 30, 2026, all of our assets in Canada were designated as held for sale. Unrealized gains or losses related to our
cross-currency swap agreements will be reclassified from accumulated other comprehensive income into net income upon the sale or
substantial liquidation of our real estate investments in Canada. Refer to “Hedge accounting” in Note 2 – “Summary of significant
accounting policies” to our unaudited consolidated financial statements for additional information.
The tables below summarize the fair value of our cross-currency swap agreements designated as net investment hedges and
the effect on our consolidated financial statements. Comparative information for the impact on the three and six months ended June 30,
2025 is not presented as there were no outstanding cross-currency swap agreements during those periods. Amounts are presented in
USD (in thousands).
Fair value of cross-currency swap agreements designated as net investment hedges
Balance Sheet Location
June 30, 2026
December 31, 2025
Other assets
$6,455
$
Accounts payable, accrued expenses, and other liabilities
$
$928
Effect on consolidated other comprehensive income
Location in Consolidated Statement of
Comprehensive Income
June 30, 2026
Three Months Ended
Six Months Ended
Total unrealized gains recognized in
other comprehensive income
Unrealized gains on foreign currency
translation, net
$4,730
$8,066
Effect on consolidated statements of operations
Location in Consolidated
Statement of Operations
June 30, 2026
Three Months Ended
Six Months Ended
Total gain recognized in net income(1)
Other income
$869
$3,648
(1)Represents net interest settlements and interest rate forward points excluded from assessment of hedge effectiveness. Refer to “Hedge accounting” in Note 2 –
“Summary of significant accounting policies” to our unaudited consolidated financial statements for additional information.
44
12. ACCOUNTS PAYABLE, ACCRUED EXPENSES, AND OTHER LIABILITIES
The following table summarizes the components of accounts payable, accrued expenses, and other liabilities as of June 30,
2026 and December 31, 2025 (in thousands):
June 30, 2026
December 31, 2025
Accounts payable and accrued expenses
$394,010
$510,580
Accrued construction
270,622
314,836
Acquired below-market leases
118,000
133,033
Conditional asset retirement obligations
34,151
34,342
Deferred rent liabilities
26,073
14,659
Operating lease liability
354,905
360,543
Unearned rent and tenant security deposits
1,180,926
876,252
Other liabilities
134,839
152,828
Total
$2,513,526
$2,397,073
As of June 30, 2026 and December 31, 2025, our conditional asset retirement obligations primarily consisted of the soil and
groundwater remediation liabilities associated with certain properties. Some of our properties may contain asbestos or may be
subjected to other hazardous or toxic substances, which, under certain conditions, require remediation. We engage independent
environmental consultants to conduct Phase I or similar environmental assessments at our properties. This type of assessment
generally includes a site inspection, interviews, and a public records review; asbestos, lead-based paint, and mold surveys; subsurface
sampling; and other testing. We recognize a liability for the fair value of a conditional asset retirement obligation when the fair value of
the liability can be reasonably estimated. In addition, environmental laws and regulations subject our tenants, and potentially us, to
liability that may result from our tenants’ routine handling of hazardous substances and wastes as part of their operations at our
properties. As of June 30, 2026, we are not aware of any additional environmental liability that we believe would require additional
disclosures or recognition in our consolidated financial statements.
45
13.EARNINGS PER SHARE
We grant two types of restricted stock awards: (i) restricted stock awards with nonforfeitable dividends and (ii) restricted stock
awards with forfeitable dividends.
Unvested restricted stock awards (“RSAs”) with nonforfeitable dividends are considered participating securities and included in
the computation of EPS using the two-class method. Under this method, we allocate net income (after amounts attributable to
noncontrolling interests) to common stockholders and these RSAs by using the weighted-average shares of each class outstanding for
quarter-to-date and year-to-date periods independently, based on their respective participation rights to dividends declared (or
accumulated) and undistributed earnings.
Unvested RSAs with forfeitable dividends do not qualify as participating securities under the two-class method because the
dividends are forfeited if the awards do not vest. As a result, undistributed earnings are not allocated to these awards prior to vesting,
and these awards have no effect on the computation of basic EPS while unvested. Once these awards vest, they are included in the
denominator of basic EPS, weighted for the portion of the reporting period they were vested. Prior to vesting, these awards are included
in the denominator of diluted EPS if they are dilutive, which is determined using the treasury stock method. Under this method,
incremental shares are calculated as the difference between the total unvested shares and the number of shares that could
hypothetically be repurchased using the assumed proceeds (including unrecognized compensation cost related to these awards).
These incremental shares are weighted for the portion of the reporting period they were unvested and are included in the diluted EPS
denominator only if their inclusion reduces EPS (i.e., if they are not antidilutive).
In addition, from time to time, we enter into forward equity sales agreements. We consider the potential dilution resulting from
the forward equity sales agreements on the EPS calculations. At inception, the agreements do not have an effect on the computation of
basic EPS as no shares are delivered until settlement. The common shares issued upon the settlement of the forward equity sales
agreements, weighted for the period these common shares were outstanding, are included in the denominator of basic EPS. To
determine the dilution resulting from the forward equity sales agreements during the period of time prior to settlement, we calculate the
number of weighted-average shares outstanding – diluted using the treasury stock method. As of June 30, 2026, no forward equity
sales agreements were outstanding.
The table below reconciles the numerators and denominators of the basic and diluted EPS computations for the three and six
months ended June 30, 2026 and 2025 (in thousands, except per share amounts):
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Net (loss) income
$(38,969)
$(62,189)
$359,408
$(23,527)
Net income attributable to noncontrolling interests
(33,814)
(44,813)
(70,538)
(92,414)
Net income attributable to unvested RSAs with nonforfeitable
dividends
(908)
(2,609)
(2,149)
(5,269)
Numerator for basic and diluted EPS – net (loss) income
attributable to Alexandria Real Estate Equities, Inc.’s common
stockholders
$(73,691)
$(109,611)
$286,721
$(121,210)
Denominator for basic EPS – weighted-average shares of
common stock outstanding
170,718
170,135
170,658
170,328
Dilutive effect of unvested RSAs with forfeitable dividends
382
Denominator for diluted EPS – weighted-average shares of
common stock outstanding
170,718
170,135
171,040
170,328
Net (loss) income per share attributable to Alexandria Real
Estate Equities, Inc.’s common stockholders:
Basic
$(0.43)
$(0.64)
$1.68
$(0.71)
Diluted
$(0.43)
$(0.64)
$1.68
$(0.71)
46
14.STOCKHOLDERS’ EQUITY
Common equity transactions
Common stock repurchase program
On December 8, 2025, we announced that our Board of Directors authorized a new common stock repurchase program that
allows for the repurchase of up to $500.0 million of our common stock through December 31, 2026. This new program replaced our
prior stock repurchase program. As of the date of this report, no repurchases have been made under the new program and
$500.0 million remains available for future share repurchases.
ATM common stock offering program
In February 2024, we entered into an ATM common stock offering program that allows us to sell up to an aggregate of
$1.50 billion of our common stock.
During the six months ended June 30, 2026, we had no activity under our ATM program. As of June 30, 2026, the remaining
aggregate amount available under our ATM program for future sales of common stock was $1.47 billion.
Dividends
During the three months ended March 31, 2026, we declared cash dividends on our common stock aggregating $125.5 million,
or $0.72 per share.
During the three months ended June 30, 2026, we declared cash dividends on our common stock aggregating $125.4 million,
or $0.72 per share.
Accumulated other comprehensive loss
The change in accumulated other comprehensive loss attributable to Alexandria Real Estate Equities, Inc.’s stockholders for
the six months ended June 30, 2026 was due to net unrealized losses of $3.6 million, and included $11.7 million of unrealized foreign
currency translation losses related to our operations in Canada, partially offset by $8.1 million of unrealized gains resulting from the
changes in the fair value of our cross-currency swap agreements due to the weakening of the Canadian dollar. Refer to Note 11 –
“Hedge agreements” to our unaudited consolidated financial statements for additional information.
Common stock, preferred stock, and excess stock authorizations
Our charter authorizes the issuance of 400.0 million shares of common stock, of which 170.7 million shares were issued and
outstanding as of June 30, 2026. Our charter also authorizes the issuance of up to 100.0 million shares of preferred stock, none of
which were issued and outstanding as of June 30, 2026. In addition, 200.0 million shares of “excess stock” (as defined in our charter)
are authorized, none of which were issued and outstanding as of June 30, 2026.
47
15.SEGMENT INFORMATION
We are a life science REIT focused on developing, redeveloping, and operating properties that provide space for lease to
tenants primarily in the life science industry. Our properties are leased predominantly through triple-net lease agreements and share
key characteristics, including generic and reusable improvements, consistent lease structures, and business and financial strategy. All
properties are located within North America, predominantly in the U.S., and operate within a comparable regulatory environment.
Operating segments
Our Chief Operating Decision Maker (“CODM”), represented by our Executive Chairman and our Chief Executive Officer,
evaluates operating results at the geographic market level to assess performance and allocate resources. Our operating segments align
with our markets, including Greater Boston, San Diego, the San Francisco Bay Area, and Seattle, among others. Regular market
performance updates are provided directly to the CODM. These updates include each market’s net operating income (“NOI”), which
serves as the profit or loss measure used by the CODM for performance assessment and resource allocation. NOI provides useful
information regarding performance of each market as it reflects income and expenses incurred in connection with real estate operations
in each market. This metric enables the CODM to evaluate the profitability and performance of each market on a consistent and
comparable basis, supporting decisions on capital resource allocation, including in connection with development, redevelopment,
acquisition, and disposition activities in each market.
Evaluation of economic similarity and aggregation of operating segments
In accordance with the segment reporting accounting standard, we evaluate the economic similarity of our operating
segments. Seven of our nine operating segments exhibit consistent long-term economic characteristics, including similar historical long-
term NOI margins, which are also expected to remain similar in the future. Additionally, these markets share similar operational
characteristics, including nature of services provided (i.e., leasing, operating, developing, and redeveloping life science properties),
tenant base (i.e., a variety of tenants involved in the life science industry), methods of operation (i.e., consistent lease structures,
property management practices, and business strategies), and nature of the regulatory environment (consistent across North America,
where all our operating segments are located). Based on shared economic characteristics, we have aggregated our seven operating
segments into one reportable segment for segment reporting purposes. The remaining operating segments, which do not meet the
aggregation criteria and individually do not meet the quantitative thresholds to qualify as reportable segments, were included in the “all
other” category in the tables below.
The following table presents the reportable segment profit or loss measure, NOI, for the three and six months ended June 30,
2026 and 2025 (in thousands):
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Reportable segment revenues:
Revenues from external customers
$629,674
$703,457
$1,250,933
$1,402,656
Other income
22,861
10,488
27,396
17,015
Reportable segment total revenues
652,535
713,945
1,278,329
1,419,671
Reportable segment total rental operating expenses
(211,334)
(212,402)
(423,992)
(424,838)
Reportable segment net operating income (reportable
segment profit or loss)
$441,201
$501,543
$854,337
$994,833
Significant expenses included in the reportable segment profit or loss measure (i.e., NOI) are represented by the reportable
segment total rental operating expenses and are disclosed in the table above. These expenses primarily include property taxes, utilities,
repairs and maintenance, engineering, janitorial, and other costs.
48
15.SEGMENT INFORMATION (continued)
Presented below is the reconciliation of the reportable segment total revenues to the consolidated revenues, the reportable
segment total rental operating expenses to consolidated rental operations, and the reportable segment NOI to the consolidated net
income (in thousands):
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Reconciliation of reportable segment revenues to
consolidated total revenues:
Reportable segment total revenues
$652,535
$713,945
$1,278,329
$1,419,671
All other revenues
10,249
48,095
55,477
100,527
Consolidated total revenues
$662,784
$762,040
$1,333,806
$1,520,198
Reconciliation of reportable segment total rental operating
expenses to consolidated rental operations:
Reportable segment total rental operating expenses
$(211,334)
$(212,402)
$(423,992)
$(424,838)
All other rental operating expenses
3,998
(12,031)
(7,486)
(25,990)
Consolidated rental operations
$(207,336)
$(224,433)
$(431,478)
$(450,828)
Reconciliation of reportable segment net operating income
to consolidated net (loss) income:
Reportable segment net operating income (reportable
segment profit or loss)
$441,201
$501,543
$854,337
$994,833
All other revenues
10,249
48,095
55,477
100,527
All other rental operating expenses
3,998
(12,031)
(7,486)
(25,990)
Other items not allocated to segments:
General and administrative
(36,861)
(29,128)
(71,546)
(59,803)
Interest expense
(64,342)
(55,296)
(128,926)
(106,172)
Depreciation and amortization
(304,384)
(346,123)
(609,825)
(688,185)
Impairment of real estate
(222,470)
(129,606)
(227,969)
(161,760)
Equity in earnings (losses) of unconsolidated real
estate joint ventures
413
(9,021)
266
(9,528)
Investment income (losses)
133,227
(30,622)
128,645
(80,614)
Gain on early extinguishment of debt
366,435
Gain on sales of real estate
13,165
Consolidated net (loss) income
$(38,969)
$(62,189)
$359,408
$(23,527)
The following table reconciles reportable segment investments in real estate to consolidated total assets (in thousands).
Reportable segment investments in real estate constitute the total assets of our reportable segment. Consolidated assets not allocated
to segments represent all asset line items presented in our consolidated balance sheets other than consolidated investments in real
estate.
June 30, 2026
December 31, 2025
Reportable segment investments in real estate
$27,578,790
$27,510,082
All other investments in real estate
1,547,105
1,179,914
Consolidated investments in real estate
29,125,895
28,689,996
Consolidated assets not allocated to segments
5,506,331
5,391,839
Consolidated total assets
$34,632,226
$34,081,835
16.SUBSEQUENT EVENTS
Sales of real estate assets in July 2026
In July 2026, we completed the disposition of one future development project aggregating 250,000 SF and one operating
property aggregating 228,000 RSF in the Palo Alto submarket of our San Francisco Bay Area market, for an aggregate sales price of
$163.0 million, with no gain or loss recognized.
Refer to Note 3 – “Investments in real estate” to our unaudited consolidated financial statements for additional information.
49
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Forward-looking statements
Certain information and statements included in this quarterly report on Form 10-Q, including, without limitation, statements
containing the words “forecast,” “guidance,” “goals,” “projects,” “estimates,” “anticipates,” “believes,” “expects,” “intends,” “may,” “plans,”
“seeks,” “should,” “targets,” or “will,” or the negative of those words or similar words, constitute “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements involve inherent risks and uncertainties regarding events, conditions, and financial trends that
may affect our future plans of operations, business and financial strategy, results of operations, and financial position. A number of
important factors could cause actual results to differ materially from those included within or contemplated by the forward-looking
statements, including, but not limited to, the following:
Operating factors, such as a failure to operate our business successfully in comparison to market expectations or in
comparison to our competitors, our inability to obtain capital when desired or refinance debt maturities when desired, and/
or a failure to maintain our status as a REIT for federal tax purposes;
Market and industry factors, such as adverse developments concerning the life science industry and/or our tenants;
Government factors, such as any unfavorable effects resulting from federal, state, local, and/or foreign government
policies, laws, and/or funding levels;
Global factors, such as negative economic, social, political, financial, credit market, banking conditions, and/or regional
armed hostilities; and
Other factors, such as climate change, cyber intrusions, and/or changes in laws, regulations, and financial accounting
standards.
This list of risks and uncertainties is not exhaustive. Additional information regarding risk factors that may affect us is included
under Part I, “Item 1A. Risk factors”; and Part II, “Item 7. Management’s discussion and analysis of financial condition and results of
operations” in our annual report on Form 10-K for the year ended December 31, 2025, and under respective sections in this quarterly
report on Form 10-Q. Readers of this quarterly report on Form 10-Q should also read our other documents filed publicly with the SEC
for further discussion regarding such factors.
50
Overview
We are a Maryland corporation formed in October 1994 that has elected to be taxed as a REIT for federal income tax
purposes. Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science
REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate
niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Megacampus ecosystems in
AAA life science and advanced technology innovation cluster locations, including Greater Boston, San Diego, the San Francisco Bay
Area, Seattle, Maryland, Research Triangle, and New York City. As of June 30, 2026, Alexandria has a total market capitalization of
$21.84 billion and an asset base that includes 36.0 million RSF of operating properties and 2.8 million RSF of Class A/A+ properties
undergoing construction.
We develop dynamic Megacampus ecosystems that enable and inspire some of the world’s most brilliant minds and innovative
companies to create life-changing scientific and technological innovations. We believe in the utmost professionalism, humility, and
teamwork. Our tenants include multinational pharmaceutical companies; life science product, service, and device companies; public
and private biotechnology companies; advanced technologies companies; biomedical institutions; U.S. government institutions; and
others. Alexandria has a long-standing and proven track record of developing Class A/A+ properties clustered in highly dynamic and
collaborative Megacampus environments that enhance our tenants’ ability to successfully recruit and retain world-class talent and
inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science
companies through our venture capital platform.
As of June 30, 2026:
Investment-grade or publicly traded large cap tenants represented 57% of our annual rental revenue;
Approximately 97% of our leases (on an annual rental revenue basis) contained effective annual rent escalations
approximating 3% that were either fixed or indexed based on a consumer price index or other index;
Approximately 91% of our leases (on an annual rental revenue basis) were triple net leases, which require tenants to pay
substantially all real estate taxes, insurance, utilities, repairs and maintenance, common area expenses, and other
operating expenses (including increases thereto) in addition to base rent;
Approximately 91% of our leases (on an annual rental revenue basis) provided for the recapture of capital expenditures
(such as HVAC maintenance and/or replacement, roof replacement, and parking lot resurfacing) that we believe would
typically be borne by the landlord in traditional office leases; and
75% of our leasing activity during the last twelve months was generated from our existing tenant base.
A key element of our business and financial strategy is our unique focus on Class A/A+ properties primarily located in
collaborative Megacampus ecosystems in AAA life science and advanced technology innovation clusters. Our Megacampus
ecosystems are designed for optionality and scalability, offering our tenants a clear path to address their growth requirements, including
through our future developments and redevelopments. Strategically located near top academic and medical research institutions and
equipped with curated amenities and services and convenient access to transit, our Megacampus ecosystems are designed to support
our tenants in attracting and retaining top talent and in meeting our tenants’ growth needs, which we believe is a key driver of tenant
demand for our properties. Our strategy also includes drawing upon our deep, broad, and long-standing real estate and life science
industry relationships in order to retain tenants, identify and attract new and leading tenants, and source additional real estate.
51
Executive summary
Operating results
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Net (loss) income attributable to Alexandria’s
common stockholders – diluted:
In millions
$(73.7)
$(109.6)
$286.7
$(121.2)
Per share
$(0.43)
$(0.64)
$1.68
$(0.71)
Funds from operations attributable to Alexandria’s
common stockholders – diluted, as adjusted:
In millions
$296.1
$396.4
$592.0
$788.4
Per share
$1.73
$2.33
$3.46
$4.63
For additional information, refer to “Funds from operations and funds from operations, as adjusted, attributable to Alexandria
Real Estate Equities, Inc.’s common stockholders” under “Definitions and reconciliations.”
A best-in-class REIT with a high-quality and diverse tenant base, strong margins, and long lease terms
(As of or for the three months ended June 30, 2026, unless stated otherwise)
Occupancy of operating properties
86.9%
Occupancy of operating properties, including executed leases with future occupancy
90.9%
Percentage of total annual rental revenue in effect from Megacampus platform
80%
Percentage of total annual rental revenue in effect from investment-grade or publicly traded large cap tenants
57%
Operating margin
69%
Adjusted EBITDA margin
67%
Percentage of leases containing annual rent escalations
97%
Weighted-average remaining lease term:
Top 20 tenants
10.0
years
All tenants
7.7
years
Strong tenant collections(1):
Rents and receivables for the three months ended June 30, 2026, collected as of the date of this report
99.9%
(1)Refer to “Tenant collections” under “Definitions and reconciliations” for additional details.
Strong and flexible balance sheet with significant liquidity; top 20% credit rating ranking among all publicly traded U.S. REITs; long-
duration remaining debt term (as of June 30, 2026)
Net debt and preferred stock to Adjusted EBITDA of 7.0x and fixed-charge coverage ratio of 3.3x for the three months ended
June 30, 2026 annualized; the respective targets for the three months ending December 31, 2026, annualized, are 5.6x6.2x
and 3.6x4.1x.
We expect improvement in our quarter-annualized net debt and preferred stock to Adjusted EBITDA ratio in the second
half of 2026 as we complete dispositions, sales of partial interests, and other capital sources.
Significant liquidity of $3.60 billion and extension of our $5.0 billion unsecured senior line of credit to 2032.
Only 6% of our total debt matures through 2028.
9.7-year weighted-average remaining debt term, the longest among S&P 500 REITs.
Total debt and preferred stock to gross assets of 31%.
Intermediate-term goal for leverage: mid-5x range.
52
Solid leasing volume exceeding 1.0 million RSF during the three months ended June 30, 2026
Total leasing volume surpassed 1.0 million RSF during the three months ended June 30, 2026, increasing 60% from the three
months ended March 31, 2026 and exceeding the average quarterly leasing volume for the period from the second quarter of
2025 through the first quarter of 2026 of 952,365 RSF by approximately 87,000 RSF.
Includes 397,919 RSF of combined previously vacant and development and redevelopment space; second-highest
amount since the second quarter of 2024, excluding the 466,598 RSF build-to-suit lease signed in the third quarter of
2025.
75% of our leasing activity during the last twelve months was generated from our existing tenant base.
Three Months Ended
Six Months
Ended June 30,
2026
June 30, 2026
March 31, 2026
Leasing volume in RSF:
Leasing of development and redevelopment space
68,771
117,935
186,706
Leasing of previously vacant space
329,148
148,734
477,882
397,919
266,669
664,588
Lease renewals and re-leasing of space
640,998
380,687
1,021,685
Total leasing volume
1,038,917
647,356
1,686,273
Lease renewals and re-leasing of space:
Rental rate changes
(0.7)%
(15.0)%
(7.4)%
Rental rate changes (cash basis)
(4.3)%
(15.8)%
(9.6)%
Ongoing execution of Alexandria’s capital recycling strategy
We plan to continue funding a significant portion of our capital requirements for the year ending December 31, 2026 through
dispositions of land, non-core assets, sales of partial interests, and other capital sources.
(in millions)
Sales Price
%
Completed as of the date of this report
$170
Pending transactions subject to non-refundable deposits, signed letters of intent, and/or sale agreement
negotiations
1,159
1,329
46%
Dispositions, sales of partial interests, and other capital sources in process
1,100
38%
Multiple alternatives under evaluation
471
16%
2026 guidance midpoint for dispositions, sales of partial interests, and other capital sources
$2,900
We expect to allocate this capital as follows (based on guidance midpoints):
(in millions)
2026 Guidance
(Midpoint)
Construction focused on highly leased developments and lease-up of vacant space
$1,750
Reduction of debt to meet our leverage goal
1,675
Net cash provided by operating activities, as adjusted
(525)
$2,900
53
Occupancy and leasing progress on temporary vacancy
Operating occupancy as of March 31, 2026
87.7%
Key changes in occupancy:
Reclassification of space at 3000 Minuteman Road from redevelopment to operating in 2Q26, fully leased with
expected occupancy in 2Q27
(0.4)
(1)
Previously disclosed 2Q26 key lease expirations with expected downtime
(0.8)
Increase in occupancy, primarily due to the commencement of leases during 2Q26
0.4
Operating occupancy as of June 30, 2026
86.9
Vacant space with executed leases and future occupancy
4.0
(2)
Operating occupancy as of June 30, 2026, including executed leases with future occupancy
90.9%
(1)Refer to “Reduction of capital spend and funding needs” within this section for additional details regarding the 159,947 RSF lease executed during the three months
ended June 30, 2026.
(2)Represents executed leases aggregating 1.4 million RSF with occupancy expected upon completion of building and/or tenant improvements. The weighted-average
expected occupancy date is approximately November 2026, with expected annual rental revenue of approximately $69 million. We expect 64% of the total 1.4 million
RSF to be occupied by December 31, 2026. These spaces are located primarily in the Greater Boston, San Diego, and San Francisco Bay Area markets.
Key operating metrics
Same property net operating income changes
Decreased by 10.6% and 8.6% (cash basis) for the three months ended June 30, 2026, compared to the three months
ended June 30, 2025.
Decreased by 11.5% and 11.2% (cash basis) for the six months ended June 30, 2026, compared to the six months ended
June 30, 2025.
The decline was due to a decrease in same property occupancy, primarily driven by previously disclosed key lease
expirations with expected downtime aggregating 657,492 RSF during the three months ended March 31, 2026 and
260,888 RSF during the three months ended June 30, 2026, with weighted-average lease expiration dates of January
2026 and April 2026, respectively.
Same properties average occupancy:
87.1% for the three months ended June 30, 2026, compared to 92.6% same properties average occupancy for the three
months ended June 30, 2025.
88.2% for the six months ended June 30, 2026, compared to 93.5% same properties average occupancy for the six
months ended June 30, 2025.
Reduction of capital spend and funding needs
During the three months ended June 30, 2026, we executed a lease aggregating 159,947 RSF with an advanced technology
tenant at our redevelopment project at 3000 Minuteman Road in our Greater Boston market. The lease enables us to pivot a
portion of the redevelopment project from future laboratory and/or biomanufacturing use to a lower-cost advanced technology
use, reducing the project’s expected aggregate construction budget by approximately $80 million. We expect to deliver the
159,947 RSF of leased space in the second quarter of 2027 upon completion of building and tenant improvements.
As a result, the leased space was reclassified from redevelopment to operating, reducing the redevelopment project from
431,550 RSF as of March 31, 2026 to 271,603 RSF as of June 30, 2026.
We continue to evaluate the business and financial strategy for five projects aggregating 1.4 million RSF, which may allow us
to further reduce future construction funding requirements within our active pipeline.
As of June 30, 2026, we executed letters of intent aggregating 108,800 RSF for advanced technology use at our
redevelopment project at 311 Arsenal Street. If we are successful in executing these potential leases, we expect to evaluate
whether all or a portion of this project will be placed back into operation without the need to further redevelop for laboratory
use.
Non-income-producing assets as of June 30, 2026 are 16% of gross assets, a 4% reduction since December 31, 2024; we are
targeting a range of 11% to 16% by December 31, 2026.
54
Alexandria’s development and redevelopment pipeline delivered incremental annual net operating income of $57 million during 2Q26,
with an additional $42 million anticipated to be delivered by 4Q26
During the three months ended June 30, 2026, we placed into service one development project aggregating 426,927 RSF that
is 100% occupied by Bristol Myers Squibb at 4135 Campus Point Court in our University Town Center submarket and
delivered incremental annual net operating income aggregating $57 million.
Annual net operating income (cash basis) from recently delivered projects is expected to increase by $40 million upon the
burn-off of initial free rent, which has a weighted-average remaining period of approximately five months.
79% of the RSF in our total development and redevelopment pipeline is within our Megacampus ecosystems.
Development and Redevelopment Projects
Incremental
Annual Net
Operating Income
RSF
Occupied/
Leased/
Negotiating
Percentage
(dollars in millions)
Placed into service during six months ended June 30, 2026
$58
532,219
91%
Expected to be placed into service:
Second half of 2026
$42
(1)
174,662
(2)
84%
(3)
Fiscal years 2027 through 2028
93
1,258,004
68%
$135
(1)Includes expected partial deliveries through 2026 from projects expected to stabilize in 20272028, including speculative future leasing that is not yet fully
committed. Refer to the initial and stabilized occupancy years under “New Class A/A+ development and redevelopment properties: under construction” in Item 2 for
additional information.
(2)Represents the RSF of projects expected to stabilize in 2026. Does not include RSF for partial deliveries through 2026 from projects expected to stabilize in 2027
2028.
(3)Represents the current leased/negotiating percentage of our 174,662 RSF development project that is expected to stabilize in 4Q26.
Continued successful management of general and administrative expenses
General and administrative expenses for the three months ended June 30, 2026 aggregated $36.9 million, an increase of
$7.7 million, or 26.5%, compared with the three months ended June 30, 2025, but a decrease of $7.8 million, or 17.4%,
compared with the three months ended June 30, 2024. The decrease relative to 2024 reflects the continued benefit from cost-
efficiency initiatives implemented in prior years. The increase relative to 2025 primarily reflects the expected return of a portion
of the cost reductions achieved in 2025 that were temporary in nature, while approximately half of the cost reductions achieved
in 2025 have continued into 2026 and are expected to continue through the remainder of 2026.
Compared to 2024, we continue to expect approximately $76 million of cumulative general and administrative expense savings
in 2025 and 2026 (based on the midpoint of our 2026 guidance range).
For the trailing twelve months ended June 30, 2026, general and administrative expenses represented 6.6% of net operating
income, approximately half the average of other S&P 500 REITs for 2023–2025.
Key capital events
In July 2026, we executed an agreement to amend our $5.0 billion unsecured senior line of credit. The amendment is expected
to become effective in September 2026, upon the satisfaction of certain conditions. The amendment extends the maturity date
from January 22, 2030 to January 22, 2032, including extension options that we control. In addition, the amendment reduces
the applicable borrowing rate to SOFR plus 0.725% from the currently applicable SOFR plus 0.835%. In connection with the
amendment, we expect to recognize a loss on early extinguishment of debt of approximately $3.3 million related to the partial
write-off of unamortized loan fees during the three months ended September 30, 2026.
In April 2026, we repaid, upon maturity, $350.0 million of 3.80% unsecured senior notes payable. The repayment was funded
temporarily with borrowings under our commercial paper program, which will be repaid through planned dispositions, sales of
partial interests, and other capital sources included in our 2026 guidance. No gain or loss was incurred in connection with this
repayment.
Under our common stock repurchase program authorized in December 2025, we may repurchase up to $500.0 million of our
common stock through December 31, 2026. As of the date of this report, no shares have been repurchased under this
program and $500.0 million remains available for future share repurchases.
55
Dividend strategy to share net cash flows from operating activities with stockholders while retaining a significant portion for reinvestment
Common stock dividend declared of $0.72 per share for the three months ended June 30, 2026, consistent with the preceding
quarter. The declared dividend per common share reflects our commitment to maintaining the strength of our balance sheet,
enhancing financial flexibility, preserving liquidity, and sharing cash flows with our stockholders.
Significant net cash provided by operating activities, as adjusted, retained for reinvestment aggregating $2.60 billion for the
years ended December 31, 2022 through 2025 and the midpoint of our 2026 guidance range.
Dividend yield of 5.4% as of June 30, 2026 and dividend payout ratio of 42% for the three months ended June 30, 2026.
Key capital metrics as of or for the three months ended June 30, 2026
$21.84 billion in total market capitalization.
$9.02 billion in total equity capitalization.
Non-real estate investments aggregating $1.69 billion:
Unrealized gains presented in our consolidated balance sheet were $223.9 million, comprising gross unrealized gains and
losses aggregating $290.5 million and $66.6 million, respectively.
Investment income of $133.2 million for the three months ended June 30, 2026, presented in our consolidated statement of
operations, consisted of $10.3 million of realized gains, $131.9 million of unrealized gains, and $9.0 million of impairment
charges.
56
Trends that may affect our future results
Currently identified key market trends and uncertainties that had or may have a negative effect on our business are discussed
below. Although we seek to minimize the risks posed by these trends and uncertainties as discussed in the mitigating factors section
below, there can be no assurance that these measures will be successful in preventing or mitigating material impacts on our future
results of operations, financial position, and cash flows. Refer to “Item 1A. Risk factors” in Part I of our annual report on Form 10-K for
the year ended December 31, 2025 for discussion of additional risks we face.
New supply and reduced demand for life science space may continue to negatively affect our rental rates, occupancy, and
operating results.
Influx of supply. During and after the COVID-19 pandemic, the shift toward hybrid and remote work arrangements as well as
exceptionally strong demand for life science space, driven by public health urgency and supported by historically low interest
rates, prompted certain office and other real estate investors to repurpose underutilized office spaces into laboratory facilities,
initiating a wave of new development activity across the sector. Our success and the success of other laboratory operators
prompted new and existing developers to commence speculative redevelopment and/or development laboratory projects in
anticipation of demand for such facilities. These conversion and speculative development projects have contributed to a
significant influx of new laboratory properties in our top three markets—Greater Boston, San Diego, and San Francisco Bay
Area. Life science real estate availability in these top markets—measured as the percentage of life science RSF available
relative to total life science RSF—rose to approximately 29% during 2025, from approximately 4% in 2021. This surge created
supply that materially exceeded current demand. As pandemic-driven urgency faded, the amount of available space became
the dominant factor influencing tenant activity, with absorption unable to match the influx of supply.
Decrease in demand. Adding to these challenges, life science tenant demand—after reaching historically high levels in 2021—
has moderated significantly. The average tenant demand, measured by life science tenants’ RSF requirements, declined by
more than 60% in 2025 compared to 2021 across our top three markets: Greater Boston, San Diego, and San Francisco Bay
Area. This reflected a shift from extraordinary tenant demand driven by pandemic-related urgency to levels more consistent
with historical pre-pandemic norms, particularly those observed during 2016-2018. Importantly, this shift occurred amid
substantially higher available supply, as discussed above, further negatively impacting occupancy and rental rates in top life
science markets.
Exacerbating the recent demand trend, the life science industry faced an unusual convergence of macroeconomic, regulatory,
policy, and political challenges in 2025 that continued to affect the sector through the first half of 2026. These included
consequential shifts in leadership at the U.S. Department of Health and Human Services (“HHS”), tariff-related measures,
operational, leadership, and staff disruptions at the NIH and the FDA, threatened reductions in NIH funding of biomedical
research and proposals to limit NIH funding of indirect grant costs, heightened scrutiny of pharmaceutical pricing, and
increased global competition from China, discussed below. Collectively, these factors, including those described below,
increased uncertainty, leading tenants to defer leasing commitments and expansion decisions pending greater clarity. As a
result, absorption of available space has been notably slower.
Prolonged biotech bear market and capital constraints. The life science sector experienced the fifth consecutive year
of a broad-based biotech bear market in 2025. Life science venture capital fundraising declined to its lowest level since
2016, reducing overall levels of venture capital funds available to deploy in the future. Life science venture funds also
continued to be highly risk averse, focusing investments on clinical-stage and asset-based opportunities that may not
drive significant laboratory space needs. The initial public offering market for biotech companies remained largely closed
in 2025, eliminating a key source of liquidity and growth capital, but began to reopen selectively in 2026. Elevated
financing costs and broader economic and regulatory uncertainty continued to constrain access to debt and equity
financing. These factors slowed company formation, reduced headcount growth, and delayed laboratory expansion
decisions, directly impacting leasing demand for specialized life science space. Although capital markets and leasing
activity showed early signs of improvement in 2026, the recovery remained uneven, and laboratory demand continued to
be constrained by disciplined capital allocation and significant excess supply.
Regulatory and policy factors affecting absorption. At the same time, the regulatory environment experienced
significant disruption. The FDA saw more than 50% turnover in senior leadership during the first half of 2025,
accompanied by employee layoffs and delays in regulatory review decisions. Leadership turnover continued in 2026,
including the departure of the FDA Commissioner in May 2026. Changing expectations related to clinical trial requirements
and flexibility for rare diseases with large unmet needs created additional uncertainty around development timelines for
certain regulated products. These conditions have reduced some tenants’ near-term confidence in expansion and capital
investment decisions.
Biomedical research institutions faced increased uncertainty around federal funding policies throughout 2025. The
proposed 15% cap on NIH institutional indirect grant spending, subsequently ruled unlawful by an appellate court, raised
concerns for biomedical research institutions about the ability to recover infrastructure and operating costs, which
materially constrained incremental real estate demand among certain federally supported entities.
57
In April 2026, the Trump administration discontinued its legal effort to implement the proposed 15% cap on NIH indirect
cost reimbursements, allowing the federal court ruling blocking the policy to become final. Existing negotiated
reimbursement rates remain in effect. Accordingly, NIH-funded research institutions continue to operate under the current
reimbursement framework.
Further, government actions aimed at reducing U.S. prescription drug prices have heightened uncertainty regarding future
returns on pharmaceutical and biotechnology investments. This has weighed on risk appetite across the sector and
constrained investment into some areas of research and development. As a result, some tenants have delayed or scaled
back expansion plans, reducing leasing activity and occupancy levels.
At the same time, global competition for life science research has intensified, with certain foreign markets, especially
China, rapidly gaining ground as biotechnology leaders through centralized funding and faster regulatory approval
timelines. Coupled with immigration-related restrictions implemented in the U.S. during 2025 that limit access to
international research talent, these policy actions not only affect current activities but also pose a significant threat to the
long-term viability of the U.S. biomedical industry. The cumulative effect of these developments may significantly reduce
tenant demand for U.S. life science real estate. Refer to “Item 1A. Risk factors” in our annual report on Form 10-K for
additional details.
Impact on our business. The surge in supply and decrease in demand for life science space have led to industry-wide elevated
vacancy rates, slower leasing activity, pressure on rental rates, higher lease concessions, and increased competition for
tenants. Our operating occupancy declined from 90.9% as of December 31, 2025 to 86.9% as of June 30, 2026, and we
project our operating occupancy to be approximately 87.0% as of December 31, 2026, representing the midpoint of our
guidance range for occupancy percentage in North America as of December 31, 2026.
To remain competitive, we have realized lower rental rate changes on renewed and re-leased spaces and have offered more
tenant improvement allowances or additional tenant concessions, including free rent, to retain existing tenants or attract new
tenants. We project our rental rate on renewed and re-leased spaces to decrease by approximately 5.0% for the year ending
December 31, 2026, representing the midpoint of our guidance range. Furthermore, to maintain long-term tenant relationships
and sustain occupancy levels within our core assets, our existing operating properties may require additional revenue- and
non-revenue-enhancing capital expenditures earlier than typically expected.
The table below reflects a trend of increasing revenue- and non-revenue-enhancing capital expenditures, including tenant
improvement expenditures. The table also presents the trend, on a per RSF basis, of increasing tenant improvement
allowance, leasing commissions, and free rent concessions, and of less favorable changes in rental rates related to our
renewed/re-leased spaces, as well as decreases in our operating occupancy (dollars in thousands, except per RSF amounts):
Revenue- and
Non-Revenue-
Enhancing
Capital
Expenditures
Tenant
Improvements/
Leasing
Commissions
per RSF
Free Rent
Concessions per
Annum
(leases executed in
trailing 12 months)
Rental Rate
Changes
(on renewed/
re-leased
spaces)
Operating
Occupancy
(as of each
period end)
2024
$273,377
$46.89
0.7 months
16.9%
94.6%
2025
$324,293
$55.34
1.5 months
7.0%
90.9%
Six months ended June 30, 2026
$269,067
$50.92
1.5 months
(7.4)%
86.9%
Midpoint of 2026 guidance range
$510,000
N/A
(5.0)%
87.0%
Additionally, we have key lease expirations with expected downtime in 2026, primarily in the Greater Boston, San Francisco
Bay Area, and Seattle markets, aggregating 451,450 RSF as of June 30, 2026 with a weighted-average lease expiration date
of August 2026. These spaces are expected to become vacant at lease expiration and re-leased to new tenants. We expect
downtime on the 451,450 RSF to be approximately 12 to 24 months on a weighted-average basis. In addition, we have
identified 1.4 million RSF of key lease expirations in 2027 that are expected to have downtime of approximately 12 to 24
months on a weighted-average basis. Considering elevated new laboratory supply in these markets, there can be no
assurance that we will be able to re-lease some or all of this space on acceptable terms, without significant capital
expenditures, or within anticipated time frames, even at reduced rates.
As of June 30, 2026, we anticipate that 1.4 million RSF of our projects undergoing construction will be placed into service from
July 1, 2026 through 2028 and will generate $135 million in future incremental annual net operating income. These projects
are 71% leased or under lease negotiations as of June 30, 2026. Furthermore, we have an additional 1.4 million RSF of
projects under evaluation which are 15% leased or under lease negotiations. For these projects, we are evaluating the
business and financial strategy, including continuing construction, repositioning for advanced technology or other non-
laboratory use, selling, or pausing development or redevelopment. If we decide to sell or pause, such actions could negatively
impact our FFO and operating metrics. Alternatively, if we decide to invest limited capital, we may place some or all of these
projects into operation, which could temporarily reduce our operating occupancy until the projects are leased and occupied.
58
Landlord-funded tenant improvement allowances have increased significantly for first-generation space, including development
and redevelopment projects, with most space in shell condition requiring landlords to fund the full build-out cost. This trend
places additional pressure on projected returns and overall economics, and further challenges our ability to attract and secure
tenants for the remaining unleased RSF related to these projects at the expected rates, or at all, which could result in a
shortfall or delay in the commencement of the projected incremental annual net operating income.
Unfavorable macroeconomic and capital market conditions may continue to adversely affect the value of our real estate and
non-real estate portfolios, which could result in additional significant impairments and may impact our ability to raise capital
efficiently to further our business objectives.
The effective execution of our development and redevelopment activities is contingent on access to the capital required to fund
these projects. We expect funding for construction spending in 2026 to aggregate $1.75 billion at the midpoint of our 2026
guidance range for construction spending. This includes significant remaining construction costs to complete our active
pipeline and anticipated increases in both revenue- and non-revenue-enhancing capital expenditures in our operating portfolio.
As a result, our capital plan and leverage management strategy have increased our reliance on real estate dispositions, sales
of partial interests, and other capital sources to generate capital. However, current real estate market conditions, including
lower property valuations and increased capitalization rates, will likely adversely affect the timing and pricing of such
transactions.
Lower property valuations and increased capitalization rates. A portion of our projected construction spending and other uses
of capital is expected to be funded through dispositions, sales of partial interests, and other capital sources in core, land, and
non-core real estate assets. Real estate investments are generally less liquid than many other investment types, which can
present challenges in selling our properties in a timely manner or at desirable prices, especially in an environment of
oversupply.
In addition to the factors discussed above specifically affecting demand for life science space, broader real estate demand has
also been impacted by macroeconomic conditions, particularly elevated interest rates. Following the onset of the COVID-19
pandemic, the U.S. Federal Reserve reduced the federal funds target range to 0%0.25% in March 2020 and maintained that
near-zero range until March 2022. To address inflation concerns, the U.S. Federal Reserve then increased the target range
rapidly, reaching 5.25%5.50% in July 2023, where it remained for an extended period. Although the U.S. Federal Reserve
reduced the federal funds target range to 4.25%4.50% during 2024, and to 3.50%3.75% during 2025, interest rates remain
elevated. This continues to limit access to debt and/or equity financing for prospective buyers of real estate assets. All other
aspects being equal, such challenges for buyers contribute to an excess of properties available for sale, which exerts
downward pressure on property valuations and elevates capitalization rates, adversely impacting the sales proceeds we can
generate from our real estate asset sales.
The oversupply of life science real estate assets, discussed above, combined with high interest rates and reduced market
liquidity, has contributed to a prolonged period of lower property valuations and higher capitalization rates, resulting in
significant real estate impairments and making it more challenging to execute asset sales within the expected timelines and at
favorable pricing. In 2026, we expect to complete dispositions, sales of partial interests, and other capital sources of
approximately $2.90 billion at the midpoint of our 2026 guidance range. However, we may not be able to achieve this and/or
other targets disclosed in our 2026 guidance as a result of the uncertainties discussed in this section as well as in “Item 1A.
Risk factors” in Part I of our annual report on Form 10-K for the year ended December 31, 2025.
The table below presents total dispositions and a trend of increasing impairments of real estate and capitalization rates
associated with dispositions, sales of partial interests, and other capital sources in our real estate assets over the last several
years (dollars in thousands), which is partly attributable to the quality of core and non-core assets sold during each period.
Aggregate Sales Price
of Dispositions, Sales
of Partial Interests,
and Other Capital
Sources
Impairment of
Real Estate
Capitalization
Rates(1)
Capitalization
Rates
(Cash Basis)(1)
2024
$1,382,453
$223,068
7.7%
6.5%
2025
$1,813,778
$2,202,818
7.7%
(2)
7.5%
(2)
Six months ended June 30, 2026
$7,350
$227,969
N/A
Midpoint of 2026 guidance range
$2,900,000
(3)
(1)Capitalization rates are calculated only for stabilized operating assets sold. Refer to “Capitalization rates” under “Definitions and reconciliations” for additional
information.
(2)Represents the weighted-average capitalization rate for stabilized operating assets sold in 2025, which accounted for only 20% of the aggregate sales price
of dispositions, sales of partial interests, and other capital sources in 2025.
(3)We are not able to forecast impairments or capitalization rates for future periods without unreasonable effort due to the inherent difficulty of forecasting the
timing and amount of transactions that depend on market conditions outside of our control.
59
For additional information about our dispositions and real estate impairments recognized during the three months ended June
30, 2026, refer to “Sales of real estate assets and impairment of real estate” in Note 3 – “Investments in real estate” to our
unaudited consolidated financial statements in Item 1.
For 2026, we have established a disposition and joint venture program with expected sales of approximately $2.90 billion at
the midpoint of our 2026 guidance range for dispositions, sales of partial interests, and other capital sources. We may utilize
multiple sources of capital, including land and non-core dispositions, sales of partial interests, and other capital sources, to
fund (i) construction focused on highly leased developments and lease-up of vacant space, and (ii) repayment of senior
unsecured debt sufficient to achieve our net debt and preferred stock to Adjusted EBITDA – 4Q26 annualized target of 5.6x to
6.2x. We continue to evaluate available alternatives and expect to execute on cost-efficient sources of capital under prevailing
market conditions. We do not anticipate the issuance of any common equity during the year ending December 31, 2026.
In 2026, we are committed to dispose of certain assets classified as held for sale with an aggregate book value of
$555.8 million as of June 30, 2026. To achieve the midpoint of our 2026 guidance range of $2.90 billion for dispositions, sales
of partial interests, and other capital sources, we continue to evaluate a broad range of opportunities, including non-core
operating properties, both stabilized and unstabilized, and land parcels.
Under GAAP, real estate assets are evaluated for impairment upon an indication of potential impairment:
For real estate assets held and used, impairments are recognized if the sum of expected future undiscounted cash
flows, including estimated proceeds from eventual disposition, is less than the carrying amount. In such cases, the
carrying amount is reduced to estimated fair value.
For real estate assets held for sale, impairments are recognized if fair value less costs to sell is less than the carrying
amount.
In evaluating potential disposition targets that do not meet the criteria for held for sale classification, we apply a
probability-weighted approach, and in each case, no impairment charge is currently required.
If circumstances change, including changes in expected cash flows, capitalization rates, or market conditions, we may incur
additional material real estate impairments in 2026. For additional information on accounting for real estate impairments, refer
to “Impairment of long-lived assets” in Note 2 – “Summary of significant accounting policies” to our unaudited consolidated
financial statements in Item 1.
We expect to substantially complete our large-scale non-core disposition program in 2026, although some of these
dispositions could close in 2027. As of June 30, 2026, 80% of our annual rental revenue is from our Megacampus platform,
and we expect this percentage to continue to grow over time, in part through our disposition program.
Increased cost and limited availability of capital. Our 2026 guidance assumes a reduction of our outstanding unsecured senior
debt by approximately $1.68 billion, at the midpoint of our 2026 guidance range.
In February 2026, we completed tender offers to repurchase an aggregate debt principal amount of $1.33 billion
across a portion of our outstanding 4.00% Senior Notes due 2050, 3.00% Senior Notes due 2051, and 3.55% Senior
Notes due 2052. The tender offers were completed at an average discount of approximately 28%, for a total cash
payment of $952.2 million, resulting in the extinguishment of approximately $380 million of debt. We funded the
$952.2 million payment through the issuance of $750.0 million of 5.25% unsecured senior notes due 2036 and
approximately $200 million of short-term borrowings under our commercial paper program.
In January 2026 and April 2026, we repaid, upon maturity, $300.0 million of 4.30% unsecured senior notes and
$350.0 million of 3.80% unsecured senior notes, respectively. These repayments, aggregating $650 million, were
temporarily funded through borrowings under our commercial paper program.
Although we repaid a portion of our outstanding unsecured senior debt during 2026, these repayments have been fully
financed through the issuance of new unsecured senior debt. As a result, we have not yet made progress toward our targeted
$1.68 billion net unsecured senior debt reduction. Accordingly, achievement of this target debt reduction remains dependent on
our ability to generate proceeds during 2026 from planned real estate dispositions, sales of partial interests, and other capital
sources.
These expectations assume our ability to execute these transactions on acceptable terms. If we are unable to sell real estate
assets at our targeted prices or within our expected timeframes, we may need to reduce the projected amount of debt
repayment, delay the timing of such repayment, and/or increase our reliance on additional debt financing to fund the
approximately $1.75 billion of construction spending, based on the midpoint of our 2026 guidance range. Elevated interest
rates may result in debt financing options that are costlier, less accessible, or even unavailable, potentially limiting our ability to
complete our development and redevelopment projects on schedule and thereby delaying our expected incremental annual
net operating income generation.
60
The table below reflects interest rates related to unsecured senior notes payable that we have issued over the last several
years and in February 2026 (dollars in thousands). There is no assurance that high debt costs will not continue into the future.
Unsecured Senior
Notes Payable Issued
Interest Rate(1)
2024
$1,000,000
5.57%
2025
$550,000
5.66%
February 2026 issuance
$750,000
5.41%
(1)Includes amortization of loan fees, amortization of debt premiums (discounts), and other bank fees.
Capitalized Interest.
The table below presents gross interest expense, capitalized interest, and interest expense (in thousands):
Gross Interest Expense
Capitalized Interest
Interest Expense
2024
$516,799
$(330,961)
$185,838
2025
$557,122
$(330,424)
$226,698
Six months ended June 30, 2026
$272,616
$(143,690)
$128,926
Midpoint of 2026 guidance range
$520,000
$(240,000)
$280,000
For 2026, we expect capitalized interest of approximately $240 million at the midpoint of our guidance range. The decrease
compared to 2025 reflects our actions taken in response to the market conditions, including re-evaluating certain projects,
ceasing or pausing certain pre-construction activities on land and uncommitted projects to conserve capital, and disposing of
certain assets. As a result, we expect our interest expense to increase to approximately $280 million (at the midpoint of our
2026 guidance range) in 2026 from $226.7 million in 2025. Continued macroeconomic and capital market pressures may
necessitate further reevaluation of our plans, including temporary suspension of our construction projects, delay of future
projects, or the sale of non-income-producing properties, which could further reduce our capitalized interest and increase
interest expense.
Volatility in the valuation of non-real estate investments. We hold strategic investments in publicly traded companies and
privately held entities primarily involved in the life science industry. These investments are subject to market- and sector-
specific risks that can substantially affect their valuation. Like many other industries, the life science industry is susceptible to
macroeconomic challenges, such as ongoing economic and geopolitical uncertainty and a tighter capital environment. These
factors may lead to increased volatility in the valuation of our non-real estate investments.
In such an environment, distributions from our investments—which we may receive as dividends, as liquidation distributions
from our investments in limited partnerships, or as a result of mergers and acquisitions involving our privately held investees—
may be limited and could result in lower realized gains. Gross unrealized gains related to our non-real estate investments held
as of June 30, 2026, December 31, 2025, and December 31, 2024 aggregated to $290.5 million, $184.4 million, and
$228.1 million, respectively. These unrealized amounts are subject to market fluctuations and may not ultimately be realized.
We may not receive distributions from our investments or may face difficulties in monetizing our non-real estate investments at
optimal prices. There can be no assurance that we will be able to realize gains in the future. In periods with limited or no
realized gains, our FFO per share, as adjusted, may be adversely affected.
For the six months ended June 30, 2026, we recognized $28.5 million in realized gains on non-real estate investments and are
projecting realized gains of $75 million in 2026 at the midpoint of our guidance range. During the six months ended
June 30, 2026, we also recognized impairment charges and unrealized gains that reflect continued valuation pressures. The
table below presents components of investment income (loss) on our non-real estate investments (in thousands):
Realized
Gains
Significant
Realized Losses
Impairments
Unrealized
(Losses) Gains
Investment
(Loss) Income
2024
$117,214
$
$(58,090)
$(112,246)
$(53,122)
2025
$115,722
$(103,329)
$(95,716)
$26,980
$(56,343)
Six months ended June 30, 2026
$28,490
$
$(21,446)
$121,601
$128,645
Midpoint of 2026 guidance range
$75,000
N/A(1)
(1)We are not able to forecast investment income (loss) of future periods without unreasonable effort and therefore do not provide the information on a forward-
looking basis. This is due to the inherent difficulty of forecasting the timing and/or amount of items that depend on market conditions outside of our control.
Unfavorable market conditions could also lead to additional impairments of our investments in privately held entities that do not
report NAV per share, as well as other‑than‑temporary impairments of our non‑real‑estate investments accounted for under the
equity method.
61
The realization of any of the foregoing risks could continue to have material adverse impacts on our revenues and operating
performance, including, but not limited to, our income from rentals, net operating income, results of operations, funds from operations,
operating margins, initial stabilized yields (unlevered) on new or existing construction projects, occupancy, rental rates, EPS, FFO per
share, FFO per share, as adjusted, and net cash provided by operating activities, as adjusted. These impacts have adversely affected,
and could continue to adversely affect, our Adjusted EBITDA, which in turn may continue to negatively impact our key metrics such as
Adjusted EBITDA margin, net debt and preferred stock to Adjusted EBITDA, and fixed-charge coverage ratios. This may also impact
our credit ratings and credit rating outlooks. To preserve liquidity and mitigate an increase to our net debt and preferred stock to
Adjusted EBITDA ratio resulting from declines in Adjusted EBITDA, we may seek additional capital by pursuing additional sales of real
estate and non-real estate investments, or through equity offerings, which could be dilutive to existing stockholders. A reduction in
earnings and/or net cash provided by operating activities, as adjusted, could potentially necessitate or make advisable a reduction in
our dividends per share, as determined by our board of directors. Any of the foregoing could further negatively affect our business and
the market value of our common stock. 
Mitigating factors:
Reinforcing the Megacampus platform as our core growth engine. We believe our Megacampus strategy represents
our most powerful competitive advantage in an oversupplied life science real estate market. Our Megacampus
ecosystems are large-scale environments designed to meet the evolving needs of the world’s leading scientific and
technological organizations, located in life science innovation hubs in close proximity to top academic and medical
research institutions. This proximity is a key driver of tenant demand. These campuses are used in two distinct ways: (i) to
house the research operations of our tenants, and (ii) to recruit and retain the best talent available from a limited pool,
which underscores why their scale, strategic design, and location are critical. With our Megacampus ecosystems, we aim
to provide a superior set of amenities, services, and access to transit. With inspiring design and people-centric amenities,
we believe these campuses enhance our tenants’ confidence in using these spaces as effective recruiting tools. In
contrast, we believe that a significant amount of the competitive supply in the market today consists of isolated facilities
that provide operational space but lack the scale and strategic design that our Megacampus ecosystems deliver.
Our Megacampus ecosystems, which offer both high visibility and a clear path for growth, are designed for scalability to
accommodate our tenants’ growth. Our future development and redevelopment projects aggregate 21.3 million RSF as of
June 30, 2026, of which 79% is concentrated within our Megacampus ecosystems. Their strategic locations and path for
growth serve as powerful incentives for tenants to lease space from us.
We believe our Megacampus strategy has enabled us to capture a greater share of available leasing demand relative to
competitors in our core life science markets, even as overall supply has increased. The strength of this strategy is
reflected in the 2026 performance metrics below, achieved despite challenging macroeconomic, regulatory, policy, and
geopolitical environments:
Our occupancy of 86.9% as of June 30, 2026:
Outperforms market occupancy levels in our top three markets: Greater Boston, San Diego, and San Francisco
Bay Area.
Additional 4.0% occupancy is expected from 1.4 million RSF (4.0% of total operating RSF) of leased space that
was temporarily vacant as of June 30, 2026, primarily in our Greater Boston, San Diego, and San Francisco Bay
Area markets. These spaces are expected to become occupied upon completion of building and/or tenant
improvements, with a weighted‑average expected occupancy date of November 2026, and are expected to
generate annual rental revenue of approximately $69 million upon lease commencement.
During the six months ended June 30, 2026, we placed into service development and redevelopment projects
aggregating 532,219 RSF that are 91% occupied in various submarkets and delivered incremental annual net
operating income of $58 million.
Expected incremental annual net operating income from projects anticipated to be placed into service from the third
quarter of 2026 to the end of 2028:
$42 million from deliveries in the second half of 2026.
$93 million from 2027-2028 deliveries.
Strength of our brand. As a recognized leader in the life science and real estate sectors, Alexandria has successfully
built a diverse and high-quality tenant base. Over the past three decades, we have fostered long-standing relationships
and strategic partnerships with our tenants, which have enabled us to maintain strong occupancy levels and leasing
volume, generate growth in net operating income and cash flows, and effectively navigate various economic cycles. Key
indicators of our brand strength include the following:
As of June 30, 2026, 75% of our leasing activity during the last twelve months was from our existing tenant base.
As of June 30, 2026, 88% of our top 20 tenant annual rental revenue was derived from investment-grade or publicly
traded large cap companies.
Our tenant collections have remained consistently high, averaging 99.9% from the beginning of 2021 to June 30,
2026.
62
Prudent financial management. Our strong and flexible balance sheet and prudent balance sheet management are key
factors in our ability to navigate macroeconomic uncertainties and capitalize on new opportunities. The strength of our
financial position is highlighted by several key indicators:
Our significant liquidity of $3.60 billion as of June 30, 2026 provides us the flexibility to address our operational needs
and to pursue strategic opportunities.
We expect to fund a large portion of our capital requirements through the following sources in 2026:
$525 million in net cash provided by operating activities, as adjusted, at the midpoint of our 2026 guidance range.
$104.0 million in capital contributions to fund construction expected from our existing consolidated real estate
joint venture partners from July 1, 2026 through 2027 and beyond.
$2.90 billion from real estate dispositions, sales of partial interests, and other capital sources at the midpoint of
our 2026 guidance range.
As of June 30, 2026, our credit ratings from S&P Global Ratings and Moody’s Ratings were BBB+ and Baa2,
respectively, which rank in the top 20% among all publicly traded U.S. REITs.
Net debt and preferred stock to Adjusted EBITDA ratio target: 5.6x to 6.2x for the fourth quarter of 2026, annualized.
As of June 30, 2026, our fixed-rate debt represents 84.4% of our total debt, which provides predictability in debt
servicing costs. Since 2022, our quarter-end fixed-rate debt has averaged 95.7%.
Our debt maturity schedule is well laddered, which provides us with financial flexibility and reduces short-term
refinancing risks. As of June 30, 2026, only 6% of our debt matures through 2028.
As of June 30, 2026, the weighted-average remaining term of our debt is 9.7 years, which is the longest among S&P
500 REITs, and demonstrates our strategic approach to debt management and our focus on maintaining manageable
annual debt maturities. Pro forma for the amended and restated unsecured senior line of credit expected to become
effective in September 2026, our weighted-average remaining debt term would have been 10.0 years.
Operational excellence of our team. Alexandria focuses on operational excellence in the direct asset management and
operations of our Labspace® asset base. Our asset management and operations team is composed of highly experienced,
educated, and professionally credentialed facilities specialists. This expertise, essential in ensuring a secure and efficient
environment for groundbreaking scientific research, has been cultivated and maintained over many years.
The demanding nature of laboratory-based scientific research requires strict adherence to safety standards set by local,
state, and federal regulatory bodies. Key compliance aspects include good manufacturing practices (“GMP”) and Clinical
Laboratory Improvement Amendments (“CLIA”) certifications, adherence to national biosafety level guidelines, proper
permitting and handling of hazardous waste generation and chemical storage, maintenance of safety stations, effective
management of ultra-low temperature freezers, and careful licensing and management of radioactive materials.
Other mitigating factors
Improvement in office market. The increase in demand for premium office space since 2024, primarily driven by the
technology sector, particularly companies focused on AI, absorbed some of the market’s supply previously anticipated
for life science use and is now being repositioned back into office space. High ceilings, improved ventilation systems,
and abundant natural light, which are all features of life science real estate, have become highly desirable, appealing
to office and advanced technologies tenants. We expect this trend may lead to the exit from the life science sector of
inexperienced life science real estate developers and expedite the resolution of the oversupply impacting the sector.
Proactive reduction in capital spending and funding needs. To address higher capital costs and slower market
absorption, we implemented a disciplined reduction in construction spending. Based on the midpoint of our 2026
guidance range, our average annual construction spending is expected to decrease to approximately $1.74 billion for
2024–2026, representing a reduction of approximately $1.02 billion, or 37%, compared to the 2021–2023 average.
Our 2026 construction spending is primarily focused on:
Leasing vacant space at operating properties
Completing active committed construction projects
Limiting future pipeline pre-construction activity
This strategy supports a more self-funded capital plan while preserving flexibility for future growth opportunities.
Decrease in general and administrative expenses. Over the past several years, we have implemented comprehensive
measures to reduce our expenditures across our organization, including our general and administrative expenses,
through a variety of cost-control and efficiency initiatives, including, but not limited to:
Personnel-related matters, including:
Reduction in headcount over the last two years.
Restructuring of various compensation plans.
Streamlining of business processes:
Implementation of systems upgrades, process improvements, and smarter technology.
Renegotiation of contracts related to legal, technology, and operational support services, and
elimination of redundancies through better alignment and consolidation of roles.
63
As a result, we have achieved the following outcomes:
During the three months ended June 30, 2026, general and administrative expenses aggregated
$36.9 million, a decrease of $5.2 million, or 12%, compared to the quarterly average for 2024.
We expect $76 million of cumulative savings in 2025 and 2026 (based upon the midpoint of our guidance
range for 2026 general and administrative expenses), compared to 2024.
For the trailing twelve months ended June 30, 2026, our general and administrative expenses were 6.6% net
operating income, approximately half the 2023–2025 average of other S&P 500 REITs.
We believe the mitigating factors discussed above will help us manage prolonged market volatility while maintaining the
flexibility to act on strategic opportunities. Through disciplined execution of non-core asset recycling, targeted capital
allocation, continued focus on our Megacampus platform, moderated construction spending, and preservation of balance sheet
strength, we are building a resilient platform designed to deliver sustainable future growth and value creation across multiple
cycles. We believe these actions position us to emerge from the current cycle in a position of strength.
64
Operating summary
Same Property Performance:
  Net Operating Income Changes
Rental Rate Changes:
Renewed/Re-Leased Space
Margins(3)
Favorable Lease Structure(4)
Operating
Adjusted EBITDA
Strategic Lease Structure by Owner and
Operator of Collaborative Megacampus Ecosystems
69%
67%
Increasing cash flows
Percentage of leases containing annual
rent escalations
97%
Stable cash flows
Percentage of triple net leases
91%
Lower capex burden
Percentage of leases providing for the
recapture of capital expenditures
91%
Net Debt and Preferred Stock
to Adjusted EBITDA(5)
Fixed-Charge Coverage Ratio(5)
25
13
37
1
(1)
(2)
(1)
(2)
49
5.6x to 6.2x
61
3.6x to 4.1x
Mid-5x Range
Refer to “Same properties” and “Definitions and reconciliations” in Item 2 for additional details. “Definitions and reconciliations” contains the definitions of “Adjusted EBITDA,”
“Fixed-charge coverage ratio,” “Net debt and preferred stock to Adjusted EBITDA,” and “Net operating income” and their respective reconciliations from the most directly
comparable financial measures presented in accordance with GAAP.
(1)Refer to footnote 1 under “Same properties” in Item 2 for additional details.
(2)Refer to footnote 2 under “Leasing activity” in Item 2 for additional details.
(3)For the three months ended June 30, 2026.
(4)Percentages calculated based on our annual rental revenue in effect as of June 30, 2026.
(5)Quarter annualized.
65
Stable Cash Flows From Our High-Quality and Diverse Tenants
1
2199023256393
(1)
(2)
(3)
Percentage of ARE’s Annual Rental Revenue
Investment-Grade or
Publicly Traded Large Cap Tenants
88%
57%
of ARE’s Top 20 Tenant
Annual Rental Revenue
of ARE’s Total
Annual Rental Revenue
Weighted Average
Remaining Term(4)
10.0 Years
7.7 Years
of ARE’s Top 20 Tenants
All Tenants
As of June 30, 2026. Annual rental revenue represents amounts in effect as of June 30, 2026. Refer to “Definitions and reconciliations” in Item 2 for additional information.
(1)Represents the percentage of our annual rental revenue generated by professional services, finance, construction/real estate companies, and retail-related tenants.
(2)83% of our annual rental revenue from advanced technologies tenants is from investment-grade or publicly traded large cap tenants.
(3)81% of our annual rental revenue from biomedical institutions is from investment-grade or publicly traded large cap tenants.
(4)Represents the weighted-average remaining term based on annual rental revenue in effect as of June 30, 2026.
66
Leasing activity
The following table summarizes our leasing activity at our properties:
Three Months Ended
Six Months Ended
Year Ended
June 30, 2026
June 30, 2026
December 31, 2025
(Dollars per RSF)
Including
Straight-Line Rent
Cash Basis
Including
Straight-Line Rent
Cash Basis
Including
Straight-Line Rent
Cash Basis
Leasing activity:
Renewed/re-leased space(1)
 
 
 
 
 
 
Rental rate changes
(0.7)%
(4.3)%
(7.4)%
(9.6)%
7.0%
3.5%
New rates
$39.03
(2)
$41.66
(2)
$43.08
$46.04
$52.71
$53.66
Expiring rates
$39.29
$43.52
$46.51
$50.94
$49.27
$51.87
RSF
640,998
1,021,685
2,543,473
Tenant improvements/leasing
commissions
$45.57
(3)
$50.92
$55.34
Weighted-average lease term
6.8 years
7.5 years
9.0 years
Previously vacant/developed/
redeveloped space leased
New rates
$33.55
(2)
$34.13
(2)
$41.49
$41.34
$72.30
(4)
$67.56
Previously vacant RSF
329,148
477,882
944,362
Developed/redeveloped RSF(5)
68,771
186,706
704,821
(4)
Weighted-average lease term
9.6 years
12.4 years
13.8 years
Leasing activity summary (totals):
New rates
$36.93
$38.77
$42.45
$44.19
$60.42
$59.13
RSF
1,038,917
1,686,273
4,192,656
Weighted-average lease term
8.0 years
10.1 years
11.9 years
Lease expirations(1)
Expiring rates
$50.81
$53.94
$53.81
$58.39
$54.22
$55.56
RSF
1,169,042
(6)
2,509,851
4,460,081
Leasing activity includes 100% of results for properties in which we have an investment.
(1)Excludes month-to-month leases aggregating 291,724 RSF and 58,516 RSF as of June 30, 2026 and December 31, 2025, respectively. During the trailing twelve months
ended June 30, 2026, we granted free rent concessions averaging 1.5 months per annum.
(2)Leases executed with advanced technology tenants represented 29.2% of our total leasing volume for the three months ended June 30, 2026. Advanced technology
space typically generates lower rental rates, and requires lower capital investment, compared to laboratory space.
(3)Includes the impact of one lease aggregating 81,220 RSF at 10955 Alexandria Way in our Torrey Pines submarket, executed in April 2026 to accommodate the
expansion needs of a growth-stage life science company advancing next-generation therapeutics and to backfill a vacancy from a tenant wind-down. Delivery of the
space is expected in the first quarter of 2027 upon completion of tenant improvements. Excluding this lease, tenant improvements and leasing commissions for the
three months ended June 30, 2026 was $28.60 per RSF.
(4)Includes the largest life science lease in company history, executed in July 2025 with Novartis AG. The 16-year expansion build-to-suit lease aggregates 466,598
RSF and is located at the Campus Point by Alexandria Megacampus in our University Town Center submarket. Excluding this lease, previously vacant/developed/
redeveloped rental rates would have been $58.31 and $58.70 (cash basis) and development/redevelopment leasing volume would have been 238,223 RSF, for the
year ended December 31, 2025.
(5)Refer to “New Class A/A+ development and redevelopment properties: summary of pipeline” in Item 2 for additional information, including total project costs.
(6)Includes previously disclosed key lease expirations aggregating 260,888 RSF that became vacant during the three months ended June 30, 2026, with a weighted-
average lease expiration date of April 2026.
67
Contractual lease expirations
The following tables summarize the contractual lease expirations as of June 30, 2026:
Year
RSF
Percentage of
Occupied RSF
Annual Rental Revenue
(per RSF)(1)
Percentage of
Annual Rental Revenue
2026
(2)
959,302
3.2%
$44.98
2.4%
2027
2,938,215
9.9%
$60.39
9.8%
2028
3,641,986
12.3%
$50.48
10.2%
2029
1,945,145
6.6%
$42.34
4.6%
2030
2,525,229
8.5%
$43.24
6.0%
2031
3,571,099
12.1%
$53.19
10.5%
2032
961,096
3.3%
$54.69
2.9%
2033
2,169,347
7.3%
$49.96
6.0%
2034
2,566,256
8.7%
$67.46
9.6%
2035
1,032,429
3.5%
$57.15
3.3%
Thereafter
7,227,517
24.6%
$87.19
34.7%
Market
2026 Contractual Lease Expirations (in RSF)
Annual
Rental
Revenue
(per RSF)(1)
2027 Contractual Lease Expirations (in RSF)
Annual
Rental
Revenue
(per RSF)(1)
Leased
Negotiating/
Anticipating
Remaining
Expiring Leases
Total(2)
Leased
Negotiating/
Anticipating
Remaining
Expiring Leases
Total
Greater Boston
101,347
12,190
93,849
207,386
$51.56
42,458
106,399
148,857
$66.73
San Diego
83,965
83,965
60.25
383,498
383,498
42.30
San Francisco Bay Area
155
17,357
17,031
34,543
37.48
375
15,212
180,738
196,325
72.94
Seattle
6,193
6,276
22,291
34,760
29.37
18,205
96,573
174,346
289,124
42.21
Maryland
6,833
7,696
14,529
81.74
170,981
170,981
29.91
Research Triangle
13,385
11,913
8,853
34,151
23.99
39,891
206,807
246,698
34.64
New York City
32,890
32,890
97.03
98,612
98,612
98.03
Texas
65,628
65,628
28.77
26,160
26,160
27.74
Subtotal
193,541
47,736
266,575
507,852
49.34
100,929
111,785
1,347,541
1,560,255
49.26
Key lease expirations with expected downtime
31,391
192,847
227,212
451,450
(3)
40.10
1,377,960
1,377,960
(3)
72.92
Total
224,932
240,583
493,787
959,302
$44.98
100,929
111,785
2,725,501
2,938,215
$60.39
Percentage of expiring leases
23%
25%
52%
100%
3%
4%
93%
100%
Contractual lease expirations for properties classified as held for sale as of June 30, 2026 are excluded from the information on this page.
(1)Amounts in effect as of June 30, 2026.
(2)Excludes month-to-month leases aggregating 291,724 RSF as of June 30, 2026. Refer to “Leasing activity” in Item 2 for additional details.
(3)See tables below for additional details.
(4)Includes 317,385 RSF of key lease expirations from Bristol Myers Squibb across four properties, generating $24.0 million of annual rental revenue with a weighted-average expiration date of April 2027. Upon lease expiration, Bristol Myers
Squibb is expected to relocate to 4135 Campus Point Court, a 426,927 RSF R&D facility delivered in June 2026. We expect the vacated space to experience a period of downtime and are currently in early discussions for 190,085 RSF.
2026 Key Lease Expirations with Expected Downtime
2027 Key Lease Expirations with Expected Downtime
Total
Annual Rental
Revenue(1)
Weighted Average
Expiration Date
Weighted Average
Expected Downtime
Total
Annual Rental
Revenue(1)
Weighted Average
Expiration Date
Weighted Average
Expected Downtime
451,450 RSF
$18.1M
August 2026
12 to 24 months
1,377,960 RSF
$100.5M
March 2027
12 to 24 months
Reason for Expected Downtime
(Based on RSF)
Reason for Expected Downtime
(Based on RSF)
2199023256190
2199023256201
Relocation to Other
ARE Properties(4)
Leases at Assets Originally
Acquired for Redevelopment
Other
Relocation to Other ARE Properties
Other
Current Leasing Status
(Based on RSF) 
Current Leasing Status
(Based on RSF) 
2199023256318
2199023256329
Leased/Negotiating
Early Discussions
Marketing
Early Discussions
Marketing
68
Top 20 tenants
88% of Top 20 Tenant Annual Rental Revenue Is From Investment-Grade
or Publicly Traded Large Cap Tenants(1)
Our properties are leased to a high-quality and diverse group of tenants, with no individual tenant accounting for greater than
8.8% of our annual rental revenue in effect as of June 30, 2026. The following table sets forth information regarding leases with our 20
largest tenants in North America based upon annual rental revenue in effect as of June 30, 2026 (dollars in thousands, except average
market cap amounts):
Remaining
Lease
Term(1)
(in Years)
Aggregate
RSF
Annual
Rental
Revenue(1)
Percentage
of Annual
Rental
Revenue(1)
Investment-Grade
Credit Ratings
Average
Market
Cap
(in billions)
Tenant
Moody’s
S&P
1
Bristol Myers Squibb Company
8.5
1,653,689
$
161,572
8.8%
A2
A
$107.1
2
Eli Lilly and Company
9.0
1,054,241
92,202
5.0
Aa3
AA-
$883.2
3
Moderna, Inc.
12.4
462,100
71,571
3.9
$15.0
4
AstraZeneca PLC
5.7
611,326
56,151
(2)
3.0
A1
A+
$273.8
5
Takeda Pharmaceutical Company Limited
10.3
386,111
41,673
2.3
Baa1
BBB+
$50.3
6
Eikon Therapeutics, Inc.(3)
13.0
299,638
38,907
2.1
$0.6
7
Illumina, Inc.
5.3
792,687
29,977
1.6
Baa3
BBB
$18.9
8
United States Government
4.1
414,499
29,340
(4)
1.6
Aaa
AA+
$
9
Uber Technologies, Inc.
56.3
(5)
1,009,188
27,869
1.5
Baa1
BBB+
$172.9
10
Boston Children's Hospital
10.7
309,231
26,294
1.4
Aa2
AA
$
11
Novartis AG
1.9
(6)
321,743
25,111
1.4
Aa3
AA-
$290.2
12
Sanofi
4.5
267,278
22,045
1.2
Aa3
AA
$115.7
13
Alphabet Inc.
1.9
418,600
21,837
1.2
Aa2
AA+
$3,530.7
14
New York University
6.1
218,983
21,073
1.1
Aa2
AA-
$
15
Massachusetts Institute of Technology
3.5
242,428
20,529
1.1
Aaa
AAA
$
16
Merck & Co., Inc.
7.8
300,930
18,895
1.0
Aa3
A+
$253.5
17
Vaxcyte, Inc.
8.5
230,755
18,656
1.0
$6.4
18
Altos Labs, Inc.(7)
14.8
158,990
18,407
1.0
$
19
Charles River Laboratories, Inc.
9.3
187,418
18,061
1.0
$8.6
20
Amgen Inc.
9.6
309,945
17,899
1.0
Baa1
BBB+
$175.8
Total/weighted-average
10.0
(5)
9,649,780
$
778,069
42.2%
Annual rental revenue and RSF include 100% of each property managed by us. Refer to “Annual rental revenue” and “Investment-grade or publicly traded large cap tenants
under “Definitions and reconciliations” in Item 2 for additional details, including our methodologies of calculating annual rental revenue from unconsolidated real estate joint
ventures and average market capitalization, respectively.
(1)Based on total annual rental revenue in effect as of June 30, 2026.
(2)Of the $56.2 million of annual rental revenue generated by this tenant, $27.0 million relates to a 232,902-RSF lease at our Alexandria Center® for Life Science – Waltham
Megacampus, which expires in the first quarter of 2027. This lease is included in the 1.4 million RSF of 2027 key lease expirations with expected downtime disclosed under
“Contractual lease expirations” in Item 2. We do not anticipate the tenant to renew its lease and are actively marketing the space.
(3)Eikon Therapeutics, Inc. is a public biotechnology company led by Roger Perlmutter, a biopharmaceutical executive who previously served as an executive vice president
of Merck & Co., Inc. As of March 31, 2026, the company held $512 million in cash and marketable securities.
(4)Includes leases, which are not subject to annual appropriations, with governmental entities such as the NIH and the General Services Administration. Approximately 2% of
the annual rental revenue derived from our leases with the United States Government is cancellable prior to the lease expiration date.
(5)Includes (i) ground leases for land at 1455 and 1515 Third Street (two buildings aggregating 422,980 RSF) and (ii) leases at 1655 and 1725 Third Street (two buildings
aggregating 586,208 RSF) in our Mission Bay submarket owned by our unconsolidated real estate joint venture in which we have an ownership interest of 10%. Annual
rental revenue is presented using 100% of the annual rental revenue from our consolidated properties and our share of annual rental revenue from our unconsolidated real
estate joint ventures. Excluding these ground leases, the weighted-average remaining lease term for our top 20 tenants was 8.3 years as of June 30, 2026.
(6)Includes one lease at 100 Technology Square at Alexandria Technology Square® Megacampus in our Cambridge submarket aggregating 255,441 RSF, which generates
annualized rental revenue of $21.0 million and expires in March 2028. We do not expect the tenant to renew the lease and are actively marketing the space for re-lease.
(7)Altos Labs, Inc. is a private biotechnology company led by Hal Barron, M.D., former Chief Scientific Officer and President, R&D at GlaxoSmithKline. Altos Labs launched
with $3.0 billion in private funding in 2022, and is backed by a group of prominent investors.
69
Locations of properties
Our properties are strategically located in AAA life science and advanced technology innovation cluster markets. The following
table sets forth the total RSF, number of properties, and annual rental revenue in effect as of June 30, 2026 in each of our markets in
North America (dollars in thousands, except per RSF amounts):
RSF
Number of
Properties
Annual Rental Revenue
Market
Operating
Development
Redevelopment
Total
% of Total
Total
% of Total
Per RSF
Greater Boston
9,500,175
566,673
1,201,425
11,268,273
29%
63
$699,694
38%
$88.73
San Diego
6,444,923
466,598
6,911,521
19
56
338,631
18
58.44
San Francisco Bay Area
5,861,540
212,657
84,157
6,158,354
16
51
307,239
17
70.78
Seattle
2,846,133
227,577
3,073,710
8
39
111,216
6
44.58
Maryland
3,676,755
3,676,755
9
47
151,419
8
45.79
Research Triangle
3,436,158
3,436,158
9
36
88,834
5
27.52
New York City
727,674
727,674
2
2
65,192
4
93.85
Texas
1,651,094
66,350
1,717,444
4
13
39,944
2
28.37
Non-cluster/other markets
170,429
170,429
6
5,679
61.58
Properties held for sale
1,718,335
1,718,335
4
23
38,554
2
29.71
36,033,216
1,473,505
1,351,932
38,858,653
100%
336
$1,846,402
100%
$60.45
2,825,437
Summary of occupancy percentages in North America
The following table sets forth the occupancy percentages for our operating properties and our operating and redevelopment
properties in each of our North America markets, excluding properties held for sale, as of the following dates:
 
Operating Properties
Operating and Redevelopment Properties
Market
6/30/26
3/31/26
6/30/25
6/30/26
3/31/26
6/30/25
Greater Boston
83.0%
(1)
83.8%
90.1%
73.7%
73.1%
76.7%
San Diego
89.9
88.4
94.8
89.9
88.4
94.8
San Francisco Bay Area
83.1
(2)
87.6
88.9
81.9
86.4
85.2
Seattle
87.7
87.8
90.3
87.7
87.8
90.3
Maryland
91.5
92.3
93.9
91.5
92.3
93.9
Research Triangle
93.9
93.8
92.8
93.9
93.8
92.8
New York City
95.5
95.8
88.9
95.5
95.8
88.9
Texas
85.3
81.8
82.1
82.0
78.7
78.9
Subtotal
87.1
87.8
91.0
83.8
84.0
86.3
Canada
N/A
N/A
90.7
N/A
N/A
85.8
Non-cluster/other markets
54.1
86.0
72.6
54.1
86.0
72.6
86.9%
(3)
87.7%
90.8%
83.6%
84.1%
86.2%
(1)Decline in occupancy was primarily due to 159,947 RSF at our 3000 Minuteman Road redevelopment project in our Greater Boston market being placed back into
operation following the execution of a lease with an advanced technology tenant during the three months ended June 30, 2026. The lease enables us to pivot a portion
of the redevelopment project from future laboratory use to a lower-cost advanced technology use, reducing the project’s expected aggregate construction budget by
approximately $80 million. We expect to deliver the 159,947 RSF of leased space in the second quarter of 2027 upon completion of building and tenant improvements.
(2)Decline in occupancy since March 31, 2026 was primarily attributable to previously disclosed key lease expirations with expected downtime, including 137,316 RSF of
office space at Alexandria Stanford Life Science District, where we are evaluating a repositioning for advanced technology space, and 71,567 RSF across two properties
in our Palo Alto and South San Francisco submarkets. Of the latter, we have re-leased 17,271 RSF, and are actively marketing the remaining space.
(3)Excludes leases aggregating 1.4 million RSF, or 4.0% of total operating RSF, executed as of June 30, 2026 and expected to be occupied upon completion of building
and/or tenant improvements. The weighted-average expected occupancy date is approximately November 2026, with expected annual rental revenue of approximately
$69 million. We expect 64% of the total RSF to be occupied by December 31, 2026. These spaces are located primarily in the Greater Boston, San Diego, and San
Francisco Bay Area markets.
70
Investments in real estate
A key component of our business model is our disciplined allocation of capital to the development and redevelopment of new
Class A/A+ properties, and property enhancements identified during the underwriting of certain acquired properties, primarily located in
collaborative Megacampus ecosystems in AAA life science and advanced technology innovation clusters. These projects are focused
on providing high-quality, generic, and reusable spaces that meet the real estate requirements of a wide range of tenants. Upon
completion, each development or redevelopment project is expected to generate increases in rental income, net operating income, and
cash flows. Our development and redevelopment projects are generally in locations that are highly desirable to high-quality entities,
which we believe may result in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term
asset value. Our pre-construction activities are undertaken in order to prepare the property for its intended use and include entitlements,
permitting, design, site work, and other activities preceding commencement of construction of aboveground building improvements.
Our investments in real estate consisted of the following as of June 30, 2026 (dollars in thousands):
Development and Redevelopment
Under Construction
Operating
2H26
Stabilization
2027–2028
Stabilization
Evaluating
Business and
Financial
Strategy
Future
Subtotal
Total
Square footage
Operating
34,314,881
34,314,881
Future Class A/A+ development and
redevelopment properties
174,662
1,258,004
1,392,771
19,372,303
22,197,740
22,197,740
Future development and redevelopment square
feet currently included in rental properties(1)
(947,156)
(947,156)
(947,156)
Total square footage, excluding properties held for
sale
34,314,881
174,662
1,258,004
1,392,771
18,425,147
21,250,584
55,565,465
Properties held for sale
1,718,335
2,013,925
2,013,925
3,732,260
Total square footage
36,033,216
174,662
1,258,004
1,392,771
20,439,072
23,264,509
59,297,725
Investments in real estate
Gross book value as of June 30, 2026(2)
$29,139,650
$201,882
$1,195,667
$1,319,039
$3,917,800
$6,634,388
(3)
$35,774,038
Properties held for sale
455,917
188,192
188,192
644,109
Total gross investment in real estate, excluding
properties held for sale
$28,683,733
$201,882
$1,195,667
$1,319,039
$3,729,608
$6,446,196
$35,129,929
1649267441852
arrow.jpg
20%
17%
Development/
Redevelopment
Under Construction
Land/Future
Development
16%
11% to 16%
Non-Income-Producing Assets(4) as a Percentage of Gross Assets
(1)Refer to “Investments in real estate” under “Definitions and reconciliations” in Item 2 for additional details, including future development and redevelopment square feet
currently included in rental properties.
(2)Balances exclude accumulated depreciation and our share of the cost basis associated with our properties held by our unconsolidated real estate joint ventures, which is
classified as investments in unconsolidated real estate joint ventures in our consolidated balance sheet.
(3)Our share of investment in our development and redevelopment pipeline as of June 30, 2026 is $6.17 billion.
(4)Excludes properties classified as held for sale. Land parcels classified as held for sale represented approximately 0.5% of total non-income-producing assets as of
June 30, 2026, compared with approximately 1% as of December 31, 2025 and 2024.
71
Dispositions, sales of partial interests, and other capital sources
The following table summarizes our 2026 sources of capital activity during the six months ended June 30, 2026 and through the date of this report, and projections for the remainder
of 2026 (dollars in thousands):
Interest
Sold
Square Footage
Capitalization
Rate
(Cash Basis)
Price
(Our Share)
Property
Submarket/Market
Date of
Transaction
Operating
Future
Development
Capitalization
Rate
Completed during the three and six months ended June 30, 2026
$7,350
Completed in July 2026:
Land:
3825 and 3875 Fabian Way(1)
Palo Alto/San Francisco Bay Area
7/14/26
100%
228,000
250,000
N/A
163,000
Total completed 2026 dispositions as of August 3, 2026
170,350
Our share of pending dispositions and sales of partial interests subject to non-refundable deposits,
signed letters of intent, and/or purchase and sale agreement negotiations
1,158,626
1,328,976
Dispositions, sales of partial interests, and other capital sources in process
1,100,000
Multiple alternatives under evaluation
471,024
$2,900,000
2026 guidance range for dispositions, sales of partial interests, and other capital sources(2)
$2,100,000 – $3,700,000
Midpoint
$2,900,000
Weighted-average projected completion date of 2026 dispositions, sales of partial interests, and other capital sources
September 2026
(1)Represents one future development project aggregating 250,000 SF at 3825 Fabian Way and one operating building aggregating 228,000 RSF at 3875 Fabian Way in our Palo Alto submarket. These assets were acquired in 2019 with the
intent to develop them for life science use. However, due to the project’s macroeconomic outlook, the assets no longer aligned with our strategy and were sold to a residential developer. Based on the annualized results for the three months
ended June 30, 2026, the assets generated approximately $6.2 million of annual net operating income.
(2)For the year ending December 31, 2026, we may utilize multiple sources of capital, including land and non-core dispositions, sales of partial interests, and other capital sources, to fund (i) construction focused on highly leased
developments and lease-up of vacant space, and (ii) repayment of senior unsecured debt sufficient to achieve our net debt and preferred stock to Adjusted EBITDA – 4Q26 annualized target of 5.6x to 6.2x. We continue to evaluate
available alternatives and expect to execute on varied cost-efficient sources of capital under prevailing market conditions. We do not anticipate the issuance of any common equity during the year ending December 31, 2026.
72
New Class A/A+ development and redevelopment properties
pipeline.jpg
INCREMENTAL ANNUAL NET OPERATING INCOME
GROWTH EXPECTED FROM ALEXANDRIA’S
DEVELOPMENT AND REDEVELOPMENT DELIVERIES
Placed Into
Service
Near-Term
Deliveries
Intermediate-Term
Deliveries
1H26
Projected Stabilization: 2H26
Projected Stabilization:
20272028
$58M
$42M
$93M
91%
Occupied
84%
Leased/Negotiating
68%
Leased/Negotiating
532,219 RSF
174,662 RSF
1.3 million RSF
(2)
(3)
(1)
(4)
(5)
For the definition of “Net operating income” and a reconciliation from the most directly comparable GAAP measure, refer to the “Definitions and reconciliations in Item 2.
(1)Excludes future incremental annual net operating income from spaces placed into service that were vacant and/or unleased at delivery.
(2)Includes expected partial deliveries through 2026 from projects expected to stabilize in 2027-2028, including speculative future leasing that is not yet fully committed. Our share of incremental annual net operating income from
projects expected to be placed into service primarily commencing through 2026 is projected to be $42 million. Refer to the initial and stabilized occupancy years under “New Class A/A+ development and redevelopment properties:
under construction” in Item 2 for additional details.
(3)Our share of incremental annual net operating income from projects expected to stabilize in 2027-2028 is projected to be $59 million.
(4)Represents the current leased/negotiating percentage of development and redevelopment projects that are expected to stabilize through the end of 2026.
(5)Represents the RSF related to projects expected to stabilize in 2026. Does not include RSF for partial deliveries through 2026 from projects expected to stabilize in 2027-2028.
73
New Class A/A+ development and redevelopment properties: recent deliveries
Incremental Annual Net Operating Income Generated From
1H26 Deliveries Aggregated $58 million
99 Coolidge Avenue
4135 Campus Point Court
10075 Barnes Canyon Road
8800 Technology Forest Place
Greater Boston/
Cambridge/Inner Suburbs
San Diego/
University Town Center
San Diego/Sorrento Mesa
Texas/Greater Houston
146,147 RSF
426,927 RSF
253,079 RSF
57,042 RSF
100% Occupancy
100% Occupancy
80% Occupancy
100% Occupancy
99Coolidge.jpg
Campuspoint4135.jpg
barnescanyon10075 v2.jpg
Techforest8800.jpg
The following table presents development and redevelopment of new Class A/A+ projects placed into service during the six months ended June 30, 2026 (dollars in thousands):
Property/Market/Submarket
2Q26
Delivery
Date(1)
Our
Ownership
Interest
RSF Placed in Service
Occupancy
Percentage(2)
Total Project
Unlevered Yields
Prior to
1/1/26
1Q26
2Q26
Total
Initial
Stabilized
Initial
Stabilized
(Cash Basis)
RSF
Investment
Development projects
99 Coolidge Avenue/Greater Boston/Cambridge/Inner
Suburbs
N/A
100%
129,413
16,734
146,147
100%
320,809
$444,000
6.0%
6.8%
4135 Campus Point Court/San Diego/University Town
Center
6/1/26
58.2%
426,927
426,927
100%
426,927
524,000
10.8
6.2
10075 Barnes Canyon Road/San Diego/Sorrento Mesa
N/A
50.0%
171,469
81,610
(3)
253,079
80%
253,079
314,000
5.5
5.7
Redevelopment projects
8800 Technology Forest Place/Texas/Greater Houston
N/A
100%
50,094
6,948
57,042
100%
123,392
112,000
6.3
6.0
Weighted average/total
6/1/26
350,976
105,292
426,927
883,195
1,124,207
$1,394,000
7.7%
6.3%
(1)Represents the average delivery date for deliveries that occurred during the three months ended June 30, 2026, weighted by annual rental revenue.
(2)Occupancy reflects total operating RSF placed in service as of each respective delivery date when the space was placed into service. Subsequent occupancy changes are not reflected.
(3)Includes 50,531 RSF that were vacant and/or unleased at delivery.
74
New Class A/A+ development and redevelopment properties: under construction
99 Coolidge Avenue
50 and 60 Sylvan Road(1)
10200 Campus Point Drive
Greater Boston/
Cambridge/Inner Suburbs
Greater Boston/Route 128
San Diego/
University Town Center
174,662 RSF
267,015 RSF
466,598 RSF
84% Leased/Negotiating
74% Leased/Negotiating
100% Leased
99Coolidge.jpg
60 Sylvan.jpg
10210 Campus Point NovartisCP.jpg
1450 Owens Street
269 East Grand Avenue
701 Dexter Avenue North
San Francisco Bay Area/
Mission Bay
San Francisco Bay Area/
South San Francisco
Seattle/Lake Union
212,657 RSF
84,157 RSF
227,577 RSF
51% Leased/Negotiating
40% Leased/Negotiating
23% Leased/Negotiating
owens1450.jpg
269EGrand.jpg
701Dexter.jpg
(1)Image represents 60 Sylvan Road on the Alexandria Center® for Life Science – Waltham Megacampus. The project is expected to capture demand in our Route 128 submarket.
75
New Class A/A+ development and redevelopment properties: under construction (continued)
96% of Development and Redevelopment RSF Under Construction
Is Within our Megacampus Ecosystem
The following tables set forth a summary of our new Class A/A+ development and redevelopment properties under construction as of June 30, 2026 (dollars in thousands):
Property
Market/Submarket
Square Footage
Percentage
Occupancy(1)
Dev/
Redev
In Service
CIP
Total
Leased
Leased/
Negotiating
Initial
Stabilized
Under construction
2H26 stabilization
99 Coolidge Avenue
Greater Boston/Cambridge/Inner Suburbs
Dev
146,147
174,662
320,809
84%
84%
4Q23
4Q26
2027–2028 stabilization
50 and 60 Sylvan Road
Greater Boston/Route 128
Redev
267,015
267,015
74
74
4Q26
2027
10200 Campus Point Drive(2)
San Diego/University Town Center
Dev
466,598
466,598
100
100
2028
2028
1450 Owens Street
San Francisco Bay Area/Mission Bay
Dev
212,657
212,657
51
51
2027
2027
269 East Grand Avenue
San Francisco Bay Area/South San Francisco
Redev
84,157
84,157
40
40
2H26
2027
701 Dexter Avenue North
Seattle/Lake Union
Dev
227,577
227,577
23
23
3Q26
2027
1,258,004
1,258,004
68
68
Total
146,147
1,432,666
1,578,813
71%
71%
Evaluating business and financial strategy; earliest potential lab
delivery in 2028(3)
311 Arsenal Street
Greater Boston/Cambridge/Inner Suburbs
Redev
56,904
333,758
390,662
16%
44%
421 Park Drive
Greater Boston/Fenway
Dev
392,011
392,011
40 Sylvan Road
Greater Boston/Route 128
Redev
329,049
329,049
3000 Minuteman Road
Greater Boston/Other
Redev
271,603
271,603
(4)
8800 Technology Forest Place
Texas/Greater Houston
Redev
57,042
66,350
123,392
46
46
113,946
1,392,771
1,506,717
8%
15%
(1)Initial occupancy dates are subject to leasing and/or market conditions. Stabilized occupancy may vary depending on single tenancy versus multi-tenancy. Multi-tenant projects may increase in occupancy over time.
(2)Represents a single-tenant project that expands the existing Campus Point by Alexandria Megacampus, where we currently have a 58.2% ownership interest. The project is fully leased to Novartis AG that currently occupies one building
within the Megacampus aggregating 52,853 RSF, that generated annual rental revenue of $4.1 million as of June 30, 2026. The tenant is expected to vacate this building during 2028. We expect to fund the majority of future construction
costs at the Megacampus until our ownership interest increases to 75%, after which future capital would be contributed pro rata with our joint venture partner.
(3)We are evaluating multiple options, including whether to continue construction of laboratory improvements, pause construction, pursue lower-investment construction alternatives (including a pivot to advanced technology use), or pursue a
disposition, based upon future leasing interest. Under a lower-investment scenario, we would expect lower rent and tenant improvement requirements, and we would evaluate whether all or a portion of the property would be placed back
into operation. If we elect to continue to pursue construction of laboratory improvements for these projects, the earliest deliveries of these projects are in 2028.
(4)The decrease from 431,550 RSF as of March 31, 2026 to 271,603 RSF as of June 30, 2026 for this project reflects 159,947 RSF being placed back into operation from redevelopment following the execution of a lease with an advanced
technology tenant, enabling a pivot of redevelopment strategy from future laboratory use to advanced technology use. As of June 30, 2026, the 159,947 RSF of leased space remains vacant within our operating pool and is expected to be
delivered in the second quarter of 2027 upon completion of building and tenant improvements.
76
New Class A/A+ development and redevelopment properties: under construction (continued)
Our
Ownership
Interest
At 100%
Unlevered Yields
Property
Market/Submarket
In Service
CIP
Cost to
Complete
Total at
Completion
Initial
Stabilized
Initial Stabilized
(Cash Basis)
Under construction
2H26 stabilization with 84% leased/negotiating
99 Coolidge Avenue
Greater Boston/Cambridge/Inner Suburbs
100%
$203,414
$201,882
$38,704
$444,000
6.0%
6.8%
2027–2028 stabilization with 68% leased/negotiating(1)
50 and 60 Sylvan Road
Greater Boston/Route 128
100%
373,082
TBD
10200 Campus Point Drive(2)
San Diego/University Town Center
58.2%
87,875
572,125
660,000
7.3%
6.5%
1450 Owens Street
San Francisco Bay Area/Mission Bay
25.0%
257,055
TBD
269 East Grand Avenue
San Francisco Bay Area/South San Francisco
100%
143,100
701 Dexter Avenue North
Seattle/Lake Union
100%
334,555
1,195,667
Total
$203,414
$1,397,549
$860,000
(3)
$2,460,000
(3)
Our share of investment(3)(4)
$200,000
$1,170,000
$560,000
$1,930,000
Evaluating business and financial strategy; earliest potential lab
delivery in 2028(5)
311 Arsenal Street
Greater Boston/Cambridge/Inner Suburbs
100%
$28,100
$318,772
TBD
421 Park Drive
Greater Boston/Fenway
100%
629,367
40 Sylvan Road
Greater Boston/Route 128
100%
233,255
3000 Minuteman Road
Greater Boston/Other
100%
95,534
8800 Technology Forest Place
Texas/Greater Houston
100%
65,588
42,111
$93,688
$1,319,039
Refer to “Initial stabilized yield (unlevered)” under “Definitions and reconciliations” in Item 2 for additional information.
(1)We expect to provide total estimated costs and related yields for each project over the next several quarters.
(2)Refer to footnote 2 on the prior page for additional details.
(3)Represents dollar amount rounded to the nearest $10 million and includes preliminary estimated amounts for projects listed as TBD.
(4)Represents our share of investment based on our current ownership percentage upon completion of development or redevelopment projects. Our share of investment will be adjusted as our ownership percentage increases at the Campus
Point project.
(5)Refer to footnote 3 on the prior page for additional details.
77
New Class A/A+ development and redevelopment properties: summary of pipeline
79% of Our Total Development and Redevelopment Pipeline RSF
Is Within Our Megacampus Ecosystems
The following table summarizes the key information for all our development and redevelopment projects in North America as of June 30, 2026 (dollars in thousands):
Market
Property
Submarket
Our
Ownership
Interest
Book Value
Development and Redevelopment
Square Footage
Under
Construction
Future
Total(1)
Greater Boston
Megacampus: The Arsenal on the Charles
Cambridge/Inner Suburbs
100%
$331,654
333,758
34,157
367,915
311 Arsenal Street
Megacampus: 480 Arsenal Way and 446, 458, and 500 Arsenal Street, and 99
Coolidge Avenue
Cambridge/Inner Suburbs
100%
226,573
174,662
560,000
734,662
446, 458, and 500 Arsenal Street, and 99 Coolidge Avenue
Megacampus: Alexandria Center® for Life Science – Fenway
Fenway
100%
629,367
392,011
392,011
421 Park Drive
Megacampus: Alexandria Center® for Life Science – Waltham
Route 128
100%
673,010
596,064
515,000
1,111,064
40, 50, and 60 Sylvan Road, and 35 Gatehouse Drive
Megacampus: 30, 200, and 3000 Minuteman Road
Other
100%
113,619
271,603
350,000
621,603
3000 Minuteman Road
Megacampus: Alexandria Center® at Kendall Square
Cambridge
100%
49,411
174,500
174,500
100 Edwin H. Land Boulevard
Megacampus: Alexandria Technology Square®
Cambridge
100%
8,982
100,000
100,000
10 Necco Street
Seaport Innovation District
100%
107,225
175,000
175,000
215 Presidential Way
Route 128
100%
6,816
112,000
112,000
Other development and redevelopment projects
100%
167,700
740,000
740,000
$2,314,357
1,768,098
2,760,657
4,528,755
Refer to “Megacampus” under “Definitions and reconciliations” in Item 2 for additional information.
(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have
future development or redevelopment opportunities. Upon expiration of existing in-place leases, we intend to demolish or redevelop the existing property subject to market conditions and leasing. Refer to “Investments in real estate” under
“Definitions and reconciliations” in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.
78
New Class A/A+ development and redevelopment properties: summary of pipeline (continued)
Market
Property
Submarket
Our
Ownership
Interest
Book Value
Development and Redevelopment
Square Footage
Under
Construction
Future
Total(1)
San Diego
Megacampus: Campus Point by Alexandria
University Town Center
58.2%
(2)
$265,441
466,598
866,816
1,333,414
10010(3), 10140(3), and 10200 Campus Point Drive and 4165, 4224, and 4275(3)
Campus Point Court
11255 and 11355 North Torrey Pines Road
Torrey Pines
100%
166,000
215,000
215,000
Megacampus: One Alexandria Square
Torrey Pines
100%
69,959
125,280
125,280
10975 and 10995 Torreyana Road
Megacampus: 5200 Illumina Way
University Town Center
51.0%
17,940
451,832
451,832
9625 Towne Centre Drive
University Town Center
30.0%
852
100,000
100,000
Megacampus: Sequence District by Alexandria
Sorrento Mesa
100%
50,290
1,661,915
1,661,915
6290, 6310, 6340, 6350, and 6450 Sequence Drive
Megacampus: SD Tech by Alexandria
Sorrento Mesa
50.0%
136,170
493,845
493,845
9805 Scranton Road and 10065 Barnes Canyon Road
Other development and redevelopment projects
(4)
50,000
50,000
706,652
466,598
3,964,688
4,431,286
San Francisco Bay Area
Megacampus: Alexandria Center® for Science and Technology – Mission Bay
Mission Bay
25.0%
$257,055
212,657
212,657
1450 Owens Street
Megacampus: Alexandria Center® for Advanced Technologies – South San
Francisco
South San Francisco
100%
149,755
84,157
90,000
174,157
211(4) and 269 East Grand Avenue
Megacampus: Alexandria Center® for Advanced Technologies – Tanforan
South San Francisco
100%
462,052
1,930,000
1,930,000
1122, 1150, and 1178 El Camino Real
Alexandria Center® for Life Science – Millbrae
South San Francisco
48.6%
164,583
348,401
348,401
201 and 231 Adrian Road and 30 Rollins Road
Megacampus: Alexandria Center® for Life Science – San Carlos
San Carlos
100%
503,588
1,497,830
1,497,830
960 Industrial Road, 987 and 1075 Commercial Street, and 888 Bransten Road
2100, 2200, 2300, and 2400 Geng Road
Palo Alto
100%
130,290
240,000
240,000
$1,667,323
296,814
4,106,231
4,403,045
Refer to “Megacampus” under “Definitions and reconciliations” in Item 2 for additional information.
(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have
future development or redevelopment opportunities. Upon expiration of existing in-place leases, we intend to demolish or redevelop the existing property subject to market conditions and leasing. Refer to “Investments in real estate” under
Definitions and reconciliations” in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.
(2)The noncontrolling interest share of our real estate joint venture partner is anticipated to decrease to 25%, as we expect to fund the majority of future construction costs at the campus until our ownership interest increases to 75%, after
which future capital would be contributed pro rata with our partner.
(3)We have a 100% interest in this property.
(4)Includes a property in which we own a partial interest through a real estate joint venture. Refer to Note 4 – “Consolidated and unconsolidated real estate joint ventures” to our unaudited consolidated financial statements in Item 1 for
additional details.
79
New Class A/A+ development and redevelopment properties: summary of pipeline (continued)
Market
Property
Submarket
Our
Ownership
Interest
Book Value
Development and Redevelopment
Square Footage
Under
Construction
Future
Total(1)
Seattle
Megacampus: Alexandria Center® for Advanced Technologies – South Lake
Union
Lake Union
(2)
$634,437
227,577
1,057,400
1,284,977
601 and 701 Dexter Avenue North and 800 Mercer Street
1010 4th Avenue South
SoDo
100%
64,266
544,825
544,825
410 West Harrison Street
Elliott Bay
100%
26,141
91,000
91,000
Megacampus: Alexandria Center® for Advanced Technologies – Canyon Park
Bothell
100%
20,823
230,000
230,000
21660 20th Avenue Southeast
Other development and redevelopment projects
100%
159,938
706,087
706,087
905,605
227,577
2,629,312
2,856,889
Maryland
Megacampus: Alexandria Center® for Life Science – Shady Grove
Rockville
100%
30,138
296,000
296,000
9830 Darnestown Road
30,138
296,000
296,000
Research Triangle
Megacampus: Alexandria Center® for Life Science – Durham
Research Triangle
100%
169,483
2,060,000
2,060,000
Megacampus: Alexandria Center® for Advanced Technologies and AgTech –
Research Triangle
Research Triangle
100%
116,137
1,170,000
1,170,000
4 and 12 Davis Drive
Megacampus: Alexandria Center® for Sustainable Technologies
Research Triangle
100%
57,622
750,000
750,000
120 TW Alexander Drive, 2752 East NC Highway 54, and 10 South Triangle
Drive
Other development and redevelopment projects
100%
1,647
25,000
25,000
344,889
4,005,000
4,005,000
New York City
Megacampus: Alexandria Center® for Life Science – New York City
New York City
100%
182,969
550,000
(3)
550,000
$182,969
550,000
550,000
Refer to “Megacampus” under “Definitions and reconciliations” in Item 2 for additional information.
(1)Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have
inherent future development or redevelopment opportunities. Upon expiration of existing in-place leases, we intend to demolish or redevelop the existing property. Refer to “Investments in real estate” under “Definitions and reconciliations”
for additional information, including development and redevelopment square feet currently included in rental properties.
(2)We have a 100% interest in 601 and 701 Dexter Avenue North aggregating 415,977 RSF and a 60.0% interest in the future development project at 800 Mercer Street aggregating 869,000 RSF.
(3)During the three months ended September 30, 2024, we filed a lawsuit against the New York City Health + Hospitals Corporation and the New York City Economic Development Corporation for fraud and breach of contract concerning our
option to ground lease a land parcel to develop a future world-class life science building within the Alexandria Center® for Life Science – New York City Megacampus. Refer to “Other” in Note 3 – “Investments in real estate” to our
unaudited consolidated financial statements for additional information.
80
New Class A/A+ development and redevelopment properties: summary of pipeline (continued)
Market
Property
Submarket
Our
Ownership
Interest
Book Value
Development and Redevelopment
Square Footage
Under
Construction
Future
Total(1)
Texas
Alexandria Center® for Advanced Technologies at The Woodlands
Greater Houston
100%
$45,211
66,350
116,405
182,755
8800 Technology Forest Place
1001 Trinity Street and 1020 Red River Street
Austin
100%
140,035
250,010
250,010
Other development and redevelopment projects
100%
61,513
344,000
344,000
246,759
66,350
710,415
776,765
Other development and redevelopment projects
100%
47,504
350,000
350,000
Total pipeline as of June 30, 2026, excluding properties held for sale
6,446,196
2,825,437
19,372,303
22,197,740
Properties held for sale
188,192
2,013,925
2,013,925
Total pipeline as of June 30, 2026
$6,634,388
(2)
2,825,437
21,386,228
24,211,665
Refer to “Megacampus” under “Definitions and reconciliations” in Item 2 for additional information.
(1)Total square footage includes 947,156 RSF of buildings currently in operation that we expect to demolish or redevelop and commence future construction subject to market conditions and leasing. Refer to “Investments in real estate” under
Definitions and reconciliations” in Item 2 for additional information, including development and redevelopment square feet currently included in rental properties.
(2)Includes $2.72 billion of projects that are currently under construction.
81
Results of operations
Same properties
We supplement an evaluation of our results of operations with an evaluation of operating performance of certain of our
properties, referred to as “Same Properties.” For additional information on the determination of our Same Properties portfolio, refer to
Same property comparisons” under “Definitions and reconciliations” in Item 2. The following table presents information regarding our
Same Properties for the three and six months ended June 30, 2026:
June 30, 2026
Three Months Ended
Six Months Ended
Percentage change in net operating income over comparable period from prior
year
(10.6)%
(1)
(11.5)%
(1)
Percentage change in net operating income (cash basis) over comparable
period from prior year
(8.6)%
(1)
(11.2)%
(1)
Operating margin
68%
66%
Number of Same Properties
289
288
RSF
31,733,905
31,448,559
Occupancy – current-period average
87.1%
88.2%
Occupancy – same-period prior-year average
92.6%
93.5%
(1)The decline was due to a decrease in same property occupancy, primarily driven by previously disclosed key lease expirations with expected downtime aggregating
657,492 RSF during the three months ended March 31, 2026 and 260,888 RSF during the three months ended June 30, 2026, with weighted-average lease expiration
dates of January 2026 and April 2026, respectively.
The following table reconciles the number of Same Properties to total properties for the six months ended June 30, 2026:
Development and redevelopment – under construction
Properties
99 Coolidge Avenue
1
1450 Owens Street
1
421 Park Drive
1
701 Dexter Avenue North
1
10200 Campus Point Drive
1
40, 50, and 60 Sylvan Road
3
269 East Grand Avenue
1
8800 Technology Forest Place
1
311 Arsenal Street
1
3000 Minuteman Road
1
12
Development – placed into service after January 1, 2025
230 Harriet Tubman Way
1
500 North Beacon Street and 4 Kingsbury Avenue
2
10935, 10945, and 10955 Alexandria Way
3
10075 Barnes Canyon Road
1
4135 Campus Point Court
1
8
Acquisitions after January 1, 2025
Other
2
2
Unconsolidated real estate JVs
3
Properties held for sale
23
Total properties excluded from Same Properties
48
Same Properties
288
Total properties as of June 30, 2026
336
82
Comparison of results for the three months ended June 30, 2026 to the three months ended June 30, 2025
The following table presents a comparison of the components of net operating income for our Same Properties and Non-Same
Properties for the three months ended June 30, 2026, compared to the three months ended June 30, 2025 (dollars in thousands). Refer
to “Definitions and reconciliations” in Item 2 for definitions of “Tenant recoveries” and “Net operating income” and their reconciliations
from the most directly comparable financial measures presented in accordance with GAAP, income from rentals and net income,
respectively.
Three Months Ended June 30,
2026
2025
$ Change
% Change
Income from rentals:
Same Properties
$434,779
$477,026
$(42,247)
(8.9)%
Non-Same Properties
51,810
76,351
(24,541)
(32.1)
Rental revenues
486,589
553,377
(66,788)
(12.1)
Same Properties
148,483
166,400
(17,917)
(10.8)
Non-Same Properties
8,138
17,502
(9,364)
(53.5)
Tenant recoveries
156,621
183,902
(27,281)
(14.8)
Income from rentals
643,210
737,279
(94,069)
(12.8)
Same Properties
Non-Same Properties
19,574
24,761
(5,187)
(20.9)
Other income
19,574
24,761
(5,187)
(20.9)
Same Properties
583,262
643,426
(60,164)
(9.4)
Non-Same Properties
79,522
118,614
(39,092)
(33.0)
Total revenues
662,784
762,040
(99,256)
(13.0)
Same Properties
187,351
200,594
(13,243)
(6.6)
Non-Same Properties
19,985
23,839
(3,854)
(16.2)
Rental operations
207,336
224,433
(17,097)
(7.6)
Same Properties
395,911
442,832
(46,921)
(10.6)
Non-Same Properties
59,537
94,775
(35,238)
(37.2)
Net operating income
$455,448
$537,607
$(82,159)
(15.3)%
Net operating income – Same Properties
$395,911